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Abstract 
 
Type 2 diabetes is a lifelong disease and a major health problem in Thai older 
people. Declining cognitive function and depressive mood can potentially present a 
barrier to self-care management. To date, there is no primary research data of 
cognitive impairment related to diabetes in Thailand, particularly in primary care 
settings which are the first important place for health care service in Thai 
community. This study contributes to the estimated prevalence of undiagnosed 
cognitive impairment and undiagnosed depressive mood in Thai older people with 
type 2 diabetes. In order to promote an early detection of cognitive impairment, a 
Thai version of Mini-Cog, a brief cognitive screening test for using in primary care 
settings was developed. 
 
A cross-sectional study design was conducted in a group of older diabetic patients 
aged 60 and over in the primary care settings of San-sai district, Chiang Mai, 
Thailand.  Overall 556 participants were recruited and the following screening tests 
were applied on them: Mini-Cog Thai version, Mini-Mental State Examination 
(MMSE) Thai 2002, and the depressive mood screening test of Thai Geriatric 
Depression Scale (TGDS). 
 
The study shows the prevalence of Thai older people with type 2 diabetes who 
were probably undiagnosed with cognitive impairment to be 65.4% (95% CI 
59.7%, 70.7%) for Mini-Cog, and 12.4% (95% CI 9.0%, 16.7%) for MMSE Thai 
2002. The prevalence of people who were probably undiagnosed with depressive 
mood by TGDS is shown to be 19.4% (95% CI 15.2%, 24.4%). Logistic regression 
has been used to identify the associated characteristics of cognitive impairment and 
the associated characteristics of depressive mood. Using Mini-Cog, age, education, 
BMI and HDL were found to have effects on cognitive impairment. While using 
MMSE Thai 2002, only the effect of age and education were associated with 
cognitive impairment. The associated factor with depressive mood was 
retinopathy.   
 
The differences of prevalence rate and associated characteristics between the two 
cognitive screening tests are probably due to the different foci on cognitive domain 
tests. Mini-Cog may be more sensitive in detecting an earlier stage of cognitive 
impairment better than MMSE Thai 2002. Mini-Cog Thai version shows a good 
inter-rater reliability (K=0.8, p<0.001, 95% CI 0.54, 1.06).  
 
This study encourages health care providers’ awareness of cognitive decline and 
depressive mood that may affect self-care diabetes. Mini-Cog Thai version might 
be used as a brief cognitive screening tool in primary care settings.  
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Chapter 1 
Introduction 
 
 
This thesis presents a prevalence study of undiagnosed cognitive impairment and 
undiagnosed depressive mood through associated factors in Thai older people with 
type 2 diabetes in one community. The study will achieve its goals using Mini-Cog 
and Mini-Mental State Examination (MMSE) Thai 2002, screening tools of 
cognitive impairment and Thai Geriatric Depression Scale (TGDS), a screening 
tool of depressive mood. In order to promote an early detection of cognitive 
impairment in the primary care setting in Thailand, this study also develops a Thai 
version of Mini-Cog, a short cognitive screening test specific to use in primary 
care centres. This test is studied along with MMSE Thai 2002, a Thai standard 
cognitive screening test. The information and results from this study will support 
appropriate self-care diabetes program and promote awareness of an early 
detection of cognitive impairment and/or depressive mood in older people with 
diabetes in primary care.  
 
This chapter discusses the study background, the potential importance of this study 
and the linkage between type 2 diabetes and cognitive impairment and depressive 
mood. This study was conducted in Thailand, therefore the overview information 
of health care system and older people population are provided as well. Finally, a 
description of the structure of the thesis is outlined.  
 
1.1 Background and significance of this study 
 
Diabetes Mellitus is a disorder in which the body does not produce or utilize 
insulin, a hormone used in the metabolism of sugars, starches and other foods, 
properly. Absence or impairment of insulin functioning in the body results in high 
levels of glucose in the blood and urine (hyperglycaemia) (Clark 2004).There are 
two common forms of diabetes: type 1 diabetes or previously known as insulin 
dependent diabetes mellitus (IDDM), and type 2 diabetes or previously known as 
non-insulin dependent diabetes mellitus (NIDDM). Around 90% of people with 
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diabetes around the world are type 2 and about 10% have type 1 diabetes (World 
Health Organisation 2011).  
 
Type 2 diabetes in adult is a global health issue. It has been estimated that the 
number of people with diabetes worldwide was 285 million in 2010 and will 
increase to 439 million in 2030 (Shaw et al. 2010). More than 80% of people with 
diabetes live in low and middle-income countries (World Health Organization 
2011). Each year more than 3.96 million people worldwide die from diabetes and 
its complications (Egede and Ellis 2010). Diabetes care is important in lowering 
blood sugar level and maintaining a good metabolic control in order to help 
prevent complication of diabetes. However, less than 15 % of adults with type 2 
diabetes met this goal in 2007 (Nam et al. 2011). For successful diabetes self-
management, individuals must commit to lifelong daily self-care tasks such as 
adhering to diet, exercise, and medication regimens and checking blood glucose. 
The coordination of these tasks often requires complex cognitive functioning 
(Okura et al. 2009). 
 
The prevalence of type 2 diabetes increases with age (Sicree et al. 2009). Research 
has linked the disease to cognitive impairment in the older people (Yeung et al. 
2009, Ganzer and Crogan 2010). Recent evidence from epidemiological studies 
suggests that type 2 diabetes is a risk factor for cognitive impairment and 
dementia, both the vascular dementia (VaD) and Alzheimer’s disease (AD), the 
two most common forms of dementia (Allen et al. 2004, Biessels et al. 2006, 
Luchsinger et al. 2007, Sastre and Evans 2008). Older individuals (aged 60-80) 
with type 2 diabetes are associated with approximately 1.5 fold risk of cognitive 
impairment compared to the control group (Cukierman et al. 2005). Given the 
potential for cognitive problems to interfere with the attempts to diabetes self-care 
management and following a physician’s recommendation, cognitive decline 
among older people with diabetes could lead to further decline in health (Sinclair 
et al. 2000).  
 
Another problem which may relate to cognitive impairment and affect self care 
diabetes is depressive mood. Depression is a common co-morbidity of type 2 
diabetes (Lustman and Clausea 2005, Katon et al. 2010). People with diabetes are 
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likely to suffer twice as often from depression as those without diabetes. 
Depressive symptoms may hinder diabetic patients’ ability to adhere to diet, 
physical activity and oral medication (Ciechanowski et al. 2000, Park et al. 2004, 
Wang et al. 2008). Moreover, depression by itself is the most common of the 
reversible causes of cognitive impairment or pseudo-dementia, particularly in 
memory part (Zrebiec 2006).  
 
Although the association between cognitive impairment and type 2 diabetes is now 
well established in many countries (Bruce et al. 2001, Bruce et al. 2003, Munshi et 
al. 2006, Rajakumaraswamy et al. 2008, Alencar et al. 2010) to date, there is no 
investigation of the relationship between diabetes and cognitive impairment and 
depressive mood in Thailand, particularly in a primary care setting. A primary care 
centre in Thai community (rural areas or sub-district level) is the first place of 
heath care service that provides primary health care, prevention and promotion 
(Prakongsai et al. 2009). Type 2 diabetes is one of the main chronic diseases which 
causes a health problem in Thai older people (Assantachai and Maranetra 2005 ) 
and the numbers of older people people are expected to increase over the next few 
decades due to the growing of ageing population (Bureau of Health Policy 2007). 
This study intends to quantify and raise awareness of undiagnosed cognitive 
impairment and undiagnosed depressive mood in older people with type 2 diabetes. 
Early detection and establishing an association between type 2 diabetes and 
cognitive impairment as well as an association between type 2 diabetes and 
depressive mood could therefore be of great importance to provide optimal 
diabetic care and good quality life to Thai older people with type 2 diabetes in this 
community.  
1.2 Definition of cognitive impairment and mild cognitive impairment 
 
Cognitive impairment is a defining feature of dementia. Dementia is characterized 
by the development of multiple cognitive deficits that include memory impairment 
and at least one of the following cognitive disturbances: Aphasia ( any impairment 
of the ability to use and/or understand words), Apraxia (difficulty in performing a 
learned movement or coordinated motor activity), Agnosia (loss of ability to 
recognize objects, people, sounds, shapes, or smells) or a disturbance in executive 
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functioning such as abstract thinking, judgement and problem solving 
accompanied by functional impairment (inability to perform independently in 
activities of daily living) (American Psychiatric Association  2000). 
Mild cognitive impairment (MCI) is cognitive impairment in the presence of 
memory complaints which can detect memory impairment on neuropsychological 
tests but no impairment of daily life activities (Petersen 2004).  
1.3 Type 2 diabetes, cognitive impairment and depressive mood: a potential 
linkage 
 
There are many pathophysiological mechanisms through which diabetes may 
affect the underlying pathologies associated with cognitive impairment (Llorente 
and Malphurs 2007). In addition, depressive mood may be linked to diabetes and 
subsequent cognitive impairment. Both Alzheimer’s disease (AD) and vascular 
dementia (VaD) are common types of cognitive impairment which can be found in 
these mechanisms as well as ageing itself (Biessels 2006). It is increasingly 
recognised that the brains of people with dementia, particularly in the very old, are 
likely to show a mixture of pathologies, particularly AD type and vascular changes 
(Neuropathology group 2001).   
1.3.1 Type 2 diabetes and cognitive impairment 
 
There are four main possible mechanisms which link type 2 diabetes and cognitive 
impairment. First, diabetes is a known risk factor for cerebrovascular diseases such 
as hypertension and dyslipdaemia (Halperin et al. 2006). Thus, it is expected that 
type 2 diabetes can cause the vascular form of cognitive impairment (Llorente and 
Malphurs 2007). Second, chronic hyperglycaemia in type 2 diabetes might lead to 
abnormalities in cerebral capillaries, such as basement membrane thickening. 
These microvascular changes might also lead to chronic and insidious ischemia of 
brain (Gispen and Biessels 2000). Third, the malfunction and damage of brain 
function due the alterations in insulin and glucose level either in hyperglycaemia 
(abnormally high level of sugar in blood) or hypoglycaemia (abnormally low level 
of sugar in blood). Hyperglycaemia affects the deposition of amyloid beta (Aβ), 
which is a protein fragment snipped from an amyloid precursor protein (APP). In a 
healthy brain, these protein fragments are broken down and eliminated. In 
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Alzheimer's disease, the fragments accumulate to form hard, insoluble plaques 
which contribute to the degradation of the nerve cells in the brain and the 
subsequent symptoms of Alzheimer's disease (AD) (Ritchie and Lovestone 2002). 
Hypoglycaemia can cause the damage of cortical area, particularly in the frontal 
lobe and hippocampus. However, due to the uncontrolled blood sugar, type 2 
diabetic patients are more likely to have hyperglycaemia (World Health 
Organisation 2011). Fourth, ageing itself is associated with changes in insulin and 
its receptor in the brain and these changes might be even more pronounced in 
patients with AD (Craft and Watson, 2004).  
1.3.2 Type 2 diabetes and depressive mood 
 
There are two main possible mechanisms to explain the relationship between 
depressive mood and diabetes. First, depressive symptoms are associated with 
biochemical changes and related to the activation of the hypothalamic-pitutary-
adrenal axia (HPA), which is a major part of the neuroendocrine system that 
controls reactions to stress and regulates many body processes, including digestion, 
the immune system, mood, emotions, energy storage and expenditure. Thus, this 
system is an important factor in disrupting overall metabolic control (Arvanitakis 
et al. 2004, Beeri et al. 2005). Second, the presence of depressive mood or 
symptoms may adversely affect life activities such as lack of exercise and poor diet 
that increase the risk of diabetes (Black et al. 2003, Saydah et al. 2003).  
 
1.3.3 Depressive mood and cognitive impairment 
 
Depressive mood affects the HPA disturbances and causes prolonged 
hypercortisolemia. As a result, it may promote hippocampal atrophy and functional 
decline. This also affects impairment in the memory functions of the brain served 
by the hippocampus (Campbell and Macqueen 2004). 
 
In summary, the pathophysiological mechanisms suggest how diabetes-related 
factors can affect cognitive impairment through the brain. Vascular disease and 
alterations in glucose and amyloid metabolism seem to be important factors. In 
addition, the neuro-hormonal changes (activation of HPA) induced by depressive 
mood symptoms can lead to insulin resistance and develop type 2 diabetes. 
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Behavioural factors with depressive symptoms (lack of exercise and poor diet) also 
increase the risk of type 2 diabetes. The mechanisms linking depressive mood and 
type 2 diabetes may cause memory impairment. 
 
 
 
Figure 1.1: Proposed scheme, association of type 2 diabetes with cognitive 
impairment and depressive mood through changes in pathophysiology  
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1.4 Cognitive function and depressive mood: Impact for diabetes self-care  
 
Cognitive impairment and depression have important consequences for diabetic 
patients and diabetes self-care management (Bayer et al. 1994). They are crucial 
components in the individual needs to control an appropriate blood glucose level 
(an optimal goal for diabetes care) by maximizing adherence to diet, exercise, and 
dosing schedules of the medicine (Biessels et al. 2008). It is important to recognize 
these two co-morbidities and great insight is needed in how cognitive impairment 
and depressive mood influence the diabetes care and quality of life in the diabetic 
patients (Katon et al. 2010) 
 
Although diabetes is considered to be a risk factor for cognitive impairment 
(Munshi et al. 2006, Allen et al. 2004, Gregg et al. 2000), the cognitive function of 
patients with type 2 diabetes is not usually evaluated in routine clinical care. 
Cognitive impairment might be another factor associated with poor diabetes 
control and also bad adherence of patients to educational approaches, such as diet 
orientations (Alencar et al. 2010). 
1.5 The importance of the early detection of cognitive impairment and 
depressive mood 
 
Although diabetes is considered to be a risk factor for cognitive impairment 
(Munshi et al. 2006, Allen et al. 2004, Gregg et al. 2000), the cognitive function of 
patients with type 2 diabetes is not usually evaluated in routine clinical care. 
Cognitive impairment might be another factor associated with poor diabetes 
control and poor adherence of patients to educational approaches, such as diet 
orientations (Alencar et al. 2010). In addition, type 2 diabetes relies heavily on the 
principles of self-management. This is in essence a series of complex behaviour 
required for lifestyle and behavioural changes as well as adherence to medical 
interventions. Successful disease management is dependent on the patient’s ability 
to execute these interventions and maintain lifelong adherence to diabetes care 
(Llorente and Malphurs 2007). 
 
Moreover, depression by itself is a reversible cognitive impairment, particularly in 
memory part (Dolan et al. 1992, Zrebiec 2006, Saez-Fonseca et al. 2007). 
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Depressive symptoms are also common in diabetic patients and may hinder their 
ability to adhere to diet, physical activity and oral hypoglycaemic agents 
(Ciechanowski et al. 2000, Park et al. 2004, Wang et al. 2008) and therefore cause 
poor glucose control as a result of reduced capacity to manage a self-care regimen 
(Goldney et al. 2004). Hence, early detection and management of cognitive 
impairment and depressive mood may become an important aspect of diabetes 
care. 
1.6 An overview of Thailand 
1.6.1 Thailand Profile  
 
Thailand is situated in the southeast of continental Asia, and is part of the 
Indochina Peninsula (see map below, Figure 1.2), with an area of 514,000 
kilometres2is the world’s 49thlargest country. Following Indonesia and Myanmar 
(otherwise known as Burma), it is the third largest country among the Southeast 
Asian nations. Thailand is a tropical country and is divided into 4 geographical 
regions: the central region (including the capital city of Bangkok), the North 
(including the country’s second city Chiang Mai), the North-East (including Udon-
Thani province) and the southern regions (Knodel and Choyavan 2008). Total 
population is around 66 million (2011 est.). The official national language, spoken 
and written by almost 100 percent of population, is Thai. More than half of the 
population (66%) lives in rural area. Life expectancy in 2011 was 71 years for 
males and 76 for females, with an average of 74 years (United Nation 2011). 
 
Since 1961, the base of the Thai economy has rapidly changed from agriculture to 
service and manufacturing. The Gross Domestic Product (GDP) per capita was US 
$4,043 in 2009, representing Thailand as a middle income country (world rank 
114/226). GDP-composition by sector is 11% in agricultural sector, 40% in 
industry and 49% in service (Sakunphanit and Suwanrada, 2011). The majority 
(80%) of people have health care insurance provided by the government (National 
Statistical Office of Thailand 2011).  
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Figure 1.2 Map of Thailand (Source: Sakunphanit, 2006) 
 
                
 
 
1.6.2 Overview of health care structure in Thailand 
Health care system in Thailand is an entrepreneurial health system with public and 
private providers. Public health facilities were rapidly expanded nationwide since 
1961 when Thailand launched the first five-year National Economic and Social 
Development Plans (1961-1966). Private hospitals also play a role in health 
service. However, they are mostly in Bangkok, a capital city and urban areas. In 
the public sector, the largest agency is the Ministry of Public health (MOPH) with 
two-third of all hospitals and beds across the country. The other public health 
services are medical school hospitals under the Ministry of University, general 
hospitals under other ministries (such as Ministry of Interior, Ministry of Defence) 
(Sukunphanit  2006).  
In 2004, 68.6% percent of hospital and 65.4% of beds belonged to the MOPH. The 
health care services in Thailand are divided in the following levels: general 
hospital (120-150 beds) or regional hospitals (501-1,000 beds) and few special 
centres/hospitals in provincial level, community hospitals (10-120 beds) in district 
level and primary care or health centre in sub-district level. The health care 
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structure under MOPH can be explained briefly as in Table1.1. It shows the 
relationship between administrative level, population size, level of care and 
providers. Currently, MOPH owns 891 hospitals which cover more than 90% of 
districts and 9,762 primary cares, which cover every sub-district or community in 
rural area (Wibulpolprasert  2004). 
 
Table 1.1: Levels of health care system in Thailand: administrative level, 
population size, level of care and provider in Thailand 
 
 
Administrative 
level 
Population  Level of care Health care 
providers 
 
Province  300,000-1,000,000 Secondary care: General 
hospital 
 
Specialists 
District 20,000-100,000 Primary and secondary 
care: Community 
hospital 
 
General practice, 
family practice 
Sub-district  2,000-5,000 Primary care: Primary 
care centre 
Nurse/technical 
nurse/health 
worker 
 
 
 
The importance of primary care system in Thailand 
 
The primary care system is the first point of contact for people to access and utilize 
health service in Thailand. It is an important mechanism for enabling people to 
access quality health care service on a continuous basis. The primary care system 
is seen as a key mechanism and strategy to achieve health equity and progress on 
health system reform, and has received support from the World Health 
Organisation for over 30 years, since 1978. Evidence from international and Thai 
literature indicate that the primary care system plays an important role in 
improving equity in health and equitable to public health care service (Prakongsai 
et al. 2009). 
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1.6.3 Overview of Thai ageing population 
 
Thailand has entered into the period of “the ageing society” since 2005, and the 
number of older people in Thailand is expected to rise significantly over the next 
25 years (Ministry of Public Health and Ministry of Social Development and 
Human Security 2007). Population ageing is defined as the increasing proportion 
of older persons (60 years and above) in the total population (United Nations 
Population Fund Thailand 2006). The proportion of the population in their elderly 
years (60+) is anticipated to increase from 8.7 percent in 2000 to 10.8 percent in 
the year 2010, 15.2 percent in the year 2020, and 30 percent in the year 2050. The 
number of older persons will continue to rise, from approximately 5.3 million at 
present to 7.2 million in 2010 and will reach 11 million by 2020 (See Figure 1.3). 
The percent increase of the old-olds is greater than that of the overall aged 
population. Among older males and females, 71% and 48% have finished grade 4 
(4 years in school) (Sakunphanit 2006). A majority (70 %) of Thai older persons 
live in rural areas and about 30 percent in municipal or urban areas. 93% of the 
older people live in the same households with many family members (The National 
Commission on the Elderly 2009). Among all persons aged 60 and above, 
especially in rural area, the most common source of income (80%) comes from 
their children (Ministry of Public Health of Ministry of Social Development and 
Human security 2007). 
 
Figure 1.3:  Total number and percent of the older population in Thailand, 1980-
2050  
 
 
 
 12 
 
1.7 The burden and gap problem of diabetes care in Thailand  
 
Diabetes Mellitus is one of the important public health concerns of Thailand in 
recent years (Rawdaree et al. 2006, Nitiyanant et al. 2007). Recent economic 
change, reflected by rapid industrialization, urbanization and increased wealth at 
both national and household levels contribute to change of lifestyles, in particular 
high fat food diet and less physically active patterns. These factors have led to an 
increasing proportion of the Thai population living with diabetes from 2.3% in 
1991 to 4.6% in 1997 and 6.9% in 2008-2009 (Akeplakorn et al. 2010, Chatterjee 
et al. 2011). In 2009, the National Health Examination Survey (NHES) IV reported 
the prevalence rate in female was higher than male. Overall in both genders, a 
highest prevalence rate (16.7%) was found in diabetic adults aged group 60-69 
while the other adult aged groups were 3.4% (30-44), 10.1% (45-59), 15.8%     
(70-79) and 11.5% (80+) (see Figure 1.4) (Akeplakorn et al. 2011).  Diabetes alone 
is responsible for 3.3 and 8.3% of total deaths in Thai men and women, 
respectively (Porapakkham et al. 2010). In addition, a high prevalence rate (6.7%) 
of diabetes in Thailand makes it among the top ten in Asia (Chan et al. 2009). 
While measuring the health status of Thai people using Disability Adjusted Life 
Years (DALYs) as an indicator, it was found that diabetes ranked eighth and third 
for males and females respectively in 2004. Moreover, the hospitalisation rate for 
diabetes in Thailand has increased and shown a rising trend. For example, the 
hospitalisation rate for diabetes has nearly doubled over 3 years from 380.7          
(x 100, 000 population) in 2003 to 586.8 (x 100,000 population) in 2006 (Ministry 
of Public Health Thailand 2009). 
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Figure 1.4:  Age-specific prevalence of diabetes in Thai adults  
 
 
 
 
 
Source: NHES IV report 2009 (Akeplakorn et al. 2011) 
 
 
People with diabetes are prone to consequences in both short-term and long-term 
complications (Chatterjeeet al. 2011). The chronic nature of diabetes and its 
devastating complications make it a very costly disease. A study based on four 
government hospitals in Thailand found that for outpatients, annual direct medical 
expenditure was more than five times higher for diabetic patients as compared to 
non-diabetics. For inpatients, the expenditure was more than two times higher in 
2002 and 2003 (Pongcharoensuk et al. 2006). Chatterjee (2011) revealed that the 
cost average of illness per diabetic patient was US$ 881.50 which was about 21% 
of per capita GDP in Thailand. This study noted that the cost of informal care (care 
from family/friends) contributed 28% of the total cost of diabetes. Therefore, 
diabetes not only affected the individual but also the family members and friends. 
This study also found associations of diabetes cost with age and complications. 
Similarly, Chaikledkaew (2008) investigated factors associated with healthcare 
expenditures and hospitalisations in patients with diabetes in four public hospitals 
in Thailand. They showed that age, male gender, type of payment, health care 
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utilization (hospitalisation or outpatient visit), co-morbidities (hypertension, 
hyperlipidaemia) and complications (neuropathy, nephropathy, retinopathy) were 
associated with health expenditures. Both studies suggested that much of this cost 
associated with the disease is preventable through improved diabetes care, 
prevention initiatives to reduce the prevalence of diabetes and its co-morbidities 
(Chaikledkaew et al. 2008, Chatterjee et al. 2011). 
 
Glycaemic control is fundamental to the management of diabetes (Llorente and 
Malphurs 2007). One measure of glycaemic control is glycated haemoglobin 
(HbA1c). The HbA1c is the most accepted indicator and accurately reflect longer-
term glycaemic control (Saudek et al. 2006, Yavari 2011). The HbA1 is the 
compound in red blood cells that transports oxygen, and the most common form of 
haemoglobin is called haemoglobin A. Glucose binds to haemoglobin A, forming 
glycated haemoglobin (HbA1c), which is elevated when plasma glucose levels are 
high. American Diabetes Association (ADA) guidelines indicate that normal 
HbA1c is less than 6.0% (42 mmol/mol), while an HbA1c value greater than 7.0% 
(53 mmol/mol) represents poor glycaemic control (American Diabetes Association 
2009).  The decomposition of glycated haemoglobin is slow and the build up of 
glycated haemoglobin lasts between 1 and 4 months. HbA1c reflects mean glucose 
levels over the past 2 weeks to 3 months (Ross and Gadsby 2004). For diabetic 
patients, the goal of diabetic care and treatment is to achieve an HbA1c less than 
7% (53 mmol/mol) in order to prevent the morbidity and mortality of diabetic 
complications (American Diabetes Association 2009). Nevertheless, a cross-
sectional study survey of primary care settings in all regions of Thailand, Nitayanat 
(2007) revealed that the outcome of glycemic control was higher than the standard 
criteria. The mean + SD of HbA1c was 8.6 + 1.9 % (70.5 + 2.3 mmol/mol). 
Furthermore, reports from health status surveys reveal that 60% of Thai people 
with diabetes are unable to maintain appropriate glycaemic control (Koshakri et al. 
2009).  
 
Barriers of glycaemic control in Thai literature included difficulty in making daily 
food choices, preparing food, and lack of knowledge (Wattana et al. 2007). The 
literature points out that proper diabetes health education programs for improving 
knowledge, diabetic control, and preventing complications for type 2 diabetic 
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patients are still needed. As mentioned earlier, diabetes self-management activities 
require complex cognitive functioning (Okura et al. 2009), however, no study was 
found to investigate the effects of cognitive function on glycemic control and 
diabetes self-care. Cognitive impairment might be another gap or factor associated 
with poor diabetes control and adherence of patients to educational approaches, 
such as diet orientations (Alencar et al. 2010). Therefore, early clinical recognition 
of cognitive impairment and its progression to dementia will bridge another gap 
toward effective self-care management in type 2 diabetic patients (Galluzzi et al. 
2010). 
 
In order to address these issues effectively, the present study will investigate the 
problem of cognitive impairment and depressive mood in Thai older people with 
type 2 diabetes at the primary care setting in a community which is required to 
provide baseline information for health care professionals (Ooi et al. 2011). In 
addition, understanding the epidemiology of cognitive impairment and dementia in 
Thai older people is crucial for planning public health strategies and rational 
allocation of resources to provide the optimal diabetic care and approach to Thai 
older people with type 2 diabetes. An early detection of cognitive decline may also 
afford individuals the opportunity to modify lifestyle and improve diabetes self-
care management for a good quality of life.  
 
It should be noted that, the incidence of type 2 diabetes increases with age, and 
90% of diabetes is type 2. Thus, this thesis focuses only on the evidences relating 
type 2 diabetes to cognitive impairment and will not cover the cognitive 
complications of type 1 diabetes. 
1.8 Structure of the thesis 
 
This thesis is divided into 10 chapters. In order to understand the background of 
the research, this chapter (Chapter 1) provided an overview of Thailand profile and 
its older people population. 
 
Chapter 2 will provide a review of the existing research related to the prevalence of 
cognitive impairment and the prevalence of depressive mood in type 2 diabetes. 
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The purpose of this chapter is to review the trend of prevalence rate, study setting 
and screening tools used in the previous studies. In addition, this information will 
provide an overview of factors related to the study of cognitive impairment in type 
2 diabetes.  
 
Chapter 3 will discuss and critique the existing cognitive screening tools 
commonly used in Thailand. The aim of this chapter is to provide a choice of the 
tests in this study.  
 
Chapter 4 will focus on the development of the Thai version of Mini-Cog, a brief 
cognitive screening test specific to use in primary care setting. This chapter will 
present the validated processes to translate original version of the Mini-Cog from 
English to Thai. 
 
Chapter 5 will present the study protocol including the research questions, aims, 
and objectives of this study. Procedures for recruitment, data collection and 
analysis will be outlined.  
 
Chapter 6 is the pilot study. This chapter aims to investigate the feasibility of 
applying the study protocol as well as the Mini-Cog Thai version to collect the data 
in the main study. This study will present the inter-rater reliability and concurrent 
validity of the Mini-Cog. Lessons learned and a summary of changes for the 
methodology (Chapter 7) will be summarised. 
 
Chapter 7 is methodology. This chapter will begin with a discussion of changes 
summarised from the lesson learned in the pilot study (Chapter 6). Then the second 
part will present an overall description of the methodology. 
 
Chapter 8 will illustrate a summary of findings in this study. This chapter has two 
parts. In order to show the reliability of data collection in this study, the first part 
will provide the results of the inter-rater reliability between the researcher and 
research assistant in all screening tools. The second part is a summary of 
participant characteristics and results from the screening tools. This will be 
presented according to the research objectives. 
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Chapter 9 will critique and discuss the findings in relation to the existing literature 
and possible limitations. The outcomes of the study will be discussed and 
summarised. 
 
Chapter 10 will provide an overall conclusion. Strengths and limitations of this 
study will be outlined. Implications for clinical and health care professions 
including recommendations for future research will be described.  
 
1.9 Summary 
 
Type 2 diabetes poses a major public health problem in Thailand and worldwide. 
The prevalence of type 2 diabetes in Thailand is about 7% and the highest 
prevalence (16.7%) is in the population aged 60 years and over. Diabetes alone is 
responsible for 3.3 and 8.3% of total deaths in Thai men and women. Keeping a 
good self-care management is an important factor in taking care of diabetes, a 
lifelong disease. Lifelong daily self-care activities include adhering to diet, 
exercise, and medication regimens including checking blood glucose. The 
coordination of these activities requires a complex cognitive functioning. Because 
of the prevalence of diabetes and cognitive impairment increase with age, 
screening cognition to identify early sign of cognitive impairment as well as 
screening depressive mood to detect a reversible cognitive impairment in older 
diabetic patients would benefit an optimal diabetes care and planning.  
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Chapter 2 
Literature review 
 
 
Evidence shows that cognitive impairment and depressive mood can be found in 
older people with type 2 diabetes (see Chapter 1). This chapter conducts a 
systematic search and synthesises of the published literature of the prevalence of 
cognitive impairment and the prevalence of depressive mood in the older people 
with type 2 diabetes. In addition, factors related to the cognitive impairment in the 
older people with type 2 diabetes will be presented.  
 
This chapter consists of the following two parts. The first part focuses on the 
published studies that assess the prevalence of cognitive impairment and 
depressive mood in the older people with type 2 diabetes. The second part is an 
overview of factors related to the study of cognitive impairment in type 2 diabetes.  
2.1 Review studies of the prevalence of cognitive impairment and depressive 
mood  
 
Prevalence refers to the proportion of a defined population at risk that has a 
defined health problem at a particular point in time (point prevalence) or during a 
period of time (period prevalence).Valid information of this basic epidemiological 
parameter is necessary to monitor trends of the disease burden and to highlight 
valuable information for preventing the problem and planning effective public 
health program (Webb and Bain 2011). In addition, prevalence study is an essential 
consideration to understand the current knowledge regarding cognitive impairment 
specific to type 2 diabetes that could lead to further primary research. 
 
Therefore, the primary aims of this section are to synthesise and quantify the 
prevalence of cognitive impairment and depressive mood in published literature, 
including risk factors associated with type 2 diabetes in old adults.  
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2.1.1 Method 
An electronic search was conducted using the following bibliographic databases: 
MEDLINE, AMED, CINAHL, EMBASE, PsycInfo and Cochrane library. These 
databases cover all the publications in medical and healthcare electronic resources. 
Each medical and healthcare database was separately searched from January 1985 
to June 2012 for English articles. The year 1985 was chosen as the earliest year 
that the literature addressed across-sectional study examining the association 
between type 2 diabetes and cognitive impairment in the Cochrane review (Mattlar 
et al. 1985, Evans and Sastre 2009). All databases were searched continuously 
during the period of this research. 
 
Search terms: 
- type 2 near diab* or DM, type II near diab* or DM, type 2 diabet*, 
NIDDM, Non- Insulin Dependent Diabetes Mellitus, Diabetes Mellitus 
- cognit*, dement*, alzheimer*, cognitive impair* , cognitive dysfunct* 
- depres* , mood, low mood 
- preval*, prevalence  
- elderl*, older, age* 
 
Both free text and the related thesaurus Medical Subject Heading (MeSH) terms 
were used for each search. 
 
Inclusion criteria 
- Primary studies reporting the frequency of (prevalence or incidence), or 
predictors for related cognitive impairment or dementia or depression in old 
adults with type 2 diabetes.  
- Written and published in English. 
- Focus on the measurement of the frequency of cognitive impairment or 
depressive mood in single point of time in order to see trend of burden 
disease 
 
Exclusion criteria  
- Qualitative research, single case studies and secondary research  
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2.1.2 Results  
 
A total of 689 citations were retrieved from all database including duplicates. The 
search papers were narrowed and selected by title. Of the 689 citations, 457 were 
excluded due to the title and duplicates. Of 232 abstracts that addressed type 2 
diabetes were read, and those that were relevant to inclusion criteria were 
identified and reviewed for the full-text.  
 
The search yielded that13 relevant studies met the criteria. The papers were read 
using Coughlan et al.’s (2007) guide to critique quantitative research. Prevalence 
studies were evaluated using a standardize checklist (Boyle, 1998). The papers 
were categorized into two categories related to cognitive impairment and 
depressive mood in type 2 diabetes as follows: 
A) Prevalence of related cognitive impairment: 6 studies 
B) Prevalence of depressive mood: 10 studies (3 papers overlapped with 
prevalence of cognitive impairment studies) 
 
The search results are summarised in Figure 2.1 
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Figure 2.1:  Results of Search Strategy  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Database Searched: 
MEDLINE (1946 to April 2012)   AMED (1985 to April 2012) 
CINAHL (1985 to April 2012)  EMBASE (1974 to April 2012) 
PsycInfo (1806 to April 2012)  Cochrane library (April 2012) 
 
Search terms employed: 
- type 2 near diab* or DM, type II near diab* or DM, type 2 diabet*, NIDDM, Non- 
Insulin Dependent Diabetes Mellitus, Diabetes Mellitus 
- cognit*, dement*, alzheimer*, cognitive impair* , cognitive dysfunct* 
- depres* , mood, low mood 
- preval*, prevalence 
- elderl*, older, age* 
689 were produced 
457 excluded 
- 274 duplicated  
- 183 excluded title (diet programs, sexual hormone, life-style, diabetes in pregnancy, 
weight loss, weight control, pro-inflammatory cytokines, sleep problems, intervention 
programs, erectile dysfunction, biochemical profiles, economic impacts, conceptual 
model) 
 
232 abstracts were read 
7 papers: 
prevalence of 
depressive mood 
 
3 papers: 
prevalence of 
cognitive 
impairment 
 
219 of following articles types were excluded 
- Qualitative studies, Alternative medicine studies, rehabilitation in diabetes, 
Pharmacological studies, diabetes in atherosclerosis, diabetes in coronary heart disease, 
diabetes in intensive care unit, mental illness studies, cognitive behavior therapy, 
biofeedback therapy, gene studies, brain imaging studies, urological symptoms 
 
13 full papers were included and reviewed 
3 papers: prevalence 
of cognitive 
impairment mixed 
with prevalence of 
depressive mood 
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A) Prevalence studies related to cognitive impairment 
 
Six studies estimated the prevalence of cognitive impairment in subjects with type 
2 diabetes in old age. Two studies were designed to examine both cognitive 
impairment and depressive mood (Bruce et al. 2003, Munshi et al. 2006). One 
study focused on mild cognitive impairment and depressive mood (Thaneerat et al. 
2009). Three published studies were conducted in hospital setting. The details in 
each study are described as the following: 
 
In Australia, the prevalence of probable dementia was studied in a Fremantle 
Diabetes Study (FDS), a community-based study of diabetes care project in 2001 
and 2003 (Bruce et al. 2001, Bruce et al. 2003). The study was conducted twice by 
the same researchers. The study in 2001 showed the prevalence rate at 11.3% of 
probable dementia with the limitation on small sample size (60). This study was 
conducted again in 2003 with a larger number of participants. In this study, 223 
(42%) participants from a total number of 529 eligible surviving participants aged 
70 were screened for cognitive impairment.  MMSE and IQCODE were used to 
screen cognitive impairment. Participants who had MMSE score less than 24 and 
IQCODE score more than 3.61 (combining the results) were defined as probable 
dementia cases. The prevalence of probable dementia was found 15.3%. 
 
Another study is related to Munshi et al. (2006) in the United States. They studied 
the association between cognitive dysfunction and glycaemic control with other 
barriers in 60 older adults with diabetes. The study took place at tertiary care 
specialty setting in the United States. Participants were recruited using 
convenience sampling. The Mini Mental State Examination (MMSE), Clock 
Drawing Test (CDT) and Clock-In-a-Box (CIB) were used as cognitive screening 
tools. This study pointed out two main weaknesses for MMSE: 1) low specificity 
(specificity = 64%, sensitivity = 96%) and 2) limitation of an executive function 
test. These weaknesses have an impact on the ability to detect the subtle changes in 
cognition and the early stage of cognitive impairment or mild cognitive 
impairment (MCI). Therefore, this study used CDT and CIB designed specifically 
to assess memory and executive function components in cognition, along with 
MMSE. The cut-off score for MMSE was less than 24/30 and the cut-off scores for 
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the CDT and CBT were 13/20 and 6/8, respectively. Of all the participants who 
were screened and were positive to cognitive impairment, 12% were diagnosed by 
MMSE, 38% by CDT and 35% by CIB. Munshi et al. (2006) stated that CDT and 
CIB were superior in identifying the patients with subtle changes in cognition and 
their vulnerability to cognitive dysfunction. They also suggested that cognitive 
impairment was one of the unrecognized barriers in diabetes control. However, due 
to the convenience sampling, the sample was unlikely to be representative of the 
population being studied because there was a high rate of Caucasian (82%) as 
compared to African American (13%) and Hispanics (5%). Another major 
limitation of this study was the small sample size. 
 
In Thailand, Thaneerat et al. (2009) estimated the prevalence of depression with 
mild cognitive impairment (MCI) in 250 Thai older people with type 2 diabetes in 
a university hospital setting. Participants were recruited using systematic random 
sampling method and the patients with cognitive impairment who had been 
screened by Thai Mental Screening Test (TMSE) were excluded. This study used 
the Montreal Cognitive Assessment (MoCA) test to detect MCI. Overall, the 
number of people who had MCI was 77.6 % (194/250). This study was limited by 
the fact that the original version (English version) of the cognitive screening test 
was applied to non-English speaking population regardless of the report of 
reliability and validity of the test. 
 
In Sri Lanka, Rajakumaraswamy et al. (2008) studied the frequency of cognitive 
function and dementia among Sri Lankan older people with type 2 diabetes in a 
diabetic clinic. The participants were recruited by random sampling of 204 
participants from a specialist diabetic clinic database. MMSE was used as a 
cognitive screening test and a score of less than 25 was defined as cognitive 
impairment. Then the participants who had cognitive impairment (MMSE score 
less than 25) were screened further with the Cambridge Cognitive Assessment 
(CAMCOG) to detect dementia. The cut-off score of less than 80 was diagnosed 
with dementia. Psychiatric disorders were excluded in all these participants by a 
psychiatric blind to cognitive assessment scores.  In total, the prevalence of 
cognitive dysfunction and dementia were 32.8 % (67/204) and 10.3 %, (21/204), 
respectively.  
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Alencar et al. (2010) conducted a study to find the prevalence of possible dementia 
in Brazilians with type 2 diabetes in a hospital setting in Brazil. The validated 
MMSE in the Brazilian version was used to detect possible dementia. The 
following criteria were set: cut-off score of MMSE of less than 26 (<26) for the 
participants who had more than 8 years in school and a cut-off score of less than 18 
(<18) for those who had 1-8 years in school. Of the 346 participants who were 
screened by MMMSE, 12.1% (42/346) were classified as possible dementia cases. 
The limitation of this study is related to the representativeness of the population; 
that is illiterate participants were excluded from the study.  
 
The 6 above-mentioned studies show the range of the prevalence of cognitive 
impairment in old adults 11.3% to 77.6%. It should be noted that the study of 
Thaneerat et al. (2009) focused on the prevalence rate of mild cognitive 
impairment (MCI) instead of cognitive impairment. Therefore, it could be possible 
that the estimated rate of MCI shows the distinctly high rate of (77.6%) compared 
to the other studies (i.e. Bruce et al. 2002, Bruce et al. 2003, Munshi et al. 2006, 
Rajakumaraswamy et al. 2008, Alencar et al. 2010). Overall, MMSE was the most 
common cognitive screening tool used in the prevalence study. Five of the six 
studies used MMSE as a screening tool for cognitive impairment. Although 
MMSE was used as a worldwide cognitive screening test, other short cognitive 
screening tools were used along with MMSE. There are two main reasons for 
applying the other cognitive screening tests along with MMSE. First, MMSE is not 
sensitive in early detection of dementia (Allen et al. 2004, Munshi et al. 2006). 
Second, MMSE is affected by age and education (Bruce et al. 2001, Bruce et al. 
2003).   
 
In summary, the prevalence rate of cognitive impairment in the literatures depends 
on the following factors: 
1) The range of age groups 
For example, there was a variety of age range in each study, from the mean 
age of 59 to 79). None of the studies reported 95% CI with prevalence rate 
(Figure 2.1) 
2) The difference of cognitive screening tools 
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3) The variety of cut-off scores in the same cognitive screening tool 
For example, the cut-off score of MMSE, particularly, in the non-English 
versions varied. The study in Brazil used the cut-off score with the level of 
education (Alencar et al. 2010), while the study in Sri-Lanka used one cut-
off score for all the levels of education (Rajakumaraswamy et al. 2008) 
(Figure 2.2). More importantly, the study in Thailand (Thaneerat et al. 
2009) had a major limitation on the report of validated study of cognitive 
screening when applied to another culture and language.  
 
 
 
Figure 2.2:  Mean age in each prevalence study 
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Figure 2.3: Prevalence rate and screening tools with cut-off scores 
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Table 2.1: Summary of the studies on the prevalence of related cognitive impairment in type 2 diabetes 
Study and setting 
 
 
Sample 
size 
Probability 
sampling 
Mean age / 
Age range 
Prevalence (95% CI) 
 
Measures Comments 
Bruce et al. (2001), 
Fremantle Diabetes 
Study (FDS), 
community- based 
study, Australia  
 
63 no 70+8.8  11.3% of probable 
dementia  
 
MMSE screening test: 
cut-off < 24/30 AND 
IQCODE screening test: 
cut-off > 3.61 defined as 
probable dementia 
 
-No report of Confidence Interval 
(CI) with the prevalence 
-Exclude 10 cases when probable 
dementia was due to language barrier 
- IQCODE uncompleted due to the 
lack of suitable informant  
- Convenience sampling 
 
Bruce et al. (2003), 
Fremantle Diabetes 
Study (FDS), 
community- based 
study, Australia  
 
223 no 76.5+4.3  15.3% of probable 
dementia  
 
 
MMSE screening test: 
cut-off < 24/30 AND 
IQCODE screening test: 
cut-off > 3.61 defined as 
probable dementia 
 
-No report of Confidence Interval 
(CI) with the prevalence 
- Sensitivity = 93% and specificity = 
85% for combining results of the two 
screening tests 
- Convenience sampling 
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Table 2.1: Summary of the studies on the prevalence of related cognitive impairment in type 2 diabetes (continued) 
Study and setting 
 
 
Sample size Probability 
sampling 
Mean Age 
/Age range 
Prevalence (95% CI) Measures 
 
Comments 
Munshi et al. 
(2006), Tertiary 
care specialty 
clinic, the United 
State 
60 no  79+5.0 12% of cognitive 
impairment by MMSE 
35% of cognitive 
impairment by CIB 
38% of cognitive 
impairment by CDT 
 
MMSE screening test: 
cut-off < 24 
CIB (clock-in- a 
box):cut-off <6 (6/8) 
CDT: cut-off <13 
(13/20) 
 
-Small sample size 
-Convenience sampling  
- No report of CI 
 
Rajakumaraswa-
my et al. (2008), 
Specialist diabetic 
clinic, Sri Lanka 
 
204 yes 63.6+8.3  32.8 % of cognitive 
impairment (MMSE) 
10.3% of dementia 
(Neuropsychological tests) 
two-phase design:  
1. MMSE screening test 
(cut-off  <  25)  
 
2.Neuropsychological 
test for the diagnosis of 
dementia  
 
-No report of Confidence Interval 
(CI) with the prevalence 
- No report of education level of 
subject when used MMSE in non-
English group  
- The paper is in research letter 
format, the information of the study 
is restricted  
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Table 2.1: Summary of the studies on the prevalence of related cognitive impairment in type 2 diabetes (continued) 
Study and setting 
 
 
Sample size  Probability 
sampling  
Mean Age 
/Age range 
Prevalence (95% CI) Measures 
 
Comments 
Thaneerat et al. 
(2009), diabetic 
outpatient clinic, 
hospital-based 
study, Thailand 
 
250 yes 62.58+10.41 77.6 % of mild cognitive 
impairment (MCI) 
 
MoCA  test (cut-off < 
26) 
-No report of Confidence Interval 
(CI) with the prevalence 
- No information of data collection 
method, i.e. no. of interviewer and 
process 
- No report of reliability and validity 
of the validated test 
Alencar  et al., 
(2010), Diabetic 
outpatient clinic, 
hospital-based 
study, Brazil 
 
 
346 unknown 58.6+ 12.1 12.1% 
 
MMSE screening test 
with two-level cut-off 
score 
1. cut-off < 26 for 
subjects with years of 
study  more than 8 years 
2.cut-off < 18 for 
subjects with years of 
study between 1 and 8 
years 
- No report of CI  
- No information of data collection 
method i.e. no. of interviewer and 
process 
- Exclude the illiterate participants 
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B) Prevalence studies of depressive mood in type 2 diabetes 
 
Eleven papers were included in the review (Table 2.2). Five studies were 
conducted in a hospital-based setting and six studies were carried out in a 
community-based setting. The prevalence rate of depressive mood in the cross-
sectional studies varies from 13.17 % to 33.4 %. The estimation of depression rate 
varied probably due to the difference of sample size, age range and depressive 
mood screening test in each study. 
 
Three of these studies show that females are more likely to have depressive mood 
than males (Bruce et al. 2003, Pibernik-Okanovic et al. 2004, Sotiropoulous et al. 
2008). Among these three studies, depressive mood is found to be related to gender 
in different subjects. For example, Bruce et al. (2003) found that females not only 
had depression, but also were more distressed than males.  Pibernik-Okanovic et 
al. (2004) revealed that apart from gender (female), there were some psychological 
problems that could predict depression, such as unsatisfaction with social support 
or the existence of psychological problems in the past. In addition, the study from 
Sotiropoulous et al. (2008) found that depressive symptoms in women with 
diabetes were correlated with HbA1c and duration of diabetes, whereas there was 
no correlation between depressive symptoms and other testing variables in men.   
Medical variables such as cholesterol, triglyceride and high-density lipoprotein 
(HDL) were found to have a relationship with depressive moods (Gary et al. 2000, 
Tsai et al. 2008). Other factors such as age (Bruce et al. 2003) and insulin injection 
as diabetes treatment (Tsai et al. 2008) were also correlated with depressive 
symptoms. Overall, some limitations were found in these studies that can be 
summarised as follows: 
 
1) Missing 95% confidence interval (CI) 
Apart from Zahid et al.’s (2007) study, most of the previous studies do not 
report the 95% CI with the prevalence rate. Due to the varied sample size in 
prevalence studies, 95% CI is used to describe the results of the prevalence 
ratein which the actual estimation value is likely to fall. Thus, the report of 
95% CI is crucial and represents the precision of an estimate (du Prel et al. 
2004).  
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2) Drawback of self-report questionnaire 
Recall bias and missing information are the drawbacks of self-report 
questionnaire screening tests. Screening test by self-report has limitation on 
recall bias. This can be found in the studies of Bruce et al. (2003) and 
Thaneerat et al. (2009). The possibility of a high number of missing 
information in the large sample study can be found in Net et al. (2012). 
 
3) Uncertain cultural validity of the questionnaire test 
Two studies used depressive mood-screening test in its English version 
regardless of the validated study (Zahid et al. 2017, Thaneerat et al. 2009). 
They reported the reliability and validity of the test in a non-English 
speaking population. Lack of precise translation of the research instruments 
may affect the generalisation of the results from the culture of origin. 
Likewise, the applicability of instruments from the original to the target 
version in different cultures and languages may be adversely affected if 
translation procedures are not validated (Su and Parham 2002). In addition, 
beyond the validated translation, the reliability and validity study of the 
instruments are important to ensure that the results of measurement are 
reliable in the target population (Kestenbaum 2009).  
 
4) Generalisation of findings 
There is a limitation in applying the results to the local populations in two 
of the above-mentioned studies. In the study of Nef et al. (2012) 97% of the 
sample was in one ethnic population, and the study of Gray et al. (2000) 
focused only on a group of African-Americans.  
 
5) Study setting 
The range of prevalence rate in a hospital setting is wider than the 
prevalence rate in a community setting (14-33% vs. 14-26%). Compared 
with the community setting, the prevalence studies in the hospital setting 
tend to focus on the association between other clinical variables such as 
glycaemic control (HbA1c) or cholesterol level and depressive mood, 
rather than the psychological problems.  
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Table 2.2: Summary of the studies on the prevalence of depressive mood in type 2 diabetes 
Study and setting 
 
 
Sample 
size  
Probability 
sampling  
Mean Age 
/Age range 
Prevalence 
(95% CI) 
Measures 
 
Comments 
Gary et al. (2000), 
Primary care Unit, the 
US.  
186 Random  
sample 
59+9 
(35-75) 
30% Center for 
Epidemiological 
Studies Depression 
Scale (CES-D) 
Cut-off score ≥ 22 
 
Structure interview 
1.No report of Confidence Interval (CI) 
with the prevalence 
2. Depression correlated with higher serum 
of cholesterol and triglyceride (p<0.05) and 
higher serum of HDL (p =0.047). 
3. The study may not represent other 
diabetic populations since it focused only 
on a group of African-Americans. 
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Table 2.2: Summary of the studies on the prevalence of depressive mood in type 2 diabetes  (continued) 
Study and setting 
 
 
Sample 
size  
Probability 
sampling  
Mean Age 
/Age range 
Prevalence 
(95% CI) 
Measures 
 
Comments 
Pibernik-Okanovic et 
al. (2001), Hospital-
based study, Croatia 
384 Random 
sample  
57+7.8 
 
22% 
(depressive 
mood by 
CES-D 
screening) 
33% (clinical 
depression) 
two-phase 
1.Screen depression: 
Center for 
Epidemiological 
Studies Depression 
Scale (CES-D) 
Cut-off score ≥ 16 
2. Structure clinical 
interview for DSM-IV 
Axis I Disorder (SCID) 
to identify clinical 
depression  
 
1.No report of Confidence Interval (CI) 
with the prevalence 
2. This study focused on psychological 
problems rather than disease -related 
variables. 
3. Gender, experienced social support, and 
variables indicating emotional well-being 
(limitations due to emotional health, mental 
health and psychological wellbeing) were 
shown to be independent predictors of 
depression (standardized B coefficients 
were 1,78; 2,18; -0.08; -0,10 and -0,47, 
respectively). 
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Table 2.2: Summary of the studies on the prevalence of depressive mood in type 2 diabetes  (continued) 
Study and setting 
 
 
Sample 
size  
Probability 
sampling  
Mean Age 
/Age range 
Prevalence 
(95% CI) 
Measures 
 
Comments 
Bruce (2003), 
Fremantle Diabetes 
Study (FDS), 
community- based 
study, Australia  
 
223 No 76.5 +4.3 14.2% 
 
Even Briefer 
Assessment Scale for 
depression (EBAS-
DEP)  
Cut-off score of 4 or 
more out of 8 (contains 
sensitivity and 
specificity more than 
80% )for clinically 
significant depression 
in community) 
Self-report 
1. No report of Confidence Interval (CI) 
with the prevalence 
2. Convenience sampling 
3. Depression was not associated with age 
(Spearman’s rho = 0.05, p=0.43). 
4. Women were significantly more likely to 
have depression than men (43.5% vs. 27%, 
p =0.011and worry (54.6 vs. 39.6%, 
p=0.026). 
 
Munshi (2006). 
Tertiary care specialty 
clinic, USA. 
60 No  79 + 5  33% Short (15-item) 
Geriatric Depression 
Scale (GDS)  
Cut-off score ≥ 5 
Interview 
1. No report of Confidence Interval (CI) 
with the prevalence 
2. Small sample size 
3. Convenience sampling 
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Table 2.2: Summary of the studies on the prevalence of depressive mood in type 2 diabetes (continued) 
Study and setting 
 
 
Sample 
size  
Probability 
sampling  
Mean Age 
/Age range 
Prevalence (95% 
CI) 
Measures 
 
Comments 
Zahid et al. (2007), 
rural community, 
Pakistan   
1290 Cluster 
sampling 44 
village  
44 14.7%  
(6.6%-22.8%) 
Montgomery-Asberg 
Depression Rating 
Scale (MADRS)  
Cut-off score ≥ 13 
 
1.Direct translation of the original English 
version of MADRS to Urdu for interview 
2. No report of  reliability or validity of 
the Urdu version 
3.No report of the validated study of Urdu 
version 
Sotiropoulos et al. 
(2008), Hospital based 
study, Greek  
320 Unknown  35-70 33.4 % 21-item Beck 
Depression Inventory 
(BDI) modified for 
diabetic patients 
Cut-off score ≥ 19  
 
1.No report of Confidence Interval (CI) 
with the prevalence 
2. Women were significantly more likely 
to have depression than men (48.4% vs. 
12.7%, p < 0.001). 
3. In women, depressive symptoms were 
correlated with HbA1c (p=04) and 
diabetes duration (p=0.004). 
4.No correlation between depressive 
symptoms and testing variables in men 
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Table 2.2: Summary of the studies on the prevalence of depressive mood in type 2 diabetes (continued) 
Study and setting 
 
 
Sample 
size  
Probability 
sampling  
Mean Age 
/Age range 
Prevalence 
(95% CI) 
Measures 
 
Comments 
Tsai et al. (2008) 
Hospital-based study, 
Taiwan, China  
167 Unknown  60.2+11.0 13.17%  Beck Depression 
Inventory II (BDI-2) in 
Chinese version  
Cut-off score BDI ≥ 17 
Self-report and 
interview for illiterate 
participants 
 
1.No report of Confidence Interval (CI) 
with the prevalence 
2.Excluding known cases of depression 
3. Depression is correlated with insulin 
injection and total cholesterol level 
compared to non-depressed patients 
 
Shehatah et al. (2009), 
Primary care setting, 
Saudi Arabia  
458 Unknown  65+8.9  17.5% Beck Depression 
Inventory II (BDI-2) 
but  
Cut-off score BDI ≥ 14 
Self-report 
1.No report of Confidence Interval (CI) 
with the prevalence 
2. State language version was not used in 
BDI-2  
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Table 2.2: Summary of the studies on the prevalence of depressive mood in type 2 diabetes (continued) 
Study and setting 
 
 
Sample 
size  
Probability 
sampling  
Mean Age 
/Age range 
Prevalence 
(95% CI) 
Measures 
 
Comments 
Thaneerat et al. 
(2009), diabetic 
outpatient clinic, 
hospital-based study, 
Thailand 
 
250 yes 62.5+10.4 28%  
 
Thai-Hospital Anxiety 
Depression Scale 
(Thai-HADS)  
 cut-off score ≥ 8 
Self-report 
-No report of Confidence Interval (CI) with 
the prevalence 
 
 
Nef et al. (2012), 
Primary care, 
Netherland  
2,460 Follow up  67+11  26% Edinburgh Depression 
Scale  
Cut-off score ≥ 12 
Self-report 
1.No report of Confidence Interval (CI) 
with the prevalence 
2. Strength: a large sample of primary care 
patients with type 2 diabetes  
3. Weakness:27% missing data in 
demographic, clinical and psychological 
data 
4. Not representing other diabetic 
populations since 97% of the cases were 
white in the study 
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2.2 Contribution of other factors on cognitive impairment in type 2 diabetes  
 
Normally, type 2 diabetes does not exist in isolation. Other important factors that 
can affect cognition could take place in older diabetic patients leading to cognitive 
impairment (Asimakopoulou and Hampson 2002). Some factors that are likely to 
confound in the study of diabetes-related cognitive impairment are briefly 
discussed below. 
 
Age  
Cognitive impairment is often seen with the increasing age (Biessels et al. 2006). 
However, age does not seem to affect all the areas of cognition in elders in the 
same way (Asimakopoulou and Hampson, 2002). Ryan and Geckle (2000) state 
that older people with type 2 diabetes are more likely to be prone to diabetes-
associated memory and learning difficulties than impairment in other areas of 
cognition. Ageing is also associated with changes in the brain. This change can be 
clearly seen in patients with Alzheimer’s disease (AD) which show a decrease of 
glucose utilisation and deficient energy metabolism occur in the early of disease. 
This suggests for a role impaired insulin signaling pathogenesis of AD (Steen et al. 
2005). Thus, the insulin receptor impaired in the brain due to ageing is also one of 
the causes of cognitive impairment.  
 
Duration of diabetes 
Longer duration of diabetes is associated with increased cognitive impairment 
(Cosway et al. 2001). In particular, longer duration of poor glycaemic control may 
lead to permanent cognitive impairment (Awad et al. 2004). Duration of diabetes 
may cause the development of vascular disease when combined with high blood 
glucose in body (Grodstein et al. 2001). 
 
Obesity 
Obesity or high BMI is associated with worse cognition (Berg et al. 2009), 
particularly in the cognitive flexibility and memory. BMI was included as a 
covariate in blood pressure and blood cholesterol level in Gustafson et al.’s (2003) 
study. There are many possibilities that BMI may link to cognitive decline in type 
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2 diabetes. A high BMI may lead to high blood pressure, and thus increase the risk 
of dementia (Zhang and Reisin, 2000). High blood cholesterol may also cause 
vascular risk factor and play a role in the etiology of AD (Skoog et al. 1996). 
 
Diabetic complications 
A diabetes complication in microvascular lead to renal failure, foot ulcer and 
vision loss (Nathan 1993). There is growing evidence that diabetes is associated 
with an increased risk of cognitive decline, physical disability and other conditions 
associated with geriatric syndrome (Strachan et al. 2003). These complications 
have an impact on the quality of life, loss of independence and may be of greater 
direct concern in older people with diabetes (Gregg et al. 2003). Diabetic 
complications may lead to chronic hyperglycaemia or long-term blood glucose and 
may also influence cerebral blood flow and neurotransmitter function, or nutrient 
to the brain (Strachan et al. 1997).  
 
Diabetic treatment  
Lack of diabetic pharmacological treatment seems to be associated with a worse 
performance of cognitive function in the older people with type 2 diabetes 
(Grostein et al. 2001). The study of Grodstein et al. (2001) suggest that women 
who receive treatment (oral medication) perform better on the cognitive measures 
than the diabetic women who are reported to receive no medication. Diabetes 
medications can help control type 2 diabetes by increasing insulin sensitivity and 
decreasing glucose output. Consistent use of diabetes medications also helps to 
control blood glucose level and keep oxygen and nutrient reach brain cells 
(Cukierman-Yaffe et al. 2009).  
 
Advanced glycation end products (AGEs) 
Advanced glycation end products (AGEs) are a heterogeneous group of modified 
proteins, lipids, and nucleic acids implicated in the aging process and diabetes 
(Rambhade et al. 2011).The modifications of proteins or lipids are the result of a 
chain of chemical reactions which follow an initial glycation reaction. Initial 
glycation involves covalent reactions between free amino groups of amino acids, 
such as lysine, arginine, and sugars (e.g. glucose, fructose and ribose), to create the 
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Schiff base and then Amadori products, of which the best known are fructosamine 
(FAM) and glycated haemoglobin (HbA1c) (Marchetti 2009).   
 
A high level of blood glucose (hyperglycaemia) is known to enhance the forming 
of early FAM and HbA1c, intermediate and advanced glycation products. These 
glycation products are a primary factor that initiates and promotes diabetic 
complications (Hanssen 1997).  FAM fraction reacts much more quickly than the 
HbA1c to a change in glucose situation and reflects a quality of diabetes control 
over the short period of 2-3 weeks, while the degree of glycation of haemoglobin 
provides information about the glucose level over the last 6-8 weeks (Gugliucci 
2000, Kostolanska et al. 2009). 
 
It has long been recognized that increased HbA1c (a precursor of AGEs) levels are 
associated with a higher incidence of vascular complications in diabetic patients 
(Marchetti 2009). Hence, hyperglycaemia or increased HA1c (a precursor of 
AGEs) will induce the formation of AGEs, which acts as an important 
pathophysiological mechanism in the development of diabetic complications 
through binding and interaction with their receptors (RAGE). RAGE is expressed 
in many tissues such as heart, lung, skeletal muscle, and vessel wall (Huijberts et 
al. 2008). The binding and interaction could then lead to an oxidative stress and 
activation of inflammatory pathways causing proatherosclerotic changes and 
inducing vessel damage (Leslie and Cohen 2009) 
 
More importantly, hyperglycaemia (increased HbA1c) could cause cognitive 
impairment by several mechanisms. Acute changes in blood glucose are known to 
alter regional cerebral blood flow and could also cause osmotic changes in cerebral 
neurons. These same mechanisms may be operative in the brain and induce the 
changes in cognitive function that have been detected in diabetic patients 
(Vijayakumar et al. 2012). Moreover, AGEs are protein modifications that 
contribute to the formation of the histopathological and biochemical hallmarks of 
Alzheimer’s disease (AD), i.e. amyloid plaques, neurofibrillary tangles and 
activated microglia in a brain (Stitt 2001). 
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AGEs may involve cognitive decline in type 2 diabetic patients from the glycation 
processes through hyperglycaemia or an increased HbA1c (precursor of AGEs). 
Therefore, reduction of blood glucose levels in diabetes, as documented by 
decreased HbA1c, remains the most appropriate way to reduce vascular 
complications in diabetic patients (Marchetti 2009). 
 
Glycaemic control 
Glycaemic control is associated with cognitive function in type 2 diabetes. In 
particular, chronic glucose level appears to be associated with cognitive 
impairment in type 2 diabetes (Cukierman-Yaffe et al. 2009, Grober et al. 2011, 
Mahakaeo et al. 2011). The level of glycaemic control (HbA1c) shows the 
association between the two cognitive domains (memory and executive function). 
HbA1c is defined in the two levels of controlled (HbA1c ≤ 7 or 53 mmol/mol) and 
inadequately controlled (HbA1c > 7 or 53 mmol/mol) (American Diabetes 
Association 2009, Grober et al. 2011). Memory impairment and executive 
dysfunction are associated with inadequately controlled diabetes in old adults with 
type 2 diabetes (Grober et al. 2011). Uncontrolled glycaemia can lead to 
hyperglycaemia and cause slowly progressive pathogenesis of brain abnormalities 
that may eventually induce Alzheimer’s disease (AD) (See Chapter 1, Section 
1.2.1). Therefore, chronic hyperglycaemia could be one of the determinants of 
cognitive changes in people with diabetes (Stewart and Liolitsa 1999).  
 
Cardiovascular problems 
Type 2 diabetes is a risk factor for vascular diseases such as hypertension. An 
interaction between type 2 diabetes and hypertension on cognitive performance is 
associated with a greater risk of poor performance on a test of memory and 
attention (Gregg et al. 2000). Hypertension may cause changes in vessel walls 
leading to ischemia or hypoxia of the brain, all of which are related to the 
development of AD pathology (Beeri et al. 2009). 
 
Inflammation 
 
Inflammation may also contribute to cognitive impairment associated with type 2 
diabetes. There is a link between inflammation and diabetes. For example, 
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hyperglycaemia is associated with an increase in proinflammatory cytokines and 
other peripheral markers of inflammation (Stentz et al. 2004). Inflammation is also 
associated with an impaired glucose regulation and predicts the development of 
diabetes (Barzilay et al. 2001). A high level of the inflammatory marker of C-
reactive protein (CRP) and interleukin-6 (IL-6) is not only associated with an 
increased risk of developing type 2 diabetes (Pradhan et al. 2007) but also 
accelerated cognitive decline in healthy older adults (Engelhart et al. 2004) and in 
older adults with metabolic syndrome (Yaffe et al. 2004). Moreover, decreasing 
brain levels of proinflammatory cytokines can reverse memory deficits (Balschun 
et al. 2004, Gemma et al. 2005)   
 
Depression 
Depression may also contribute to cognitive impairment in older people with type 
2 diabetes because it is independently associated with poor cognitive function 
(Solanki 2009). A successful treatment of depression is associated with 
improvements in glycaemic control by increasing adherence with treatment 
(Anderson et al. 2001). Depression may also be associated with hippocampal 
atrophy caused by elevated glucocorticiod secretions, resulting in memory 
impairment and dementia in later life (Awad et al. 2004). Depression might also 
play an important role in the maintenance of optimal glycaemic control in 
supporting the treatment adherence.  
 
2.3 Summary  
 
Although the findings of the previous studies on prevalence can be used to guide 
this study, they are limited in terms of the differences in screening tools, method of 
administering and sample. There is no consensus on the measurement of cognitive 
impairment and depressive mood in type 2 diabetes. The differences in study tools 
depend on the purpose of the study and the group of subjects. This review provided 
the range of prevalence rate of cognitive impairment and depressive mood in the 
published papers in many regions.  
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The factors related to cognitive impairment in type 2 diabetes suggest that there are 
many factors related to cognitive impairment. Thus, in general, the study of 
cognitive impairment in type 2 diabetes contains a variety of factors 
(Asimakopoulou and Hampson 2002). It seems that none of these studies have 
been specially developed to address the cognitive process in older patients with 
type 2 diabetes.  
 
In Thailand, there seems to be only one study on mild cognitive impairment and 
depressive mood in hospital setting. However, this study focuses on depression 
more than cognitive function. Moreover, although the study was conducted in a 
hospital setting in the capital city where patients tend to be highly motivated, 
educated and have excellent support system, there were still a certain number of 
the older people with diabetes who were undiagnosed with depression and mild 
cognitive impairment. These unrecognized conditions might affect the ability to 
perform self-management in diabetes patients in the long-term care. In order to 
perceive diabetes knowledge to perform in a long-term care, cognition of diabetic 
patients is crucial and needed to process diabetic self-care management. 
 
Bearing in mind that uncontrolled diabetes is frequently found in community level 
and rural areas (Nitayanat, et al. 2007), no study on cognitive impairment and 
depressive mood in the older people with type 2 diabetes in community setting has 
been conducted. Considering that undiagnosed dementia is high in primary care 
settings in Thailand (Jitapunkul et al. 2009), there is a significant gap that requires 
further study in the prevalence rate to estimate the magnitude of these conditions in 
Thai older people in community level.  
In order to support routine cognitive screening and promote the detection of 
cognitive impairment in primary care setting, the screening test should be efficient, 
specific and practical to be used in primary care settings. The significance of the 
study and screening test could help primary care staff to be aware of the early signs 
of cognitive impairment in the older people with type 2 diabetes and provide an 
appropriate care program. In the next chapter, an overview of cognitive screening 
tests in Thailand including the choice and rationale for the screening tests used in 
this study will be presented.  
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Chapter 3 
Cognitive screening tests in Thailand and choice of the 
screening tests 
 
 
In Chapter 2, a review of the previous prevalence studies and factor-related 
cognitive impairment and depressive mood was provided. To achieve the 
prevalence rate in this study, a review of the cognitive and depressive mood 
screening tests that used in Thailand are needed in order to select the screening 
tools or instruments in the current study. This chapter provides this information in 
two parts. The first part presents an overview of the commonly used cognitive 
screening tests in Thailand. The second part provides the rationale for the selection 
of cognitive and depressive mood screening tests in this study. 
 
3.1 Cognitive screening tests in Thailand 
 
In order to find the cognitive and depressive mood screening tests used in Thai 
older people either in clinical practice or literature, a manual search was conducted 
to locate Thai journals or literatures in the following databases: Journal of the 
Medical Association of Thailand, Siriraj Medical Journal, Thai Library Integrated 
System database and Mental Health Project database, the Ministry of Public 
Health, Thailand. It should be noted that this search was gathered before June 
2009, prior to the development of this research protocol.  
Five cognitive screening tests were found which were commonly used in Thai 
older people. A summary of the details including the advantages and disadvantages 
of all the tests are presented in Table 3.1.    
3.1.1 Mini Mental State Examination (MMSE) Thai 2002 
Mini Mental State Examination (MMSE) Thai 2002 is a current clinical mainstay 
cognitive screening instrument in Thailand (Prasat Neurological Institute 2008) 
(see Appendix D2). It has been used to detect cognitive impairment to follow the 
course of an illness and to monitor response to treatment (Ageingthai 2008). The 
MMSE Thai 2002 is translated from the original English version of MMSE 
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(Folstein et al. 1975). This is an 11 item test with a total score of 0 (severe 
impairment) to 30 (no impairment). These 11 items are grouped into seven 
categories: orientation to time, orientation to place, registration of three words, 
attention and calculation, recall of three words, language and visual construction.  
It has been assessed in four regions of Thailand and includes specific questions 
related to attention, orientation, memory, calculation, and language.  
Since MMSE is created in a developed country, where education level is high with 
a standard cut-off score of MMSE (English version) 24, a score of 23 or below is 
at risk of cognitive impairment. The standard cut-off score may therefore produce 
false-positive results when used in developing countries, where the rate of low-
educated population is high (Salmon and Lange 2001). In order to minimize the 
problem of score results when using MMSE in developing countries, it was 
suggested to adjust the cut-off score according to education levels in developing 
countries (Liu et al. 1994, Caldas et al. 2011). Thus, the MMSE Thai 2002was 
assessed in four regions of Thailand in order to find the suitable cut-off scores for 
Thai people. It includes specific questions related to attention, orientation, 
memory, calculation and language. The results show an appropriate measure’s 
scoring for Thai older people based on 30 total scores as the following: a cut-off 
score of 14 is used for an uneducated person (illiteracy) (sensitivity = 0.35, 
specificity = 0.81), a cut-off score of 17 is used for those who attended primary 
school (sensitivity = 0.57, specificity = 0.94) and a cut-off score of 22 for those 
who attended secondary school or higher education (sensitivity = 0.92, specificity 
= 0.93) (Ageingthai 2008). The limitation of MMSE Thai 2002 is its low 
sensitivity in the group with a low level of education (Wongchaisuwan et al. 2005).  
MMSE is the most commonly used cognitive screening test but it is not sensitive to 
detect the early sign of cognitive impairment or mild cognitive impairment (MCI) 
(Nasreddine et al. 2005, Nazem et al. 2009, Aggarwal and Kean 2010). In addition, 
MMSE does not have any tasks to assess executive functions like tests of the 
capacity to abstract. These intellectual abilities have been found to be altered in the 
early stage of Alzheimer’s disease (Munshi et al. 2006, Hatfield et al. 2009).  
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Although several studies including the study in Thailand found the limitation of 
MMSE in the very old and those with limited education (Lorentz et al. 2002, 
Shulman and Feinstein 2003, Nys et al. 2005, Wongchaisuwan et al. 2005), it is 
most often used as a known reference standard against which other cognitive 
screening tests are compared (Clark et al. 1999, Cullen et al. 2007). Moreover, 
MMSE is a tool for cognitive screening used worldwide for global evaluation and 
has the major advantage of being very widely understood (Simard 1998). 
3.1.2 Thai Mental Sate Examination (TMSE) 
Thai Mental Sate Examination (TMSE) (Thai Train the Brain Forum committee 
1993) was modified from MMSE as the standard mental status examination for 
Thai subjects. TMSE contains the six items of orientation (6 scores), registration (3 
scores), attention (5 scores), calculation (3 scores), language (10 scores) and recall 
words (3 scores). The test was applied to 180 normal Thai older people, aged 60-
70 throughout the country.  The measure’s scoring is based on 30 total scores. The 
mean total score of TMSE is 27.38 + Standard deviation (SD) 2.02 and a cut-off 
score less than 23 is used for a cognitive impairment. The estimated time for 
applying the test is approximately 10 minutes. Although, the content validity is the 
strength of this test, the study of reliability or diagnosis of the test (sensitivity and 
specificity) could not be found in the literature search. Thus, the absence of 
diagnostic test information is the major weakness of the test. In addition, this test is 
limited to use only in the literate group.  
3.1.3 Chula-test 
Chula-test was modified from TMSE (Jitapunkul 1996). It contains 13 items that 
cover the areas of cognition, memory, orientation, perception, abstract thinking, 
judgment attention, language, and recall part. The test was applied to 212 older 
people in an older people home care in the capital city of Thailand. The total 
summation of scores was 19. The test score less than 15 (cut-off scores) indicated 
cognitive impairment with high sensitivity (74%) and specificity (86%). The 
estimated time for applying the test has not been reported. The limitation of the test 
is that this study was applied to the older people living in a care home. This cannot 
be a representative of general Thai older population. In addition, the test was 
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developed from TMSE which did not show basic evidences of psychometric 
property such as reliability and validity of the tool. 
3.1.4 Clock drawing test-Chula (CDT-Chula) 
CDT-Chula (Jitapunkul 2000) is a modified version of Clock drawing test (CDT) 
developed by Goodglass and Kaplan (1982). CDT is used to measure the executive 
function of the brain (Woodford 2007). A testee is asked to draw a clock on a 
preprinted 12-centimeter circle showing the time of 11.10. CDT-Chula uses the 
same assessment method as the original version except the scoring method. The 
CDT-Chula is scored using Chula Clock-drawing Scoring System (CCSS) 
developed and validated in 669 Thai older people in one community at the capital 
city. The CCSS is a quantitative systematic scoring system. It considers 5 domains 
consisting of number of digits, errors in number in the worst quadrant, spatial 
arrangement and number sequencing, hand and placement of hands 
(Kanchnatawan et al. 2006). The cut-off score is 7 (less than 7 means abnormal) 
and has the sensitivity and specificity of  88% and 74%, respectively. The 
estimated time for applying the test has not been reported. Although the test 
contains a good sensitivity and specificity, the limitation is that the testee must be 
illiterate. In addition, in order to score CDT test correctly, training is needed 
because there are 15 scoring criteria to score the drawing of CDT.  
3.1.5 Informant Questionnaire for Cognitive Decline in the Elderly (IQCODE) 
Thai version  
IQCODE Thai version (Sukhontha et al. 2006) is developed and modified from the 
original English version of the IQCODE by Jorm et al. (1989).  The IQCODE 
assesses cognitive decline over time, based on ratings of everyday cognitive 
abilities. Informants are asked about the subject’s change in capabilities in relation 
to performance 10 years ago, rating the changes on a 5-point scale (1 = much 
better, 3 = little change, 5 = much worse). The original 26-item version of 
IQCODE was translated into Thai and certified by a professional translator. In 
addition, six more items were added to the modified IQCODE in the Thai version; 
three of these items assessed cognitive functions, and three of them assessed daily 
life activities. The test was studied in 200 pairs of older people subjects and their 
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informants who visited a Geriatric Clinic in Bangkok, the capital city.  The optimal 
cut-off score on the modified IQCODE Thai version was 3.42, with 90% 
sensitivity and 95% specificity. However, the estimated time for applying the test 
has not been reported.  Although this test has a higher sensitivity and specificity, it 
needs an informant or proximal who can provide reliable information and should 
have known the older people for at least 10 years in order to report changes of the 
older people over the last 10 years (Jorm et al. 1989). 
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Table 3.1 Summary of the cognitive screening tools used in Thailand with some advantages and disadvantages 
 
Screening test Description Estimated time to 
complete the test 
 
Advantage Disadvantage 
MMSE Thai 2002 
(Agingthai 2008)  
11-item test with a total score of 0 
(severe impairment) to 30 (no 
impairment).  
 
 
 
10-20 minutes  
 
Main instrument for test 
cognitive screening in 
Thailand  and worldwide  
 
Cut-off score is adjusted 
and suitable for Thai 
population 
 
sensitivity and specificity 
compared to diagnosis by 
a health professional  
-Influenced by education, 
and age (Wongchaisuwan et 
al.2005) 
 
-Low sensitivity in low 
education levels 
 
-Lack of sensitivity to the 
early sign of cognitive 
impairment  or mild 
cognitive impairment  
(MCI) 
 
 
TMSE 
(Thai Train the Brain 
Forum committee 
1993) 
6-item test with a total score of 0-
30   
 
10-minutes Content validity by Thai 
experts  
-No information of 
psychometric property  
 
-Testee must be literate  
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Table 3.1 Summary of cognitive screening tools used in Thailand with some advantages and disadvantages (continued) 
 
Screening test Description Estimated time to 
complete the test 
 
Advantage Disadvantage 
Chula test 
(Jitapunkul 1996) 
13- items test with a total 19 scores  
 
No report sensitivity and specificity 
compared to diagnosis by 
a health professional  
-The study was conducted in 
a specific group of Thai 
older people in a care home  
 
-Developed from TGDS 
which does not provide an 
evidence of psychometric 
property  
 
CDT - Chula test 
(Jitapunkul 2000) 
draw a clock on preprinted 12 
centimeters circle showing time of 
11.10 
 
No report  sensitivity and specificity 
compared to diagnosis by 
a health professional 
 
-Needs training for 
interpretation and scoring  
of clock drawing  
 
 
IQCODE Thai 
version  
(Sukhontha et al. 
2006)  
Asking information about the 
subject’s change in capabilities in 
relation to performance 10 years 
ago 
 
No report sensitivity and specificity 
compared to diagnosis by 
a health professional  
-Needs an informant who 
has known the tester very 
well for at least 10 years 
 
-The relationship between 
the informant and testee 
may affect the score results  
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3.2 Limitations of using existing screening tools in primary care settings 
A number of conclusions can be drawn with regard to the existing measures used 
for cognitive screening in Thailand. The obstacles and the practical time of using 
cognitive screening tests in primary care setting were mentioned in Section 3.1.The 
following limitations of the existing cognitive screening tests are mainly based on 
the feasibility and validation of using the tests in primary care settings, the study 
area in this research.  
Based on the review of cognitive screening commonly used in Thailand, the 
screening tests can be divided in two types: the test is given to the patient (MMSE 
Thai 2002, TMSE, Chula test and CDT Chula test) or the test is given to the 
informant or carer who can provide reliable information about the patient 
(IQCODE). The MMSE Thai 2002 is the main clinical screening test that has been 
use in hospital (Ageingthai 2008). Since the test remains the most familiar and 
widely used cognitive screening test worldwide, it is also used as the reference 
standard with other cognitive tests for research purposes (Silpakit et al. 2007). 
 
The main limitation of the MMSE Thai 2002 is the impracticality of its 
administration time in Thai primary care setting, low sensitivity of the test in low 
education level and lack of sensitivity to detect early sign of cognitive impairment. 
Nevertheless, the MMSE Thai 2002 is still a main clinical screening test that is 
used in Thai hospitals (Ageingthai 2008). TMSE is the most restricted test to be 
used in primary care settings not only because of the length of administration time 
but also because of lacking the validation study of the test. The length of time to 
administer the Chula-test, CDT-Chula test and IQCODE in Thai population is not 
clear. These three tests have varied limitations and biases to be used in primary 
care settings. The Chula-test may be susceptible to the older people in home care. 
The CDT-Chula is complicated on the scoring of the clock drawing test and 
training is needed before using it. The IQCODE is impractical for routine use at 
primary care settings because the test results depend on the informant who knows 
the subject very well and because not all older patients access informants.  
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It is clear from the review that none of the screening tests were considered to be 
used in the current study due to the major limitation of administration time as a 
routine screening test in Thai primary care settings.  Therefore, the current study 
aims to find and use a cognitive screening test which is specific to and validated in 
primary care settings in order to overcome the limitations of the existing screening 
tests.  
3.3 Choice of screening tests in the current study 
3.3.1 Cognitive screening tests 
3.3.1.1 Cognitive screening tests which specific for primary care setting  
 
There have recently been few tests that are recommended to be used in primary 
care settings. Based on a systematic review of short cognitive screening for 
primary care setting, the following three tests are the most valid and best suited in 
primary care applications (Woodford and George 2007): the General Practitioner 
Assessment of Cognition (GPCOG) (Brodaty et al. 2002), the Memory Impairment 
Screen (MIS) (Buschke et al. 1999) and the Mini-Cog (Borson et al. 2000). In 
addition, another survey study of cognitive screening used in primary care setting 
show that these three tests are recommended for clinical practice by the general 
practitioner (GP) in primary care settings (Milne et al. 2008). The Mini-Cog, MIS, 
and GPCOG are identified as relevant to primary care setting and are 
recommended for use due to the brevity and validity of the tests (Ismail et al. 2010)  
 
GPCOG has been designed for primary care settings with a six-item patients test 
and a six-item informant interview. The length of time to use the test is 
approximately 4.5 minutes with the sensitivity of 85% and specificity of 86%. 
Although GPCOG is suitable to use in primary care settings, this test needs 
informants which may not be practical in the routine use.  
 
MIS is a test of memorisation task that requires the testee to read and remember 
items in response to its category i.e. city, animal, musical instrument and 
vegetable. The sensitivity and specificity are 80 and 96 %, respectively. The length 
of time to complete the test is around 4 minutes. This test is limited to literate 
subjects. Therefore, it may not be practical to use in Thai rural area.  
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Mini-Cog consists of a simple memory test (3-item recall) and an executive 
function test (clock drawing test-CDT) (see appendix D1). The test has a 
sensitivity of 99% and a specificity of 96%. The length of time to administer the 
test is approximately 2-4 minutes with a simple scoring system of CDT. The 
concordance for rating the test result between the expert and naïve is high at 96% 
(Scanlan and Borson 2001). 
 
Based on the information of the three cognitive screening tests validated in primary 
care settings, GPCOG contains a good psychometric property. But this test needs 
informants and this may not be practical in routine use. MIS is limited to literate 
subjects, since it requires reading ability. Compared to the other two tests,       
Mini-Cog is less affected by education and is directly tested on the patients.  
Considering the length of time to administer, Mini-Cog is suitable to apply in Thai 
primary care settings compared to GPCOG and MIS. Since the duration of time to 
visit primary care settings in Thailand varies between 3 to 5 minutes, Mini-Cog, 
which can be used in approximately 2-4 minutes is appropriate.  The overall 
information of the three tests shows that Mini-Cog has a balance between 
minimum administration time and maximum performance which makes it the most 
suitable tool to apply in primary care settings. Thus, Mini-Cog is selected as a 
cognitive screening test in the current study. 
3.3.1.2 Mini-Cog  
Mini-Cog (Borson et al. 2000) was originally developed in an ethnolinguistically 
diverse American sample, to screen dementia in primary care settings. It is 
composed of a memory test (recall of 3 unrelated words) and a very simple free-
hand version of the clock drawing test (CDT) included as a distractor for the 
memory task. Mini-Cog can be administered in an average of 3.2 minutes and 
contains a high sensitivity (99%) and specificity (96%) in a community sample of 
249 ethnolinguistically diverse older people, one-half of whom had dementia and 
one-half of whom were cognitively intact (Borson et al. 2000). In a community-
based study with a low level of educated participants and non-English speaking 
groups it has proved to be superior to MMSE in identifying dementia. Mini-Cog’s 
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sensitivity of 76% and specificity of 89% contrasts MMSE’s sensitivity of 79% 
and specificity of 88% (Borson et al. 2003).  
 
Unlike MMSE, Mini-Cog is not affected by education and language (Borson et al. 
2000). Moreover, in a multiethnic sample, Mini-Cog detects most of the subjects 
with a mild cognitive impairment as well as subjects with a moderate and severe 
cognitive impairment, many of whom were not recognized by their physicians 
(Borson et al. 2006).   
 
Mini-Cog is new and has not been validated in Thai population. In order to 
propose Mini-Cog as a new cognitive screening tool, the test should be compared 
with a known reference standard on the same population, such as MMSE, the most 
clinical cognitive screening test in Thailand (Deeks 2001, Lorentz  2002). 
3.3.2 Depressive mood screening test 
 
Thai Geriatric Screening Test (TGDS) is the only test that has been validated 
among Thai older people (Laing et al. 2009). The original version of GDS is a 
validated mood assessment tool for use among older people with dementia 
(O’Riordan et al. 1990).This test is also one of the most widely used measures of 
depression in older people (Nouwen and Oyebode 2009). Therefore, TGDS is 
selected and used as the screening test for depression in the current study.   
Thai Geriatric Screening Test (TGDS)  
 
Thai Geriatric Screening Test (TGDS) is developed from Geriatric Depression 
Scale (GDS) by Yesavage et al. (1983). TGDS was studied for validity and 
reliability by Train the Brain Forum Thailand (1994). The objective for the study 
was to develop a clinical standard questionnaire for screening depression among 
Thai older people throughout the country. It has been tested for reliability (internal 
consistency) in 275 Thai older people, 154 females and 121 males, aged between 
60-70 years old in all the regions of the country. The results show that the average 
time to complete the questionnaire is 10.09 minutes. The reliability of internal 
consistency with the high Cronbach’s α coefficients degree is 0.93.This means that 
each item in this questionnaire measures the same characteristic. The questionnaire 
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contains 30 questions with a “yes/no” answer format. The optimal cut-off score of 
TGDS yields at 0-12 for normal, 13-18 for mild depression, 19-24 for moderate 
depression and 25-30 for severe depression. TGDS questionnaire has recently been 
used for both research and clinical assessment of geriatric depression in Thailand 
(Ageingthai 2008).  
3.4 Summary 
A routine cognitive screening in primary care is useful in many ways. It can help 
the health care staff to be aware of cognitive decline in older diabetic patients. This 
may affect their quality of care, decrease the burden of health cost and support the 
health care strategies for diabetic patients and their families. In order to support a 
routine cognitive screening and promote the detection of cognitive impairment in 
primary care settings, a screening test which is superior because of its brevity, 
effectiveness and simplicity will be used and studied in a primary care setting.  
A typical visit to Thai primary care is short, about 3-5 minutes, because primary 
care is the first contact of medical service and consultant for a large number of 
people in the rural and semi-rural areas with no appointment (Lotrakul and 
Saipanish 2006). Due to limitation in time, a cognitive screening test such as Mini-
Cog that can be administered in 5 minutes or less seems the most suitable and 
useable in primary care settings (Borson et al. 2003, Moorhouse 2009). 
As mentioned earlier in chapter 1, it is important that patients who undergo a 
cognitive screening test should then undergo a mood screening test such as GDS 
(Sinclair 2011). Cognitive impairment and depression may share similar 
symptomologies, such as memory loss (Sinclair 2011). Although the time to screen 
cognitive function by Mini-Cog is suitable for a typical visit in primary care         
(5 minutes), it is suggested that when combining the cognitive and depressive 
mood screening tests, the time allowed for the visit is longer than 5 minutes. If a 
significant depressive mood is detected, the patient will be offered and received 
further appropriate treatment (Sinclair and Aimakopoulou  2009).  
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Overall the three choices of selected screening tools in the current study are  
1) Mini-Cog for the cognitive screening test 
2) MMSE Thai 2002 for the cognitive screening test and used as a standard 
test in Thailand to compare and study validation with Mini-Cog 
3) TGDS for depressive mood screening test 
 
The original version of Mini-Cog is in English and it has never been used in the 
Thai population. In order to ensure the validity of the use of Mini-Cog in Thai 
culture, it is necessary to develop its Thai version. The reliability and validity of 
the test should also be studied in the target population before proceeding to data 
collection. All these processes of developing Mini-Cog in its Thai version will be 
presented in the following chapter.  
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Chapter 4 
Development of Mini-Cog Thai Version 
 
 
As mentioned in Chapter 3, Mini-Cog will be used for data collection in Thai older 
people. However, the original version of Mini-Cog is in English, and it is 
necessary to translate it from English into Thai before its administration in this 
study. Therefore, this chapter presents the development of the Thai version of 
Mini-Cog, describes the background and composition of Mini-Cog including the 
processes of developing the Thai version Mini-Cog.  
 
4.1 Background and development of Mini-Cog  
 
Mini-Cog was originally developed from a very simple free-hand version of clock 
drawing test (CDT) (Borson et al. 1999). The free hand version of CDT is 
uncomplicated to score and requires little language interpretation in a community 
sample of multi-ethnic and multilingual older adults. The overall sensitivity is 
adequately at 79% but it still lacks a test of new learning, which is a critical point 
for the diagnosis of dementia. In order to enhance the psychometric properties in 
including a test of new learning into this cognitive screening test, Borson et al. 
(2000) added a simple 3-item memory test based on the Cognitive Abilities 
Screening Instrument (CASI) (Teng et al. 1994) to the clock drawing test and 
created a composite screening instrument named Mini-Cog. CASI is a screening 
test designed for cross-cultural application. The 3-item memory test of CASI is 
simple to adapt for a variety of language groups (Teng et al. 1994).  
 
The original scoring of the CDT in Mini-Cog was based on the Consortium to 
Establish a Registry for Alzheimer’s disease (CERAD). The CERAD is 
standardised, reliable and valid instruments for the evaluation and diagnosis of 
patients with Alzheimer’s disease (AD). They are used by all Alzheimer Disease 
Centres established by the National Institute on Aging (NIA) in the United States 
(Fillenbaum et al. 2008). The CDT scoring of CERAD generates four possible 
scores based on an overall mark of the clock (0 = normal, 1 = mild, 2 = moderate 
and 3 = severe impairment). In order to minimise the complexity of CDT that can 
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be scored without reference to the complex system of rules,  Borson et al. (2000) 
finally reduced the scoring of the CDT into the binary scores of  0 and 2(0 = 
abnormal or incorrectly clock, 2 = normal or correctly clock) (see Figure 4.1). 
 
Figure 4.1: Composition of Mini-Cog test 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mini-Cog has been studied in a population-based sample of ethnically and 
linguistically diverse older adults (Borson et al. 2006, Borson et al. 2000). It takes 
3-5 minutes to administer and performs as well as or better than the Mini-Mental 
State Examination (MMSE) for screening cognitive impairment and dementia. 
Borson et al. (2006) show the overall accuracy of cognitive impairment detection 
at 83% for Mini-Cog and 81% for MMSE. Mini-Cog is superior in recognizing 
patients with Alzheimer-type dementias (P = 0.05) and is not influenced by 
language and education (interclass correlation = 0.97, sensitivity = 0.99, specificity 
= 0.93) (Borson et al. 2003, Borson et al. 2000). In addition, Scanlan and Borson 
(2001) show the results of the high level of concordance (98 %) between expert 
and naive rater for scoring Mini-Cog.  
Mini-Cog 
Total 5 scores 
Part II: Clock Drawing Test 
(CDT) 
Part I: recall memory 
3 unrelated 
items 
(3 scores) 
0 = abnormal clock  
2= normal clock  
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4.2 Development of the Thai version of Mini-Cog 
 
There were 3 phases for the development and validation of the Thai version of 
Mini-Cog in: 
 
Phase 1: Permission for copyright 
Phase 2: Selection of an expert panel  
Phase 3: Translation processes  
Phase 1: Copyright permission 
 
Mini-Cog was created by Dr. Soo Borson (Borson et al. 2000) and the publisher’s 
permission was necessary before beginning the translation. Therefore, the 
researcher requested Dr. Borson for copyright explaining the purposes of the 
translation. In the original version of Mini-Cog, the 3-item recall words are apple, 
table and penny. These words are not familiar in the Thai culture. Thus, following 
a discussion with Dr. Borson, the researcher was granted the copyright for the 
translation using a new set of the 3-item words consisting of house, cat and green. 
The selected 3-item recall words are based on the simplicity of the words and that 
they can be recognised by Thai older people and culture (see the attached 
permission email and copyright of Mini-Cog Thai version in Appendix A3).  
 
Phase 2: Selecting the expert panel in the research team for translation 
 
The expert panel in the research team for translation is required to assists in 
determining whether the translation of the questionnaire test is well constructed 
and suitable for testing. According to McGartland Rubio et al. (2003), a range of 
two to twenty experts is suggested to establish the number of the expert panel in 
research team for translation. This depends on the desired level of expertise and 
knowledge diversity. In addition, the panel of experts should be comprised of 
content and lay experts. The content experts are professionals who have work 
experience relevant to the measure and the lay experts are people who can address 
issues on language and understanding (McGartland Rubio et al. 2003). 
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In this study, the expert panel in research team for translation consisted of Dr. 
Nahathai Wongpakaran, a physician in geriatric psychology and expert on 
psychogeriatric screening tests. She acted as the content expert. The lay expert was 
the researcher, an academic staff in Thai university.  
Phase 3: Translation of Mini-Cog  
 
When an instrument is used in a different language, across-cultural translation 
process is needed to reduce the risk of introducing bias into a subsequent study 
(Gjersing et al. 2010). An individual clinician may make a mistake when 
translating verbally, which could lead to inconsistency and misunderstanding when 
administering the test. This may in turn make an analysis of results more difficult 
(Bradley 1994).  
 
Beaton et al. (2002) suggested that if the instruments are to be used across cultures, 
not only should they be translated well linguistically, but the content validity of the 
instrument should also be contained at the same level across different cultures. 
Thus the aims for the translation of Mini-Cog into Thai are as follows: 
 
- To achieve the conceptual equivalence of Mini-Cog Thai version to Mini-
Cog English version  
- To ensure equivalence of meaning  
- To prevent the participants of being misled and to ensure the instruction of 
the test is correct 
 
Although there is agreement that it is not suitable to simply translate and use an 
instrument in another linguistic and cultural context, there is no universal standard 
guideline on how to translate an instrument for use in another cultural setting 
(Gjersing et al. 2010). Maneesriwongul and Dixon (2004) recommend applying 
multiple techniques into the translation processes.  
 
In the current study, the guidelines for cross-cultural translation of medical health 
research (Beaton et al. 2000) and diabetic psychology (Bradley et al. 1994) were 
primarily applied. These suggest that there are four steps for the development and 
validation of the cross-cultural instrument. They are as the following: 
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Step 1: Forward translation  
 
Forward translation is the first stage in the instrument adaptation. It is 
recommended that at least two forward translations be made of the instrument from 
the original language to the target language (Beaton et al. 2000). In this way, 
obscure wording in the original version or difference in the translation will be 
noticed. In order to choose the suitable wording in translation, however, fluency in 
language alone is not a sufficient qualification for the translation. The translator 
needs to understand the purpose of the instrument and the basic aim of designing 
the instrument (Bradley et al. 1994). 
 
In this study, both translators (1 and 2) speak Thai fluently (target language) and 
English (original language). Both translators have doctoral degrees from Australia 
and the United States and have experience in neuro-cognitive screening 
questionnaire design and development. Therefore, they are familiar with the 
terminology covered by the screening test. Both translators produced an initial 
forward translation of Mini-Cog independently. They were instructed to aim for 
conceptual rather than literal translation, and to keep the language easy to 
understand for the individuals without the knowledge of technical terminology (see 
Appendix B1). 
Step 2: Synthesis of the translation  
 
In this step, the results of the translation from the two translators were compared 
by the expert panel. They looked for discrepancies of meaning in the translations. 
If any discrepancies were found, both the translators would discuss them and come 
to an agreement (Bradley et al. 1994). Consensus of translation is important rather 
than one person’s opinion to resolve the issue. This process is called the synthesis 
process (Beaton et al. 2000) (see Appendix B2). 
Step 3: Back translation 
 
Back-translation is important and is needed to identify any discrepancies between 
the meaning of the translation and the original version (Bradley et al. 1999). In the 
process of backward translation, a target language version is translated back into 
the source language version, and then the two language translations are compared 
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in order to verify the translation of the test (Maneeseriwongul and Dixon 2004). 
The two back-translators should preferably be without the knowledge in the area 
covering the instrument. The main reasons are to avoid information bias and to 
bring out unexpected meaning in the translated questionnaire (Beaton et al. 2000). 
 
In this study the Thai version of Mini-Cog was back-translated blindly into an 
English version by two back-translators in order to verify the translation of Mini-
Cog. Two different translators (3 and 4) were invited for back translation. The 
back-translators were bilingual and bicultural. They spoke Thai and English 
fluently (both were half Thai-British who had grown up in Thailand and graduated 
from a university in the UK). The back translators did not have a background in 
medicine or the area that covers cognitive screening test. They were blinded to the 
original version of Mini-Cog and translated the approved Thai Mini-Cog into 
English. No discrepancies of meaning between the two back-translators were 
found (see Appendix B3).  
Stage 4: Equivalence testing  
 
The back translation of the original and the back-translated version need to be 
examined and compared by an original developer who will examine the differences 
found in back-translation. Basically, the measuring of equivalence in the 
instrument translation is mostly evaluated in two types: semantic and content 
equivalence (Willgerodt et al. 2005). Semantic equivalence is used to ensure that 
the contents of the translation in the two versions keep the same meaning 
(Maneesriwongul & Dixon 2004), while content equivalence is used to ensure that 
the contents in the two versions have a consistent cultural relevance. 
 
 
The results of back-translation in this study indicate that there was no difference in 
the meaning of the words or concepts between the two English versions of Mini-
Cog test (original and back-translated version).  
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4.3 Summary 
 
Mini-Cog will be used as the cognitive screening tool in this study. Since there was 
no formal translation of Mini-Cog available for use with Thai population, the Thai 
version of Mini-Cog was developed by the researcher who aimed to screen 
cognitive function of Thai older people with type 2 diabetes at the primary care 
setting.  
 
Accurate translation is a first requirement in the process of transferring a test from 
the original (English) version to target (Thai) version (Beaton et al. 2000). An 
individual’s direct translation of the test without any reference to the formal 
version can affect validity and reliability of results (Bradley 1994). In order to 
ensure a conceptually equivalent version, this study showed the translation 
methodology used for transferring Mini-Cog from English to Thai version. This 
chapter also revealed the success of the translated Mini-Cog that ensured 
consistency and quality in the content or face validity between the original and 
target versions of the screening test. Content or face validity refers to the subject 
matter based on the judgements of experts concerned with whether the test 
measures the content are accurately (Crookes and Davies 2004). 
 
The translation does not guarantee the good quality of instruments, such as inter-
rater reliability in different cultures (Kimberlin and Winterstein 2008). Inter-rater 
reliability (also called inter-observer agreement) refers to the equivalence of 
ratings obtained with an instrument when used by different observers. If a 
measurement process involves ratings by observers, a reliable measurement will 
require consistency between different raters (Crookes and Davies 2004). 
 
Mini-Cog is new and has not been validated in Thai population. Thus, in order to 
propose Mini-Cog as a new cognitive screening tool in Thailand, Mini-Cog is 
needed to establish the concurrent validity by comparing its performance with a 
known reference standard, such as MMSE Thai 2002, on the same population 
(Lorentz 2002). The concurrent validity means measuring the relationship between 
the new and the existing standard test (Sim and Wright 2000). Therefore, following 
the translation, the inter-rater reliability and concurrent validity of the translated 
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Mini-Cog Thai was measured. This will be addressed in Chapter 6 (the pilot 
study).  
 
In the next chapter, the research protocol of the current study will be presented in 
order to reveal the research aims and objectives including the overall steps of the 
study. 
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Chapter 5 
Study protocol 
 
 
This chapter provides information regarding the study protocol which is common 
to both the pilot study (Chapter 6) and the main study (Chapter 7). The chapter 
starts with the research questions and objectives of this study. It then provides the 
details regarding the research design, criteria of the participants, plan and processes 
of data collection in the fieldwork including the ethical issues and considerations.  
5.1 Research questions 
 
As stated in Section 1.1 (Chapter 1), to the best of the researcher’s knowledge, 
there is no investigating study to date of Thai older people with type 2 diabetes 
related to cognitive impairment and depressive mood in community or rural areas. 
The present study addresses this issue. The two main questions of the study are: 
 
1. What is the prevalence rate of cognitive impairment in rural Thai 
older people with type 2 diabetes who have never received a formal 
diagnosis of  cognitive impairment in the primary care setting?  
2. What is the prevalence rate of depressive mood in rural Thai older 
people with type 2 diabetes who have never received a formal 
diagnosis of depressive mood in the primary care setting?  
 
To investigate this main question in detail, there are four secondary questions as 
the following: 
 
i) What are the predictors of rural Thai older people with type 2 
diabetes who have cognitive impairment?  
ii) What are the predictors of rural Thai older people with type 2 
diabetes who have depressive mood?  
iii) What is the relationship between cognitive impairment and 
depressive mood? 
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iv) What is the relationship between cognitive impairment and 
glycaemic level, and what is the relationship between depressive 
mood and glycaemic level? 
v) Are there any differences between good (HbA1c ≤ 7 % or ≤ 53 
mmol/mol) and poor (HbA1c > 7% or > 53 momol/mol) glycaemic 
control groups in the cognitive screening tests and depressive 
mood-screening test? 
5.2 Research objectives 
 
In order to find out an accurate answer for the research questions, in this study the 
following specific objectives are set to achieve: 
 
 Ascertaining the prevalence of undiagnosed cognitive impairment 
in Thai older people (aged 60+ years) with type 2 diabetes 
 Ascertaining the prevalence of undiagnosed cognitive impairment 
and undiagnosed depressive mood in Thai older people (aged 60+ 
years) with type 2 diabetes 
 Investigating the characteristics of rural Thai older people with type 
2 diabetes who have and have not experienced cognitive 
impairment 
 Investigating the characteristics of rural Thai older people with type 
2 diabetes who have and have not experienced depressive mood 
 Examining the association between cognitive impairment and 
depressive mood in rural Thai older people with type 2 diabetes 
 Identifying the association between the level of cognitive 
impairment or depressive mood with the degree of glycaemic 
control (HbA1c) 
 Comparing the results of cognitive and depressive mood screening 
tests between the good (HbA1c ≤ 7 % or ≤ 53 mmol/mol) and poor 
(HbA1c > 7% or > 53 momol/mol) glycaemic control groups 
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5.3 Research design 
 
An observational study using cross-sectional research design is applied in this 
study. In order to achieve the aims of the study, the logic of cross sectional study is 
suitable for this research for a number of reasons. First, it is the best method of 
determining the prevalence of disease or any other health-related event in a defined 
population at a point in time (Mann 2003).  In other words, the current disease 
status is examined in relation to the current exposure level. All participants are 
contacted at a point in time and relevant information is obtained from them (Mann 
2003). Second, the basis of this information is classified as having or not having 
the outcome of interest (e.g. cognitive impairment or depressive mood). Last, a 
cross-sectional study is carried out to investigate the associations between potential 
risk factors (e.g. clinical variable of diabetes) and the outcome of interest (e.g. 
cognitive impairment and depressive mood) (Levin 2006). 
 
The advantage of a cross-sectional study is an ability to study a large number of 
subjects at a relatively small cost and time when compared with other methods 
such as a longitudinal study (Mann 2003). More importantly, the data from the 
cross-sectional study provides a good picture of health care needs of target 
population. A prevalence study is a valuable method of obtaining information on 
the pattern of morbidity of a population and to assist health care staff to plan and 
establish health priorities. The data can generate hypotheses for other related 
studies in the same population or area (Levin 2006). A disadvantage of this type of 
study is that it does not provide a cause and effect study (Mann 2003). This issue 
does not affect the research area of this study which examines association at one 
point in time or a short period of time.  
 
To conclude, using a cross-sectional study to execute the research objectives is 
considered to be sufficient to discover the precise answer to the research questions 
in this study.  
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5.4 Sample size  
 
In order to ensure that the proposed number of participants to be recruited into this 
study is appropriated to answer the research objectives, an appropriate sample size 
calculation is selected and applied.  
 
There are two main approaches to sample size calculation. One is based on the 
concept of power of a study, that is, the ability to detect a statistically significant 
change if the true magnitude of the effect is anticipated. This approach focuses on 
the significant test that will be performed at the end of the study or intervention. 
The second approach focuses on the precision of the estimate, that is, the level of 
sampling error regarded as acceptable (Dos Santos Silva 1999). The 95% 
Confidence Interval (CI) provides an indication of how precise the sample estimate 
is in relation to the true population value (Shakespeare et al. 2001). Thus, this 
approach focuses on the width of confidence interval that will be obtained when 
the results of the study are analysed.  
 
In this study, the primary research objective focuses on the detection and 
estimation of the prevalence rate (percent) in the true population rather than 
statistically significant change of intervention. The sample size calculation is 
therefore based on the precision of 95% Confidence Interval (CI) if true prevalence 
is required.  
 
 
Formula for 95% Confidence Interval (CI) for prevalence is calculated by  
 
p +z(α/2)sqrt (pq)/n   (Daniel, et al 1999)  
 
where  
 
p = prevalence in sample 
 
α = probability of type I error, = 0.05 (2-sided) 
 
z(α/2) = z-score (the z-score for 95% CI is the value of z such that 0.025 is in each 
tail of the distribution (Peacock and Peacock 2011) 
n = sample size 
q = 1-p 
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In order to estimate pwith 95% CI of size d (width of the interval) 
 
d (size of the width of the interval) is zα/2 sqrt (pq)/n   
 
Hence, given a required size is needed to solve the equation for n 
 
d  = z(α/2) sqrt (pq)/n   
 
 
This given  
 
d
2 
= (z (α/2))
2
 x pq/n 
 
n = (z(α/2))
2   
x  pq /d
2
 
 
 
d = size of width of the interval in this study estimated from d = z(α/2) sqrt (pq)/n  
(in this formula, n = total number of older people with type 2 diabetes with HbA1c 
test = 283. As mentioned earlier in Chapter 1, HbA1c test in the most widely 
accepted measure of overall, long term blood glucose control in diabetes (Llorente  
and Malphurs 2007,Saudek et al. 2006). It reflects a beneficial effect on the 
immediate clinical consequence of diabetes (hyperglycaemic), which may affect 
the study outcome measures (either in cognitive function or mood) (Alencar et al. 
2010). In addition, based on Chapter 2, this study intends to 1) assess the 
generalisability of association between HbA1c test and the outcome measures and 
2) estimate the effect of poor glycaemic control (indicated by the presence of 
HbA1c result) on the outcome measures. Thus, HbA1c is important to select as an 
appropriated primary endpoint to support a claim based on glycaemic control.  
Therefore, d = (1.96)
2
 0.5 x (1-0.5) / 283, thus total width= 0.12 (12%) and the 
margin of error + 6% (0.06).  
 
Since there are no previous studies on the rate of cognitive impairment in Thai 
older people with type 2 diabetes, this study uses the proportion at 50% (use 0.5 in 
the formula), which is the most conservative estimate in the maximum value of 
error in order to yield the maximum sample size (Daniel et al 1999, Peacock and 
Peacock 2011). 
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Sample size in this study n = (1.96)
2
 0.5 x (1-0.5) / (0.06)
2   
 
 
n = 267 
 
 
In the current study, the calculation of sample size equals 267, the required number 
of participants in this study. 
 
5.5 Research setting and target population 
 
This study is carried out in primary care settings. It was mentioned in Chapter 1 
that Thai primary care settings are health care centres at the sub-district level (rural 
areas). The primary care provides frontier, ongoing, comprehensive, and co-
ordinate care (Ministry of Public Health 2009). Primary prevention including 
health promotion and specific protection from disease are the key activities of Thai 
primary care settings. Since type 2 diabetes prevalence increases with age, the 
numbers of older persons with diabetes are expected to grow as the older 
population increases in number (Cukierman et al. 2005, Aekplakorn et al. 2007).  
In this study, the older people with type 2 diabetes in all the primary care settings 
of San-sai district are found to be a good representative of patient population 
because San-sai district is located in the northern part of Thailand which has the 
highest old population (12.6%). It should further be mentioned that primary care 
centres are important public healthcare services in Thai community (National 
Statistical Office Thailand 2007). As stated in Chapter 1, Section 1.6.2, the health 
care system in Thailand consists of public and private providers. Private clinics 
and polyclinics are wide spread only in the capital city and urban areas. Due to the 
financial problems and poverty in Thailand, it is difficult to encourage private 
health facilities to provide services in rural area (Sukunphanit 2006). Therefore, it 
is uncommon for people in the rural areas to use private clinic.  
 
Public health facilities were rapidly expanded nationwide since 2001 when 
Thailand launched the Universal Healthcare Coverage Scheme (Prakongsai et al. 
2009). This scheme is provided mainly by the public sector-in primary health care 
centres and district hospitals geographically accessible to the rural poor 
(Sukunphanit  2006). Ministry of Public health (MOPH) is the largest agency with 
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two-third of all hospitals and beds across the country. The other public health 
services are medical school hospitals under the Ministry of University, general 
hospitals under other ministries (such as Ministry of Interior, Ministry of Defence) 
(Sukunphanit  2006). MOPH owns 891 hospitals that cover more than 90% of the 
districts, and 9,762 primary care centres that cover every sub-district or community 
in rural area (Wibulpolprasert  2004). 
 
According to the Ministry of Public Health (MOPH), 98% of all the primary care 
centres are registered with Universal Healthcare Coverage Scheme (Prakongsai et 
al. 2009). Distribution of health care infrastructure nationwide is a necessity for the 
universal coverage of health (Prakongsai et al. 2009). All primary care centres 
under the scheme of Universal Healthcare Coverage must have the same 
infrastructure, premises and equipments. As the primary care centres in San-sai 
district are under MOPH, they are similar to the other ones in Thailand. In 
addition, chronic diseases (e.g. diabetes, hypertension and heart disease) are a 
major problem of non-communicable diseases (NCD) in ageing population at 
primary care centres in Thailand (National Statistical Office of Thailand 2011). 
Moreover, a higher prevalence rate (16.7%) of diabetic adults from the national 
health survey was found in the aged group of 60-69 (Akeplakorn et al. 2011) 
comprising to 64% of the population visiting the diabetic clinic in San-sai district.  
 
In addition, diabetic clinics have been set in all primary care settings at San-sai 
district, thus, it is possible to identify and recruit diabetic patients in the 
community or rural areas. In addition, more than half (67%) of the diabetic patients 
in the primary care centres of San-sai district are unable to maintain appropriate 
glycaemic control, defined as FBS >140 mg/dl or mmol/l or 7.8 mmol/l (San-sai 
district health office 2009). The increasing number of diabetic cases and the 
persistent ineffective management of patients with diabetes present a serious 
challenge in identifying cognitive impairment or depressive mood in older people 
aged 60 and over with type 2 diabetes in San-sai district.  
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5.6 The criteria of the participants 
 
In order to provide clear and manageable limits to the information that would be 
gathered and synthesized as evidence, certain parameters are set to refine the 
criteria of the participants in this study. These parameters, called inclusion and 
exclusion criteria, are then used to select the studies that best provide the information 
needed to answer the research questions (Boyle 1998). The inclusion criteria enlist 
characteristics of potential participants who accurately represent a target 
population in the study. The exclusion criteria are the characteristics of participants 
that may confound the results of the study (Lunsford and Lunsfords 1995).  
 
5.6.1 Inclusion criteria  
 
In this study, participants are included if they meet the following main criteria for 
eligibility.  
 
 Thai people aged over 60 years with type 2 diabetes who have had at least 
one year of diagnosis. 
- A one-year time period following the diagnosis is selected in 
order to know the HbA1c result of the participants. Because of 
the limitation of resources, primary care settings  in San-sai 
district perform physical examination and laboratory tests 
including HbA1c test once a year  
 
 Thai people aged over 60 years with type 2 diabetes who have had all types 
of diabetic treatment (e.g diet control alone, medication or insulin injection 
or combined diabetic treatments) were included in this study. 
- This criterion is preserved for generalisability of the diabetic 
patients in the study.  
 
 The result of HbA1c test must have not been obtained more than one year 
prior to the date of recruitment.  
- In order to see the valid findings of an association between 
glycaemic control (HbA1c result) and cognitive function / 
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depressive mood, the result of HbA1c test must be updated 
within a year of recruitment and the screening tests applied. 
According to the recommendation of Diabetes UK, a one-year 
period of HbA1c is appropriate. Doctors should check the long-
term diabetes control of diabetic patients by HBA1c test 
(Diabetes United Kingdom (UK) 2011). 
 
 The participants must be competent Thai speakers.  
- In order to complete the screening tools, the participants must 
communicate and understand the instructions provided by the 
researcher.  
5.6.2 Exclusion criteria 
Participants are excluded if they have the following criteria.  
 
 Thai people aged over 60 years with type 2 diabetes who have been 
previously diagnosed with any stage of dementia or Alzheimer's disease 
(AD) either before or after diabetes diagnosis because this group of people 
are classified as known cases of cognitive impairment and dementia.   
 
 Participants with a formal diagnosis of depressive disorder, schizophrenia 
or epilepsy in any stages. Schizophrenia and epilepsy are chronic disorders 
that are characterized by abnormalities in thinking, emotions and 
behaviour. Since the screening tools for cognitive impairment have not 
been validated in this group, they have been excluded in the study. 
 
 Those who are receiving medical treatment with psychoactive drugs (anti-
cholinergics, anti-convulsants, anti-parkinsonians or anti-psychotics), 
complicated hypertension and renal failure were excluded due to the effect 
of these medications on the cognitive function. The effect of these 
medications can be described as follows: 
- Anti-cholinergic agents have been causally linked to the 
development of memory impairment in healthy subjects. Memory 
impairment may be associated with basal forebraincholinergic 
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pathways. Moreover, acetylcholine is also involved with attention 
and other aspects of cognitive functioning (Rumman et al. 1995) 
- All anticonvulsants may cause drug-induced delirium or dementia, 
even at therapeutic drug levels. These effects appear to be dose 
related. Furthermore, uncontrolled seizures can affect cognition 
(Flaherty 1998). Anti-depressants have side effects to central 
nervous system such as delirium, disorientation. Short-term memory 
dysfunction can be found in persons on anti-depressant drugs 
(Oxman 1996). 
- Anti-parkinsonism such as Levodopa is one of the anti-
parkinsonism drugs associated with changes in cognitive function 
and mental status (Cummings 1991).  
- Anti-psychotics such as thioridazine and chlorpromazine may partly 
cause cognitive decline and delirium in patients who are on anti-
psychotics drugs (Moore and O'Keeffe 1999). 
- A cerebrovascular disease such as stroke or complicated 
hypertensions, and renal failure is the most common cause of 
cognitive impairment and dementia. Severe hypertension may cause 
damage to the brain i.e. a stroke, which is an accumulation of 
lacunar infarcts, ischemic white matter disease and cerebral 
hypoperfusion that are the most common causes of cognitive 
impairment/dementia. Severe damage to the kidneys leading to 
renal failure is also a cause of cognitive impairment (Llorente and 
Malphurs 2007). 
 
 Participants who have communication difficulty such as hearing loss  
- The participants must have a good hearing in order to participate in 
the cognitive tests to recall words told only once by the researcher.  
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5.7 Study instruments and outcome measure 
 
In order to investigate cognitive impairment and depressive mood in the target 
population, the screening tests of cognitive impairment and depressive mood are 
selected and used as study instruments in this study. As mentioned earlier in 
Chapter 3, the overview and rationale for selecting the cognitive and depressive 
mood screening tests are appropriated to use in this study. Following are the three 
selected study instruments: 
 
5.7.1 Cognitive screening tests 
 Mini-Cog  
 
Mini-Cog was developed as a very brief screening tool for primary care 
settings (Borson et al. 2000, Borson et al. 2006). It is a simple tool to 
screen cognition and has been validated in a population-based sample of 
ethnically and linguistically diverse older adults. It consists of two orally 
presented tasks (a three-item word recall) combined with an executive 
clock drawing task (CDT). It takes 3 minutes to administer the test.     
Mini-Cog scores, therefore, range from 0 (worst) to 5 (best) (Borson et al. 
2006). A cut-off of 2 out of 5 provides the optimal combination of 
sensitivity (99%) and specificity (96%) for detecting cognitive impairment 
(Borson et al. 2000, Borson et al. 2003, Borson et al. 2005, Scanlan and 
Borson 2001). (see Chapter 3 for more details and Chapter 4 for translated 
version of Mini-Cog from English to Thai).  
 Mini Mental State Examination (MMSE) Thai 2002 
 
The Mini Mental State Examination (MMSE) Thai 2002 (Boonkerd et al. 
2003) is translated from its original version in English (Folstein et al. 
1975). MMSE remains the most commonly used screening instrument as a 
global cognitive test (Nazem et al. 2009) and is used as a current clinical 
mainstay cognitive screening instrument in Thailand. The MMSE Thai 
2002 is scored in terms of the number of correctly completed items; lower 
scores indicate poorer performance and greater cognitive impairment. The 
total score ranges from 0 to 30 (perfect performance), a cut-off score of 14 
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is used for uneducated participants (illiteracy), a cut-off score of 17 is used 
for those who completed primary school, and a cut-off score of 22 for those 
who completed secondary school (Ageingthai 2008). (see Chapter 3 for 
details).  
5.7.2 Depression screening test 
 Thai Geriatric Screening Test (TGDS) 
Thai Geriatric Screening Test (TGDS) is used as a depressive mood 
screening test in this study. It is developed from the Geriatric Depression 
Scale (GDS) by (Yesavage et al. 1983). The TGDS questionnaire contains 
30 questions with a “yes/no” answer format. The optimal cut-off score of 
TGDS yields 0-12 for normal, 13-18 for mild depression, 19-24 for 
moderate depression and 25-30 for severe depression (Ageingthai 2008). In 
the available literature, TGDS is the only test that has been studied for 
validity and reliability specific to the Thai older population (Ageingthai 
2008,  Liang et al. 2009). (see refer to Chapter 3 for more details). 
 
 
5.8 Study plans and processes 
 
 
5.8.1 Pilot study 
 
 A pilot study is undertaken in order to test the translated Mini-Cog Thai 
version and the study protocol including data collection and processes in 
preparation for the main study. The pilot study provides tentative 
information regarding the impact of the instruments and feasibility study.  
 
5.8.2 Main study 
 
 The information from the pilot study is considered to make changes in the 
research protocol. The main study is carried out in 15 primary care settings 
in San-sai district, Chiang Mai, Thailand. 
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5.9 Data collection 
 
There are three steps for the data collection as follows;  
Step 1: Demographic data interview 
 
Interview is used to collect the demographic data (Appendix E1). It comprises of 
basic demographic data including age, education, and years in school, marital 
status, living arrangement (alone or with family), income and type of health cost 
support. Information is collected directly from the participant to ensure the 
accuracy of the data. This information is used to study the characteristics of 
participant with the outcome of interests (cognitive impairment and depressive 
mood).  
Step 2: Application of the screening tests  
 
The second stage is applying the screening tests. This stage takes around 25 
minutes. The screening tests are applied in the following order: 
1. Mini-Cog (5 minutes) 
2. MMSE Thai 2002 (10 minutes)  
3. TGDS (10 minutes) 
Mini-Cog is applied first not only because it is the priority test in this study but the 
short duration of the test is also perceived as less stressful to the patient compared 
to MMSE test which is a longer test with a series of questions for concentration 
and attention (Doerflinger 2007). TGDS is the last test to administer because of its 
simple yes/no format which can easily be used and understood by older people 
who have short attention spans or feel easily fatigued which may happen after 
testing the cognitive screening tests (Holroyd and Clayton 2000). 
 
Step 3: Recording medical information  
 
After the researcher administers the screening tests, the recording medical data of 
each participant is recorded on a separate sheet by viewing the medical history 
profile. 
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5.10 Statistic analysis 
 
The data analysis is performed using the Statistical Package for Social Sciences 
(SPSS) program for Windows version 16. The statistical analysis consists of 
descriptive and inferential statistics.   
 
Descriptive statistics 
Percentage, mean and standard deviation are used to explain the characteristics of 
the participants, and provide initial views of the data prior to applying inferential 
statistics. 
 
Interferential statistics 
The prevalence rates of cognitive impairment and depressive mood are estimated 
by calculating the percentage of individuals at the cut-off point score and 95% 
confidence intervals is constructed. 
 
A logistic regression analysis is conducted on the binary outcome data through 
which the relationship between cognitive impairment and independent potential 
risk factors is examined. A similar analysis is undertaken for depression.  
 
To study the correlation between Min-Cog and MMSE Thai 2002 tests and TGDS 
test, Pearson’s correlation is used for parametric data and Spearman’s correlation is 
used for nonparametric data. In order to compare the score result of cognitive 
impairment and depressive mood in the levels of glycaemic control (HbA1c), 
statistics comparing the two groups is used. 
 
5.11 Ethical approval 
 
Ethical approval is obtained separately for the pilot and the main study (Appendix 
A1 and A2, respectively). The research proposal and related documents in the pilot 
and main studies are submitted initially to the Faculty of Health Research Ethics 
Committee, University of East Anglia (UEA), the United Kingdom (UK). When 
approved, the research proposals are submitted further for ethical approval to the 
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Ethical Review Committee for research in Human Subjects, Department of 
Medical Service of Public Health, Ministry of Public Health, Thailand. 
 
5.12 Ethical considerations 
 
Eligible patients are invited to participate on a voluntary basis. They are invited to 
provide written informed consents and are informed of their right to withdraw from 
the study at any time without any negative effect or prejudice to their regular or 
further service at the primary care centre.  
 
Confidentiality and anonymity are assured through the following 
procedures:  
 None of the patients’ personal data is reported in any study report.  
 All personal details and completed questionnaires are stored in a 
locked cupboard in each primary care setting (this has already been 
negotiated with each of the primary care settings to which only the 
researcher has access or password protected on the researcher’s 
computer.  
 If an emerging health problem is identified for any patient during 
the study by the researcher, the researcher would, with the consent 
of the patient, notify a clinical member of staff within the primary 
care setting to enable appropriate care to be provided. If necessary, 
any interview is terminated, and/or the patient’s participation in the 
trial is ended. 
 
 
5.13 Summary 
 
The study plan and protocol is provided in order to present the research questions 
and objectives. The details of the research design, instruments and criteria of the 
participants will be presented in Chapters 6 and 7 (pilot and main studies). A pilot 
study is conducted to test the Mini-Cog Thai version and to establish the feasibility 
of the study protocol for the main study. The lesson learned and the information 
achieved from the pilot study will be used to adjust into the methodology in the 
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main study. The information and details of the pilot study will be presented in the 
next chapter.   
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Chapter 6 
Pilot study 
 
 
This chapter provides details of and information about the pilot study in the current 
research. First, a definition and the objectives of the pilot study are provided. Next, 
the procedures and outcomes of the pilot study are discussed. Finally, a summary 
of the pilot study and its application are included; and the lesson learned from the 
pilot study in adjusting the methodology in the main study is presented.   
6.1 What is a pilot study? 
 
The pilot, or feasibility study, is a small version of the study designed, as well as 
the specific pre-testing of a particular research instrument (Thabane 2010). The 
advantage of conducting a pilot study is that it might reveal whether the proposed 
methods or instruments are inappropriate or too complicated in the main study. 
Pilot study provides vital information to improve the quality and efficiency of the 
main research protocol (Teijlingen and Vanora 2001). Therefore, the pilot study is 
set in order to test the logic of the study and gather the appropriate research 
procedure and method to prevent the potential pitfall in the main study.  
6.2 Objectives of the pilot study  
 
This pilot study has two objectives: 
 
1. As mentioned in Section 6.1, the pilot study tests the study protocol and its 
feasibility in applying it in the main study. 
2. It was mentioned in Chapter 4 that Mini-Cog has never been used in 
Thailand. In order to propose Mini-Cog as a new cognitive screening tool, 
it is necessary to establish the good quality of the test already in use in Thai 
population. Therefore, the second objective of the pilot study is measuring 
the inter-rater reliability and the concurrent validity of Mini-Cog. The inter-
rater reliability (also called inter-observer agreement) refers to the 
equivalence of ratings obtained from an instrument used by different 
observers. If a measurement process involves ratings by different 
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observers, a reliable measurement will require consistency between the 
raters (Crookes and Davies 2004). The purpose of the inter-rater reliability 
of Mini-Cog is supporting the practical, effective and uncomplicated 
method for the scoring system in the clock drawing part (CDT) of Mini-
Cog.  In addition, in order to see the performance of the new test with a 
known reference standard on the same population (Lorentz 2002), the 
concurrent validity is used to measure the relationship between Mini-Cog, a 
new test in Thailand and MMSE Thai 2002, the existing standard test (Sim 
and Wright 2000).  
 
6.3 Setting and population 
 
As stated earlier in the study protocol (Chapter 5), this study was conducted in 
Chiang Mai because it has the highest older population in Thailand (12.6%) 
(National Statistical Office Thailand 2007). The primary care centre is an 
important public health care service in community or rural areas (Ministry of 
Public Health 2009).  The pilot study was conducted in one primary care centre 
(Nong-han) in San-sai district, the study area for the current study in Chiang Mai, 
Thailand. The potential participants who visited the diabetic clinic in April 2010 
on a regular basis at Nong-han primary care were invited to participate in the pilot 
study. 
 
6.4 Sample size  
 
It was suggested that in general a minimum number of 30 participants or greater is 
appropriate to estimate a parameter for the pilot study and that it has adequate 
power to detect any trends in the study (Lancaster 2004, Thabane et al. 2010).      
In this study thirty-two (32) participants took part in the pilot study based on the 
availability of the potential participants visiting Nong-han primary care during the 
study.  
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6.5 Procedure 
 
In order to access the participants, two weeks before the beginning of the pilot data 
collection in Nong-han primary care, the researcher contacted and informed the 
nurse in the diabetes clinic at Nong-han primary care centre about the purpose, 
processes and inclusion/exclusion criteria for the potential participants in the pilot 
study. It should be mentioned that this primary care centre had already agreed to be 
a part of this study. 
 
The potential participants visited the primary care centre on the date. After they 
received the routine diabetes care, the nurse identified the older patients with type 
2 diabetes and asked whether they were interested to participate in the study. If 
they were interested, the researcher contacted them individually, explained the 
study and gave them the “information sheet” (Appendix C) containing the purpose 
of the research. All the interested potential participants were given time (at least 24 
hours) to decide whether they wanted to participate in the study. Those individuals 
who agreed to join the study had an opportunity to ask any questions. They were 
assured that they could refuse to participate in the research without giving reasons 
at any time if they disagreed or were unsatisfied during the process with no effect 
on their medical care. If the participants decided to take part in the study, they had 
to sign a consent form (Appendix C) in writing or by thumb print (if they were 
illiterate) to show their willingness to participate. After receiving the informed 
consent, the participants were interviewed and asked to complete all the 
questionnaires by the researcher within the primary care centre. 
 
6.6 Measure outcomes 
6.6.1 Inter-rater reliability of Mini-Cog  
 
The inter-rater reliability is a method of measuring reliability of the test to 
determine the extent to which two or more raters obtain the same result when using 
the same instrument to measure a concept (Porta 2008). Kappa statistics measures 
the degree of non-random agreement between two raters of the same categorical 
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variables the equivalence and consistency of ratings obtained with an instrument 
between different raters (Crookes and Davies 2004). 
 
In this study, the reliability of CDT scoring was assessed by comparing the scores 
given by the researcher and an expert on 32 participants. The score results (normal 
and abnormal) of CDT between the researcher and the expert were blinded to each 
other. The rationale for studying the inter-rater reliability only in the CDT part of 
the study is the following. First, the recall memory part of Mini-Cog is a short-term 
memory test of unrelated 3 objects. The raters would score exactly the same if the 
participants answered the recall word correctly, unlike the CDT part where the 
scoring criteria are applied, the score of CDT may be biased depending on the 
judgement of raters.  Second, the previous study of inter-rater reliability of Mini-
Cog focused only on the CDT part. Thus this study can be compared with the 
previous study. To compare the inter-rater reliability of Mini-Cog in Thai with the 
previous study, the inter-rater reliability was focused in the part of CDT scoring.  
6.6.2 Concurrent validity 
 
The concurrent validity is meant to measure the relationship between the new test 
and the existing standard test. In order to validate a new measure, the results of the 
measure are compared to the results of the standard obtained at approximately the 
same point in time (Sim and Wright 2000). This approach is useful in situations 
when a new or untested tool is potentially more efficient, easier to administer and 
more practical than another more established tool and is being proposed as an 
alternative instrument (Porta 2008). In order to see whether Mini-Cog can used as 
an alternative tool of cognitive screening test in Thai primary care settings, the 
concurrent validity was conducted by measuring the correlation between the score 
results of Mini-Cog and MMSE Thai 2002. 
 
6.7 Data analysis 
 
The data were entered and the analyses were performed using SPSS Software 
Package version 16. 
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- Kappa (K) statistic (Fleiss et al. 2003) was applied to measure the inter-
rater reliability between the researcher and the expert on the scores of CDT. 
- Pearson Product-Moment Correlation Coefficients (Pearson’s r) (Cohen 
and Cohen 1983) was applied to examine the concurrent validity or 
correlation between the score results of Mini-Cog and MMSE Thai 2002.  
- Descriptive statistics, including percentages, mean, median and standard 
deviation were used to summarise the data collected from the sample 
(demographic and clinical characteristic of the participants).  
 
6.8 Ethical approval          
The research protocol and related documents were submitted to the Faculty of 
Health Research Ethics Committee, University of East Anglia, the United 
Kingdom. After the ethical approval was obtained from the UEA in November 
2009 (Appendix A1), the research protocol was then submitted again to the Ethical 
Review Committee for research in Human Subjects, Department of Medical 
Service of Public Health, Ministry of Public Health, Thailand. The ethical approval 
of the pilot study was obtained from Thailand in April 2010 (Appendix A2).  
6.9 Ethical considerations 
 
Eligible participants were invited to participate on a voluntary basis. They were 
invited to provide written informed consents or thumb print and were informed of 
their right to withdraw from the study at any time without any negative effect or 
prejudice to their regular or further service at the primary care setting.  
 
Confidentiality and anonymity were assured. None of the participants’ personal 
data was reported in any study report. All questionnaire tests were stored safety in 
a locked cupboard or password protected in the researcher’s computer file. All 
information obtained from the participants was coded and kept in the researcher’s 
locked files in the post-graduate research room during and after the study. Only the 
researcher holds the key to the code. 
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In case of emerging any health problem on the part of any participant, the 
researcher would immediately cease the interview or study, and refer the 
participant to the nurse in the diabetic clinic or a health professional who can offer 
support in the primary care setting. 
 
6. 10 Results  
Inter-rater reliability of CDT scoring in Mini-Cog 
 
Both the raters’ scores for each participant in CDT scoring are presented in Table 
6.1 The inter–rater reliability of CDT scoring r in the Mini-Cog classified as 
‘normal CDT’ and ‘abnormal CDT’ are presented in Table 6.2. Rater 1 and 2 both 
agreed on the ‘normal CDT of 25% and the ‘abnormal CDT’ of 65.6%. In9.4% of 
the cases rater 2 disagreed with rater 1 on ‘normal CDT’. In total, the agreement on 
normal and abnormal CDT from both raters is 90.6 %. The Kappa statistics for the 
inter-rater reliability of CDT scoring shows a good agreement (K = 0.8, p <0.001, 
95% CI= 0.54, 1.00). The levels of agreement by Kappa  (K) value are suggested 
by Altman (1991) and can be interpreted as follows: 
 
Value of K   Strength of agreement 
< 0   less than chance agreement 
<0.20   Poor 
0.21-0.40  Fair 
0.41-0.60  Moderate 
0.61-0.80  Good 
0.81-1.00  Very good 
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Table 6.1: Raw data scores of CDT in Mini-Cog Thai version from the researcher 
and expert, a pilot study in a sample of 32 older people with type 2 diabetes in 
Nong-han primary care centre, San-sai district. 
 
 Mini-Cog score 
 
Participant Researcher Expert 
 
1 2 2 
2 0 0 
3 2 2 
4 0 0 
5 0 0 
6 2 2 
7 2 2 
8 2 2 
9 0 0 
10 0 0 
11 2 2 
12 0 0 
13 2 2 
14 0 0 
15 0 0 
16 0 0 
17 0 0 
18 0 0 
19 2 2 
20 0 0 
21 2 2 
22 0 0 
23 2 0 
24 0 0 
25 0 0 
26 0 0 
27 0 0 
28 2 0 
29 0 0 
30 0 0 
31 2 0 
32 0 0 
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Table 6.2: 32 participants are scored by the researcher and expert for Mini-Cog. 0 
(zero) denotes the participants with incorrectly drawn clock, 2 (two) denotes the 
participants are classified with correctly drawn clock 
 
 
 
 
Expert 
N (%) 
 
Total 
N (%) 
0 
 
2  
 
Researcher 
N (%) 
 
0 
 
21(65.6%) 0(0%) 21(65.6%) 
2 3(9.4%) 8(25%) 11(34.4%) 
Total  24(75%) 8(25%) 32(100%) 
 
 
Concurrent validity of Mini-Cog   
 
Table 6.3: Pearson correlation coefficients between the scores of Mini-Cog Thai 
version and MMSE Thai 2002 
 
   
MMSE Thai 2002 
 
 
 
 
Mini-cog 
Pearson’s r (r) 
 
 
0.47  
P 
 
 
0.007 
 
95% Confidence 
Interval (CI) 
 
0.37-0.55 
 
 
 
In order to see the concurrent validity between Mini-Cog and MMSE Thai 2002, 
Pearson correlation was analysed. The scores of Mini-Cog showed a significantly 
positive and moderate correlation with Pearson correlation (r) of 0.47, 95% CI 
0.37, 0.55 (p = 0.007) with the scores of MMSE Thai 2002 (Table 6.3). Pearson 
correlation (r) ranges from -1 to 1, including 0. Each level of measurement has an 
appropriate test of association. Values closer to +1 indicate a positive relationship 
while values closer to -0.1 indicate a negative relationship (Pallant 2009). Values 
closer to 0 represent the absence of relationship between the two tests. Below is the 
interpretation of Pearson correlation (r) (Cohen and Cohen 1983).  
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Correlation coefficient (r)  Interpretation 
0.10-0.29    small correlation 
0.30-0.49    moderate correlation 
0.50-1.00    strong correlation  
 
Characteristics of the participants 
 
Of the 32 participants, 75% were female with the mean age of 70 + 6 years old. 
Half of the participants (50%) were married, 44% were widowed and 6% were 
single.  More than half of the participants (81%) finished primary school and had a 
duration of 4 years in schools. Most of the participants (97%) lived with family 
and 31% lived with their children. 
 
The mean BMI (24.63+4.1 kg/m
2
) was in the normal range for international 
classification of BMI (19-25 kg/m
2
). The mean cholesterol (206+48 mg/dl or 11.4 
mmol/l) was higher than the normal level guideline (200 mg/dl or 11.1 mmol/l) but 
triglyceride (137+64 mg/dl or 7.6 mmol/l) was in the normal range of the guideline 
(< 150 mg/dl or 8.3 mmol/l) (Diabetes Association of Thailand 2009). The average 
duration of time for having diabetes in the participant was 4 years. As for the 
treatment of diabetes, 50% of the participants were on oral medication, 47% on 
diet control and 3% took insulin injection. Demographic and clinical 
characteristics of the participants are summarised in Table 6.4. 
 
Table 6.4 Demographic and clinical characteristics of the participants 
 
Demographic variables 
 
N (%) 
Gender 
- male  
- female 
 
 
25% (8) 
75% (24) 
Age (years) 
 
70+6 
Education 
- never attended school 
- primary school (4 yr in school,) 
- secondary school (7-9 yr. in school) 
- high school (10-12 yr. in school) 
 
6% (2) 
81% (26) 
10% (3) 
3% (1) 
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Demographic variables 
 
N (%) 
Marital status 
- single 
- married 
-widowed 
 
 
6%  (2) 
50% (16) 
44% (14) 
Living status  
- alone 
- not alone (multiple answers) 
    - with spouse 13% (4)  
    - with son/daughter 31 % (10)  
    - with grandchild 6% (2)  
    - with spouse+son/daughter 16%(5) 
    - with spouse+grandchild 3 %(1) 
    - with spouse+son/daughter+grandchild 19%(6) 
    - with son/daughter+grandchild 6% (2)   
 
6% (2) 
94% (30) 
 
Income support (multiple answers) 
-from government (500 baht or 10 pounds/month) 
-from bank saving 
-from son/daughter 
 
 
100% (32) 
16% (5) 
22% (7) 
Clinical variables 
 
 
Body Mass Index(kg/m
2
) 
 
24.63+4.1 
Blood pressure (mm Hg) 
-systolic  
-diastolic 
 
 
130 (100-150) 
73 (60-90) 
Fasting Blood Sugar (mg/dl or mmol/l) 
 
109 mg/dl (91-190) 
6 mmol/l (5-10.5) 
 
Haemoglobin A1c (% or mmol/mol) 
 
7.58% (5.8% -12.5% 
59.34 mmol/mol (40-113) 
 
Duration of HaemoglobinA1c result (months) 
 
10 (9-11) 
Total Cholesterol (mg/dl or mmol/l) 
 
206+48 mg/dl 
11.4+3 mmol/l 
 
Low density lipoprotein (mg/dl or mmol/l) 
 
118 + 42 mg/dl 
6.5+2 mmol/l 
 
High  density lipoprotein (mg/dl or mmol/l) 
 
44 (24-89) mg/dl 
2.4 (1.3-4.9) mmol/mol 
 
Triglyceride (mg/dl or mmol/l) 
 
137+64 mg/dl 
7.6+3.5 
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Clinical variables 
 
N (%) 
Diabetes treatment 
-diet control 
-oral medication 
-insulin injection 
 
 
47% (15) 
50% 16) 
3% (1) 
 
 
Duration of HbA1c test (months)  
 
10 (9-11) 
Diabetes complication 
- retinopathy 
 
 
6% (2) 
History of chronic disease 
-  Hypertension 
- Chronic obstructive pulmonary disease (COPD) 
- dyslipidemia 
- Osteoarthitis (OA)  
- Osteoarthitis (OA)+dyslipidemia 
 
72% (23) 
6% (2) 
9% (3) 
3% (1) 
3% (1) 
 
Health behaviour (present) 
Drinking 
Yes 
Smoking 
Yes 
 
 
 
 
16% (5) 
 
10% (3) 
 
Data are given as % (N), Mean+ SD and median (range). 
 
6.11 Discussion 
 
There is a good level of agreement (inter-rater reliability) of CDT scoring in the 
Mini-Cog Thai version with a Kappa (K) value of 0.8 (p<0.001, 95% CI 
0.54,1.06). According to Altman (1991) and Fleiss et al. (2003), the value of K = 
0.61-0.80 shows a good strength of agreement. The inter-rater reliability in this 
study is in line with the Mini-Cog in Italian version, which shows the inter-rater 
reliability (intraclass correlation coefficient) of ri = 0.89 (Scanlan et al. 2007). Both 
Kappa value and the intraclass correlation coefficient measure inter-rater reliability 
(Fleiss 2003). The results of inter-rater reliability in both Thai and Italian studies 
show a good inter-rater reliability for clinical measurement (Altman 1991, Portney 
and Watkins 2000). Kappa requires that the two raters should use the same rating 
categories, while the intraclass correlation coefficient is used when the raters are 
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preferably more than two (Howell 2006). In this study, there were two raters for 
the CDT scoring, whereas in the study of Scanlan et al. (2007), there were 40 raters 
due to the large area of study setting (11 regions of Italy).Concurrent validity was 
established by comparing the performance of Mini-Cog against MMSE Thai 2002, 
an independent standard clinical cognitive screening test in Thailand, in respect of 
the same entity at the same time (Sim and Wright 2000, Polit et al. 2006). 
Pearson’s correlation (r = 0.467, 95% CI 0.37, 0.55, p = 0.007) between Mini-Cog 
and MMSE indicated a positive correlation between Mini-Cog and MMSE Thai 
2002 scores. This information shows an acceptable validity of Mini-Cog with 
MMSE Thai 2002. This implies that Mini-Cog Thai version is a relatively new 
instrument producing data that agrees with the existing measure use in Thailand.  
 
The results of the pilot study gave an overview of characteristic data in the target 
population. In particular, the result shows that most of the participants (81%) 
finished primary school. This makes Mini-Cog suitable for applying within this 
group because it is designed for low educated people, people with language barrier 
or the two combined (Borson 1999).  It was found that the proportion of females 
was three times more than males, which might be due to the higher number of 
females in Thai community (Jitapunkul and Bunnag 1999 ). In addition, 97% of 
the participants do not live alone and 31% live with their children. This 
demonstrates the Asian culture where the primary responsibility for the older 
people has traditionally been with the family (Knodel et al. 1999).  
 
The pilot study carried out in this research demonstrates the feasibility of 
conducting data collection in the main study. It suggests that the research design is 
appropriate to conduct data collection. In other words, Mini-Cog Thai version is 
practical to administer and acceptable in Thai language and culture. The 
participants demonstrate that they can clearly understand the wordings and 
instructions of the test and there is no need for revision. The time of interview and 
administration of the test (5 minutes) are acceptable to the participants, as well. 
 
Recruitment of the potential participants was practical in the study area. The 
participants were willing to participate. However, due to the limitation of public 
transport and the travelling cost of Thai older people in rural areas, the potential 
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participants who decided to take part in the study provided informed consents on 
the date of receiving “information sheet” rather than taking time (at least 24 hours) 
to consider their participation. It is to be noted that sending “information sheet” by 
post would not suit Thai rural older people who have limited abilities in reading 
and understanding information. In particular, a formal letter from the primary care 
centre would make them worried about the details of the letters and cause 
increased anxiety. A Verbal explanation of “the information sheet” is much more 
suitable for Thai rural older population.  
 
Three lessons are learned from the pilot study. They are summarised below. 
 
1. Although the identification and recruitment of Thai older people with type 
2 diabetes in San-sai district were feasible through the existing research 
protocol, it became apparent that the limitation of HbA1c measurement in 
the research area might result in a biased sample. Because of the limited 
resources and budget of primary care settings in San-sai district, only the 
patients who have a good ability to control their FBS (<140 mg/dl or 7.8 
mmol/l) in two of the last three visits to the primary care centre receive 
HbA1c measurement. Uncontrolled and unstable FBS (>140 mg/dl or >7.8 
mmol/l) in the three last visits imply that the patient has poor control of 
blood sugar and would be prone to have the HbA1c more than target 
control (>7% or >53 mmol/mol). Due to the limitation of the resources in 
primary care centres, this group of patients are not selected to receive 
HbA1c measurement from the health care staff. Another reason for 
selecting only the group of stable FBS for HA1c test is to follow one of the 
recommendations for HbA1c measurement in American Diabetes 
Association (ADA) diabetes care, which suggests that the HbA1c test 
should be performed at least twice a year, particularly in the patients 
meeting treatment goals (who have stable glycaemic control) (American 
Diabetes Association 2012). 
 
2. Therefore, in this study, the participants who receive HbA1c measurement 
tend to have a better control of FBS than the participants who do not 
receive it. 
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The research question in this study aims to find out the prevalence of 
cognitive impairment and depressive mood in Thai older people with type 2 
diabetes in the community. Prevalence data shows the actual number of the 
outcome measures in the target population; however, if the data is 
influenced by differences in some variables in the population, it then may 
have an impact on the validity of the prevalence study (Dolin et al, 1999).  
 
It is necessary, therefore, to prevent the selection bias of the participants 
from the study area and to ensure that the difference in criterion for 
receiving HbA1c measurement may not influence the outcome measures 
(cognitive impairment and depressive mood). This study needs to assess the 
outcome measures in the participants who do not receive HbA1c 
measurement and then to compare it with the participants who receive 
HbA1c measurement. The comparison of the prevalence between the two 
groups is likely to measure whether there is a problem of selection bias 
between the groups with and without HbA1c in the study. 
 
3. The information from the pilot study reveals that diabetic clinics in all 
primary care settings in San-sai district are open two days a week, and that 
some of these primary care settings run diabetic clinic on the same day and 
time. Due to the constraints of time for data collection including the need to 
collect the data of the participants with and without HbA1c, this study 
required a research assistant (RA) to help with the main data collection.  
 
4. With regard to RA in the main data collection and in order to assure the 
reliable administration of all the instruments used by the researcher and the 
RA, the study of inter-rater reliability of all the instruments used in the 
main study must be tested. 
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6.12 Summary 
 
The findings of the pilot study show that the inter-rater reliability of CDT is in 
good agreement (K=0.8) between the researcher and the expert. Although Mini-
Cog Thai version is relatively new in Thailand, the findings reveal a positive 
correlation, concurrent validity or the same direction of the screening results with 
MMSE Thai 2002. Thus, Mini- Cog can perform with MMSE Thai 2002, which is 
a standard test of cognitive screening in Thailand.  
 
In conclusion, the identification and recruitment of the older people with type 2 
diabetes in primary care centres in San-sai district were feasible through the 
research protocol. However, drawing on the results of the pilot study, the 
methodology for the main study should be adjusted to the following three issues 
a) The number of the older people with type 2 diabetes who do not receive 
HbA1c measurement should be added to the main study  
b) A research assistant should help with data collection in the main study 
c) The inter-rater reliability of all the instruments used by the researcher and 
the research assistant should be tested in the main study.  
 
All the details of these adjustments will be explained and summarised in the 
following chapter. 
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Chapter 7 
Methodology 
 
 
The pilot study in the previous chapter demonstrated the feasibility of the study 
protocol to be carried out in the main study. This chapter presents the methods and 
procedures used to collect data for the main study. Firstly, a summary of the 
lessons learned in the pilot study about the necessary changes in the methodology 
is outlined. This is followed by a rationale and discussion of the changes. 
Secondly, an overall description of the methodology for the main study is 
provided.  
 
7.1 Summary of the necessary changes for the study protocol  
Changing the number of the sample size 
 
As mentioned in Chapter 5 (Study Protocol), only the potential participants who 
have a HbA1c test will be included in the current study. However, due to the 
limited resources of primary care settings, not every diabetic patient receives a 
HbA1c test. The selection of diabetic patients who receive HbA1c measurement is 
based on their ability to control FBS (< 140 mg/dl or 7.8 mmol/l) in two of the last 
three visits to the primary care centre. Hence, the patients who receive HbA1c 
measurement tend to have a better control of blood sugar than the participants who 
do not. As a result, the inclusion criteria for this study, that intends to focus on the 
potential participants with HbA1c results, seems to have a selection bias of the 
sample in the study area.  
 
In order to test for selection bias of the participants in the study area it is important 
to ensure that the criterion difference in the group who receives HbA1c 
measurement will not influence the outcome measures (cognitive impairment and 
depressive mood). This study, therefore, needs to assess prevalence of cognitive 
impairment and prevalence of depressive mood in the participants who do not 
receive HbA1c measurement and then compare the prevalence with the 
participants who receive HbA1c measurement. This comparison of the prevalence 
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between the two groups is likely to measure whether there is a problem of selection 
bias between the groups with and without HbA1c. If the results show that there is 
no difference of the outcome measures between the group with HbA1c and the 
group without HbA1c, only the group with HbA1c will be used in data analysis in 
order to 1) assess the generalisability of association between HbA1c test and the 
outcome measures and 2) estimate the effect of poor glycaemic control (indicated 
by the presence of HbA1c result) on the outcome measures. In summary, the 
sample size in the research protocol will be doubled to include the participants 
without HbA1c test. In total, the minimum sample size of five hundred and thirty-
four (534) older people with type 2 diabetes (two hundred and sixty-seven (267) 
with HbA1c test plus two hundred and sixty-seven (267) without HbA1c test) will 
be used in the main study.  
 
The importance of HbA1c result  
As mentioned in Chapters 1 and 2 , glycaemic control (HbA1c) appears to play a 
role and may be related to cognitive impairment and depressive mood in the older 
people with type 2 diabetes (please see Chapter 2).  For example, three studies 
have demonstrated an inverse relationship between HbAlc and working memory, 
executive functioning, learning and complex psychomotor performance (Reaven et 
al. 1990, Munshi et al. 2006, Ryan et al. 2006) in patients with type 2 diabetes. 
These findings support the hypothesis that worsening glycaemic control leads to 
worsening cognitive function. Moreover, HbA1c is a precursor of AGEs, which 
may involve cognitive decline in type 2 diabetic patients from the glycation 
processes through hyperglycaemia. Therefore, document blood glucose levels by 
HbA1c are important to see the possibility of vascular complications, which may 
affect to cognitive impairment in diabetic patients (Marchetti 2009). 
 
Glycaemic control (HbA1c) is a vital goal for diabetes treatment and may be 
related to the outcome measures. In addition to the knowledge of the researcher 
through the literature search, no study in Thailand has investigated the association 
between glycaemic control (HbA1c) and cognitive impairment in the older people 
with type 2 diabetes. It would therefore be of interest to see whether glycaemic 
control (HbA1c) is related to cognitive impairment and depressive mood. The 
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findings will be compared with the previous studies from other countries in order 
to find out the different or similar trends of glycaemic control (HbA1c) towards 
cognitive impairment.  
The need for a Research Assistant (RA) 
 
During the pilot study, the researcher found that each primary care setting in the 
study area provide services in its diabetic clinics two days a week. Some primary 
care settings run diabetic clinics on the same date and time. Considering the time 
constraints for data collection (4 months) and sample size, a research assistant is 
required for the main study. The recruitment and training of RA will therefore be 
added to the research protocol in the main study. The details of this process will be 
presented later in this chapter.   
 
Inter-rater reliability of all the study instruments 
 
Prior to data collection in the main study, all the instruments (Mini-Cog, MMSE 
Thai 2002 and TGDS) will be tested between the researcher and the RA in order to 
assure the reliable administration of the tests. The details and processes will be 
presented later in Section 7.6.   
 
To summarise, the following three strategies are added to the methodology in the 
main study in order to meet the already mentioned issues  
a) The number of older people with type 2 diabetes who do not receive 
HbA1c measurement will be added to the main study  
b) A Research Assistant (RA) will help collect the data in the main study 
c) The inter-rater reliability between the researcher and the research assistant 
will be studied 
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Table 7.1: Summary of the differences between the pilot and the main study 
 
Consideration issues 
in the pilot study 
Old protocol Changes in the main 
study  
 
Rationale 
Sample size 
 
Sample with HbA1c 
test   
 
Adding the number 
of participants in the 
sample without 
HbA1c test  
 
Testing the selection 
bias in the study 
sample 
 
Research Assistant 
(RA) 
No RA Adding RA Time restriction in 
data collection 
because diabetic 
clinics are run on 
the same day and 
time   
 
 
Inter-rater 
reliability study of 
the application of 
all instruments  
No study of inter-
rater reliability in 
the application of 
the study 
instruments  
Adding the study of 
inter-rater reliability  
 
To ensure the 
reliable 
administration of the 
tests and achieving 
valid results 
 
 
 
After discussing the changes concerning the information in the research protocol, 
the methodology for the main study is presented below. 
 
7.2 Area of the study 
 
This study was conducted in San-sai district which is one of the districts in Chiang 
Mai, Thailand. Chiang Mai is located in north of Thailand. It is approximately 700 
kilometres from Bangkok, the capital of Thailand. The province consists of 24 
districts, 204 sub-districts, 1,999 villages and 262 primary care settings. With a 
population of 1.6 million, Chiang Mai is one of the largest provinces in the 
northern part of Thailand with the highest older people population (12.6%) 
(National Statistical Office, Thailand 2007). For more details, please refer to 
Chapter 5 (The Study Protocol). 
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Figure 7.1 Map of Chiang Mai provinces and sub-districts community within San-
sai district, Thailand 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sources: http://chaingmai.sawasdee.com and courtesy map from San-sai district 
health office   
 
 
 
 
 
 
 
                               
 
Chaing Mai province     San-sai district 
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7.3 Study population and sampling procedures 
 
Population 
 
The target population will include all the patients aged 60 and over, who reside and 
are registered with the primary care settings in San-sai district.  
Sample size and sampling 
 
As mentioned earlier, in order to test the selection bias of HbA1c results in the 
participants and to ensure that the target population (group with HbA1c) is 
representative of the actual population (the entire older people with type 2 
diabetes), the sample size of the methodology is amended by adding an equal 
number of participants without HbA1c results. The comparison between the 
prevalence of the outcome between the groups with and without HbA1c is 
analysed to see whether this study assesses the actual population value. 
 
The total minimum number of the participants in this study is planned to be 534 
(267 with HbA1c result and 267 without HbA1c result). All the eligible older 
people with type 2 diabetes from 15 PCUs in San-sai district have the same 
probability of being included in the sample.  
 
A list of the target population (participants with HbA1c results) will be provided 
by the gatekeeper, a diabetes nurse of San-sai hospital where HbA1c is measured. 
It should be mentioned that the target population is dispersed within 13 of the 15 
primary care settings. Random sampling will be applied in this study so that an 
eligible target population of 267 patients with HbA1c measure and 267 patients 
without HbA1c measure are included in the study 
7.4 Ethical issues and considerations  
 
The ethical approval for the main study will be sought first from the Faculty of 
Health Research Ethics Committee, University of East Anglia, the United 
Kingdom; and then from the Ethical Review Committee for research in Human 
Subjects, Department of Medical Service of Public Health, Ministry of Public 
 102 
 
Health , Thailand (see Appendices A1 and A2). Ethical considerations are given in 
relation to the following: 
 
 After giving the participant an information sheet in Thai, the researcher 
asks them if they feel comfortable to receive the information in written 
form or they want it explained verbally. If the participant is illiterate, the 
researcher will read the form out. The patients are assured that their 
participation or non-participation will not have any impact on their routine 
health care service. If the potential participants agree to take part, they will 
be invited to give their consent either in writing or by thumb-print (in case 
they are illiterate). As with all other documents, the consent form will be 
read to the illiterate participants who have ‘signed’ using their thumb print 
in the presence of two health care staff as witnesses. The researcher will 
also sign the consent form to indicate that the she has explained the purpose 
of the study to the participants. Participants will have an opportunity to ask 
any questions, and may refuse to participate without giving reasons at any 
time if they disagree or are unsatisfied during the process. Many Thai older 
people in the study area have only a primary school level of education and 
require extra help. The researcher will therefore explains verbally all the 
information on the information sheet. 
 
 The researcher will be alert for any emerging health problems that may 
arise during the study in the participants. If any problem arises, the 
researcher will, with the consent of the patient, notify a clinical member of 
staff within the primary care setting to provide appropriate care for the 
patient. If necessary, any interview will be terminated, and the participation 
in the study will be ended. 
 
 All the data produced in this study is anonymous and is kept strictly 
confidential. Each study participant is given a code number for 
identification purposes. The researcher is the only person to know the 
identity of the participants. All the data is kept in a secure storage on a 
UEA computer and is protected by the researcher’s personal identification 
number. It can only be accessed by the researcher during the lifetime of the 
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study. Once the Doctorate Thesis and any publications arising from the 
work have been completed, all recordings will be confidentially erased and 
all transcripts will be stored in electronic form for 5 years.  
7.5 Identification and recruitment of the participants 
 
There are two steps for the identification and recruitment of the participants as 
follows: 
 
1) Prior to data collection, the researcher will formally contact the nurse who 
works in the diabetic clinic of each primary care centre and will explain the aims 
and objectives including the inclusion and exclusion criteria in this study.  
 
2) A list of the potential participants who have a routine visit date at the diabetic 
clinic during the researcher’s visit for data collection will be provided by the nurse 
at each primary care centre. On the date that the potential participants visit the 
primary care centre and after receiving the routine diabetes care, the nurse will 
assist the researcher by identifying the older people with type 2 diabetes and 
enquires if they are interested in to take part in the study. If the potential 
participant is willing to take part, the researcher will explain the project and give 
them the “information sheet” (Appendix C). Those that agree to join the study will 
be invited to sign a consent form (Appendix C) to show their willingness to 
participate. After obtaining informed consent, the participants will be interviewed 
and asked to complete all the questionnaires by the researcher within the primary 
care centre. It should be noted that due to the context of the study area in a Thai 
older people population, it is not possible to hand out “the information sheet” to 
the potential participants and allow them time for consideration (see Chapter 6 
Section 6.11 ). 
7.6 Recruitment and training of the research assistant 
 
A research assistant is recruited at the psychogeratric department, Faculty of 
Medicine, Chiang Mai University. The assistant is qualified as a registered nurse 
and works as a research assistant on psychogeriatric research with Dr.Nahathai 
Wongpakaran, a specialist psychogeriatric physician and the fieldwork mentor for 
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this study. A one-day training is provided to the qualified research assistant by the 
researcher. The purpose of the training is to ensure that the research assistant fully 
understands the research objectives, and that the questionnaire tests are 
consistently conducted under the research protocol.  
Inter-rater reliability study of the instruments 
 
After establishing the training, an inter-rater reliability of all the instruments (Mini-
Cog, MMSE Thai 2002 and TGDS) between the researcher and the research 
assistant is assessed in the first twenty-one (21) participants of the main study. 
 
The instruments (Mini-Cog, MMSE Thai 2002 and TGDS) used for data collection 
are investigated to establish the reliability and accuracy of the administration 
process between the researcher and the RA. The researcher and RA perform the 
test independently from the individual participants in an alternating fashion and are 
blinded to each other’s results. The researcher and RA’s results obtained from each 
instrument are then analysed for inter-rater reliability. This discussion will be 
presented in Chapter 8.  
7.7 Data collection for the main study 
 
The data collection of the main study was conducted January-April 2011. The 
researcher and RA collected the data from the individual participants separately as 
the following: 
Procedure for applying the instruments  
 Demographic data interview 
The interview of demographic data is the first stage of applying the 
instrument. It comprises of basic demographic data including age, 
education, and years in school, marital status, living arrangement (alone or 
with family), income and type of health cost support. The information is 
collected directly from the participants to ensure its accuracy. It is then 
used to study the characteristics of the participants. (see Appendix E1). 
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 Application of the screening tests  
The second stage is applying the screening tests. The screening tests are 
applied in the following order: first Mini-Cog (5 minutes), then MMSE 
Thai 2002 (10 minutes) and last the TGDS (10 minutes). This whole stage 
will take 25 minutes. Mini-Cog is applied first because it is the primary test 
in this study, and the short duration of the test is perceived as less stressful 
to the patient compared to MMSE, which is longer with a series of 
questions for concentration and attention span (Doerflinger 2007). TGDS is 
the last test to administer because of its simple yes/no format. It can easily 
be understood by older people who have short attention spans or may feel 
easily fatigued after testing the cognitive screening tests (Holroyd and 
Clayton 2000). 
 Recording data 
The details of data record are divided into three parts. The first part is the 
demographic data that provides the characteristics and personal information 
of the participants through the interview and patients’ profile record. The 
second part is the medical information obtained by viewing the medical 
annual report profile recorded 5-9 months prior to the recruitment. Only 
FBS is recorded on the day of recruitment. The last part is the results of 
cognitive screening and depressive mood screening tests. The details of all 
the data records are in Appendix E1. 
 
7.8 Data analysis and statistical procedures 
 
The researcher used the Statistical Package for Social Sciences (SPSS) program for 
Windows version 16 for data management including data entry, checking and 
analysing. 
7.8.1 Preparing the data for analysis 
 
This step include scoring the data by assigning numeric values to each response, 
cleaning data entry errors from the database, recording items on instruments with 
 106 
 
inverted scores or computing new variables that comprise multiple items from 
scales.  
 
 Data coding: the variables of the study are divided into numeric and string. 
The data from the outcome measure of the screening tests are categorized 
as numeric, and some demographic data are categorised as string. Although 
categorical variables are entered into the statistical package for social 
science (SPSS) as labels, it is easier to code the labels and to facilitate 
statistical analysis, it is recommended to enter the codes as numeric data 
(Creswell and Plano Clark 2011).Therefore, males are coded as 0 and 
females are coded as 1. For the dichotomous variables such as the results of 
the screening tests, 0 and 1 are used as codes to show the patients’ normal 
and impaired conditions, respectively (Appendix E2).   
 
 The major descriptive statistics such as minimum and maximum values, 
means and standard deviations are calculated by SPSS in order to check 
briefly the range and distribution of the variables. 
 
 To ensure the accuracy of the data file, 10% of the computerised data file is 
randomly selected to proofread against the original file (Tabachnick and 
Fidell 2007). The errors in the database are found to be acceptable at       
0.1 %. The six errors of data are found in the following variables: height, 
Low Density Lipoprotein (LDL), duration time of HbA1c before 
recruitment, DM duration (groups), DM treatment and co-morbid diseases. 
 
7.8.2 Analysing the data by using inferential statistics 
 
Before using inferential statistics, several assumptions such as normal distribution, 
multicollinearity and outlier are required to ensure the validity and reliability 
statistical calculation as follows: 
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 Assumption of normality 
Checking the normality of variables is one of the important assumptions of 
using statistical test. A Kolmogorov-Smirnov testis used to assess the 
normality of the distribution of variables. In statistics, a non-significant 
result (p value more than 0.05) indicates normality (Pallant 2009).  In this 
study, the Kolmogorov-Smirnov test shows the significant p value (less 
than 0.05) of the data set suggesting the non-normality of the data (Pallant 
2009) (see Appendix F1).   
 
 Assumption of multicollinearity 
In order to analyse the reliable data of logistic regression, it is important to 
check the multicollinearity, which can pose a threat to the validity of 
correlation and a logistic regression analysis (Field 2009). Mutlicollinearity 
exists when there is a strong correlation between two or more predictors in 
correlation and logistic regression. The variance inflation factor (VIF) 
indicates whether a predictor has a strong linear relationship with other 
predictors. If the value of VIF is more than 10, it indicates problem with 
multicollinearity, which may be biasing the correlation and logistic 
regression analysis. Tolerance, which is VIF’s reciprocal (1/VIF), is 
another statistics to check the multicollinearity. Values of tolerance are 
very low (below0.1) indicating that the variable has high correlations with 
other variables in the model (Pallant 2009). In this study, the VIF and 
tolerance value were checked and multi-collinearity was not found in the 
data set (Appendix F2). 
 
Demographic data  
 
Descriptive statistics, including percentages, mean, and standard deviation are used 
to examine the demographic data and study the variables of the participants with 
and without HbA1c  
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Comparison of the demographic and clinical data between the groups with and 
without HbA1c group 
 
A Mann-Whitney U test is used to compare the difference in the demographic and 
clinical data in two categorical variables, while the Kruskal-Wallis test is used to 
compare the difference in three or more sets of categorical variables between the 
groups with and without HbA1c.  
Prevalence study 
 
Crude prevalence rate (percentage number) with the 95% confidence interval (CI) 
of screening positive for cognitive impairment by Mini-Cog test and MMSE Thai 
2002 and the crude prevalence rate with the 95% confidence interval (CI) of 
depressive mood screening by TGDS are calculated in the groups with and without 
HbA1c test result. 
Comparison of prevalence study 
 
The chi-square test (χ2) is calculated to compare the prevalence of cognitive 
impairment and depressive mood between the groups with and without HbA1c test. 
To ensure the results of the p-value from Chi-square test, the difference of 
proportion in 95% confidence interval (CI) is analysed to see whether or not there 
is a difference on the study outcomes. 
 
Relationship between cognitive impairment and depressive mood 
 
Partial correlation analysis involves studying the linear relationship between two 
dependent variables after excluding the effect of one or more independent variables 
(Choudhury 2010). In order to get a correct picture of the relationship between two 
variables, the influence of confounding variables should be removed. As in simple 
correlation, the strength of the linear relationship between two variables is 
measured without taking into consideration the fact that both these variables may 
be influenced by a third variable or confounding variable (Pallant 2009).  
 
Based on the discussion in chapters 2 and 3, age and years in school are the 
confounding variables of performance scores on cognitive and depressive mood 
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screening tests. In order to obtain an accurate picture of the relationship between 
the cognitive function and depressive mood, partial correlation analysis is applied 
in this study to analyse the relationship between cognitive impairment and 
depressive mood by excluding the effect of age and years in school. 
 
Predictors of cognitive impairment and depressive mood in Thai older people with 
type 2 diabetes  
 
In order to investigate the independent predictor or individual characteristics 
associated with cognitive impairment and depressive mood, logistic regression is 
used in the data analysis. The logistic regression is used to explore which 
characteristics are associated with cognitive impairment and depressive mood by 
univariate logistic regression. Based on the results of univariate logistic regression, 
the variables that were significant at p = 0.10 level are applied in multivariate 
logistic regression with Backward Elimination Likelihood Ratio or Backward LR 
method. The results of this step will create a prognostic model, which might be 
individual predictors associated with the cognitive impairment and individual 
predictors associated with depressive mood.  
 
Backward LR is important in the process to distinguish between relevant and less 
relevant predictors, meaning that the final model can be developed with as few 
predictors as possible, but would still lead to reliable predictions. Subsequently the 
variables with the highest p-values are manually removed. Then the model is re-
run. This step is repeated until there are no variables left with a p-value smaller 
than 0.10.A p-value of 0.10 or 0.20 is commonly used in prognostic models, as 
variables that are less strongly associated with the outcome may still make a 
relevant contribution to the prediction. Final pruning of the model in this study is 
carried out with backward LR at p < 0.05 (Bursac 2008). 
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Differences of test score between the good glycaemic control (HbA1c ≤ 7% or 53 
mmol/mol ) and poor glycaemic control (HbA1c > 7% or or 53 mmol/mol ) groups  
 
In order to investigate and compare whether there is a difference between the cut-
off score in the cognitive screening tests and depressive mood test, and between 
the level of good glycaemic control (HbA1c ≤7% or 53 mmol/mol) and poor 
glycaemic control (HbA1c > 7% or 53 mmol/mol) groups, A Mann-Whitney U 
test) is used. It is meant to compare the difference in the score results of the 
screening tests between the participants with good and poor glycaemic control 
(Field 2009). 
 
7.9 Summary 
In order to achieve the research aims and objectives for the current study, this 
chapter provided the methodology, which is adapted and based on the practical 
information from the pilot study. The results of data collection from the main study 
are analysed and presented in the next chapter.  
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Chapter 8 
 
Results 
 
 
In the previous chapter the methodology employed within this study was presented 
and discussed. In this chapter the results from the data analysis of the main study 
will be presented. The results are organised into eight parts. The first part includes 
the results of the inter-rater reliability between the researcher and the RA of all the 
instruments initially conducted during the data collection. The second through the 
six parts of this chapter outline the findings of the data analysis. 
 
8.1 Inter-rater reliability of Mini-Cog, MMSE Thai 2002 and the TGDS 
 
The raw scores of 21 participants in all the instruments (Mini-Cog, MMSE Thai 
2002 and TGDS), used in this study between the researcher and the RA are 
presented in Table 8.1.  The results of inter-rater reliability of Mini-Cog , MMSE 
Thai 2002 and TGDS are presented in Tables 8.2 ,8.3 and 8.4 respectively.  
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Table 8.1: Raw data scores of Mini-Cog Thai version, MMSE Thai 2002 and TGDS between the researcher and the RA in a sample of 21 older 
people with type 2 diabetes in the main study 
Participants Mini-Cog MMSE Thai 2002 TGDS 
 Researcher RA Researcher RA Researcher RA 
1 0 0 0 0 0 0 
2 0 0 0 0 0 0 
3 1 1 0 0 0 0 
4 0 0 0 0 1 1 
5 0 0 0 0 0 0 
6 0 0 0 0 1 1 
7 0 0 0 0 0 0 
8 0 0 0 1 1 1 
9 1 1 0 0 0 1 
10 0 0 0 0 1 1 
11 0 0 0 0 0 0 
12 0 0 0 0 0 0 
13 1 1 0 0 0 0 
14 0 0 0 0 0 0 
15 0 0 0 0 0 0 
16 1 1 1 1 1 1 
17 0 1 0 0 0 0 
18 0 0 0 0 0 0 
19 0 0 0 0 0 0 
20 1 1 1 1 0 0 
21 0 0 0 0 0 0 
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Inter-rater reliability of Mini-Cog 
 
The researcher and RA both agreed in Mini-Cog on the ‘normal cognition’      
(57.1%) and the ‘cognitive impairment’ (33.3%). In 9.5% of the cases RA and the 
researcher disagreed on the ‘normal cognition’. In total, the agreement on ‘normal 
cognition’ and ‘cognitive impairment’ between the researcher and RA was 90.4% 
(Table 8.2).  
 
 
Table 8.2: 21 participants are scored by the researcher and RA for Mini-Cog. 0 
(zero) denotes the participants with normal cognition. 1 (one) denotes the 
participants with cognitive impairment. 
 
 
 
RA 
N (%) 
 
Total 
N (%) 
0 
 
1  
 
Researcher 
N (%) 
 
0 
 
12(57.1%) 2 (9.5%) 14 (66.7%) 
 
 
1 0 (0%) 7 (33.3%) 7 (33.3 %) 
 
 
 
Total 
  
12 (57.1%) 
 
9 (42.9%) 
 
21 (100%) 
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Inter-rater reliability of MMSE Thai 2002 
 
In MMSE Thai 2002, the researcher and RA both agreed on ‘normal cognition’ 
(85.7%) and ‘cognitive impairment’ (9.5%). In 4.8% of the cases the RA disagreed 
with the researcher on ‘normal cognition’. In total, the agreement on the ‘normal 
cognition’ and ‘cognitive impairment’ between the researcher and RA was 95.2% 
(see Table 8.3).  
 
 
Table 8.3: 21 participants are scored by the researcher and RA for MMSE Thai 
2002. 0 (zero) denotes the participants with normal cognition, 1 (one) denotes the 
participants with cognitive impairment. 
 
 
 
RA 
N (%) 
Total 
N (%) 
0 1 
 
 
 
Researcher 
N (%) 
 
0 
 
18 (85.7%) 1(4.8%) 19 (90.5%) 
 
 
1 0 (0%) 2 (9.5%) 2 (9.5%) 
 
 
 
Total 
 
  
18 (85.7%) 
 
3(14.3%) 
 
21 (100%) 
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Inter-rater reliability of the TGDS 
 
In the TGDS, the researcher and RA both agreed on ‘normal mood (76.2%) and 
‘depressive mood’ (19.0%). In 5.9% of the cases the RA disagreed with the 
researcher on ‘normal mood’. In total, the agreement on ‘normal mood’ and 
‘depressive mood’ between the researcher and RA was 95.2 % (see Table 8.4).  
 
 
Table 8.4: 21 participants are scored by the researcher and RA for the TGDS. 0 
(zero) denotes the participants with normal mood, 1 (one) denotes the participants 
with depressive mood 
 
 
 
RA 
N (%) 
Total 
N (%) 
0 1 
 
 
 
Researcher 
N (%) 
 
0 
 
16 (76.2%) 1(5.9%) 17 (81%) 
 
 
1 0 (0%) 4 (19%) 4 (19%) 
 
 
 
Total 
  
16 (76.2%) 
 
 
5 (23.8%) 
 
21 (100%) 
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The Kappa (K) statistics for the inter-rater reliability between the researcher and 
RA showed a good agreement for all the instruments used in this study. The results 
are as the following (see Table 8.5); K = 0.8, p = 0.000, 95% CI 0.54, 1.06 for 
Mini-Cog, K = 0.77, p = 0.001, 95% CI 0.51, 0.90 for MMSE Thai 2002 and K = 
0.86, p = 0.000, 95% CI 0.68, 0.94).  
 
 
Table 8.5: Agreement between the researcher and RA on the instruments (Mini-
Cog, MMSE Thai 2002 and the TGDS) used in the study.  
 
 Kappa P 95% CI 
 
Upper 
 
Lower 
Mini-Cog 
 
0.80 0.000 0.56 0.92 
MMSE Thai 2002 
 
0.77 0.000 0.51 0.90 
TGDS  
 
0.86 0.000 0.68 0.94 
 
 
Summary of the inter-rater reliability between the researcher and RA 
 
The findings of the inter-rater reliability of all the instruments used in this study 
were in the good level of agreement at K=0.8 for Mini-Cog, K= 0.77 for MMSE 
Thai 2002 and K=0.87 for the TGDS (Altman, 1991) (see section 6.10 for the 
levels of agreement). These findings showed the evidence of a good reliability 
between the researcher and the RA.  
 
As mentioned earlier in Chapter 7, using the RA was needed in this study. Because 
of limitation of time with a double increased number of subjects, and some primary 
care settings ran diabetic clinics in the same date and time. This finding suggests 
that the researcher and RA could administer all the instruments with each other in a 
reliable manner for the data collection in the main study. 
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8.2 Participant recruitment 
 
The initial recruitment of the sample for this study identified 570 Thai older people 
with type 2 diabetes who had routine visits at diabetic clinic from January to mid 
of May 2011 within 13 primary care centres at San-sai district. Potential 
participants were invited to take part in the study.  Fourteen (14) potential 
participants were excluded due to: moving out (3), dying (2), not meeting inclusion 
criteria (6), and being referred to hospital (3). Five hundred and fifty six (556) Thai 
older people with type 2 diabetes who participated and completed data collection 
were subsequently divided into the group with HbA1c (283) and the group without 
HbA1c (273). All the participants gave informed consents and completed 
screening test instruments. A flow chart diagram (see Figure 8.1) shows the 
summary of the recruitment in this study. 
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Figure 8.1: Flow chart diagram of participant recruitment  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Excluded (n= 14   ) 
- Not meeting inclusion 
criteria (n=6  ): severe 
kidney disease (2), stroke 
(1), dementia (1) and hearing 
impairment (2)  
-  Other reasons(n=8): moving 
out (3), refer to hospital 
(3)and dead (2) 
 
 
Without hbA1c result (273)  
Completed data collection  
 
 
 
Consented and 
Completed screening test instruments 
(n=556) 
 
 
With HbA1c result (283) 
Completed data collection 
 
 
 
Initially included (n=570) 
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8.3 Demographic characteristic data of the participants 
 
The characteristics of 556 participants who participated in the study and completed 
the data collection and screening test instrument are outlined in Table 8.6. In this 
study 556 participants took part, 367 (66%) of which were females and 189 (34%) 
of which were males. A similar pattern of gender representation was found in both 
groups of with and without HbA1c test. There were 180 (63.6%) females in the 
group with HbA1c test and 187 (68.5%) females in the group without HbA1c test. 
Males represented 103 (36.4%) in the group with HbA1c test and 86 (31.5%) in the 
group without HbA1c test. There was no statistically significant difference in the 
mean age between the two groups (68+6 with HbA1c test vs. 68+7 without HbA1c 
test, p=0.709). Likewise, there was no statistically significant difference in the age 
group between the two groups. 93% of all the participants (with and without 
HbA1c test) had attended school. The percentage of the participants who attended 
school for less than 4 years was found to be the same between the groups with and 
without HbA1c test, with no statistically significant difference (89.4% and 89.7% 
in the group with HbA1c and without HbA1c respectively, p=0.894). Nevertheless, 
the data showed that the number of people who lived alone in the group without 
HbA1c test was higher than the group with HbA1c test (20 vs. 10) with a 
statistically significant difference (p=0.048). Health behaviours (current smoking, 
drinking and exercise) between the two groups were not statistically significant. 
Ninety percent (90%) of the participants in both groups received health cost 
support from the government.  
 
Overall, it can be observed that living arrangement was the only one demographic 
characteristic data that was found to be statistically significant between the two 
groups. It is possible that the people who lived alone were less likely to have 
HbA1c test compared to people who live with family. 
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Table 8.6: Characteristics of participants 
 
Characteristics With 
HbA1c 
Without  
HbA1c 
Total P 
 n=283 n=273 N=556  
Gender     
Male 103 (36.4%) 86 (31.5%) 189 (34%) 0.224 
Female 180 (63.6%) 187(68.5%) 367 (66%)  
Age
a
 67.60+6.42 67.59+6.77 556 (100%) 0.709 
Age (years)     
60-64 121 (42.8%)  124 (45.4%) 245(44.1%) 0.695 
65-69 60 (21.2%) 53 (19.4%) 113(20.3%)  
70-74 52 (18.4%) 46 (16.8%) 98 (17.6%)  
75+ 50 (17.7%) 50 (18.3%) 100 (18%)  
Education     
Never attended to school 19 (6.7%) 20 (7.3%) 39 (7%) 0.778 
Attended to school 264 (93.3%) 253 (92.7%) 571 (93%)  
Year in school     
≤4 253 (89.4%) 245 (89.7%)  498(89.6%) 0.894 
>4 30 (10.6%)  28 (10.3%)  58 (10.4%)  
Living arrangement      
Alone 10 (3.5%) 20 (7.3%) 30(5.4%)  0.048* 
With family 273 (96.5%) 253 (92.7%) 526(94.6%)  
Working     
Yes 99 (35.0%) 108 (39.6%) 207(37.2%) 0.265 
No 184 (65.0%) 165 (60.4%) 349(62.8%)  
Current smoking     
Yes 20 (7.1%) 25 (9.2%) 45 (8.1%) 0.367 
No 263 (92.9%) 248 (90.8%) 511(91.9%)  
Current drinking     
Yes 23 (8.1%) 31 (11.4%) 54 (9.7%) 0.199 
No 260 (91.9%) 242 (88.6%) 502(90.3%)  
Current exercise     
Yes 149 (52.7%) 160 (58.6%) 309(55.6%) 0.158 
No  134 (47.3%) 113 (41.4%) 247(44.4%)  
Health cost support      
- national health care  
(30 baht scheme policy) 261 (92.2%) 247 (90.5%) 
 
508(91.4%) 
 
0.548 
- Social/Welfare health care 6 (2.1%) 10 (3.7%) 16 (2.9%)  
- Self-funding/family 
support  16 (5.7%) 16 (5.9%) 
 
32 (5.8%) 
 
 
*p ≤ 0.05 , a mean + SD  
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Characteristics of the clinical data 
 
The clinical characteristics data in Table 8.7 shows that the group without HbA1c 
test had a significantly higher number of people with a BMI range of 23-25 
kg/m
2
and > 25+ kg/m
2 
than the group with HbA1c test (p = 0.043). As expected, 
the group without HbA1c had a poor control of FBS (> 140
+
 mg/dl or >7.8 mmol/l) 
and a total cholesterol level of > 200
+
 mg/dl or 11.1 mmol/l when compared to the 
group with HbA1c (with a statistical significance of p = 0.000 and p=0.017 
respectively). Systolic and diastolic blood pressure, LDL, HDL, triglyceride, 
HbA1c, diabetes complications and co-morbidity diseases were not found to be 
statistically different between the two groups.
 
 
Diabetes treatment between the two groups was statistically significant (p = 0.006). 
The group with HbA1c test had a higher number (48) of people who were on diet 
alone (without medication) than the group without HbA1c test (25); while the 
group without HbA1c test had a higher number of participants who were on oral 
medication, insulin injection and combined treatment (oral medication plus insulin 
injection) than the participant with HbA1c test (234 vs. 225, 9 vs. 8 and 5 vs. 2, 
respectively). Duration range of diabetes (years) was also significantly different 
between the two groups (p = 0.01). The group without HbA1c test had a higher 
number of participants in the duration range of 1-4 years than the group with 
HbA1c (111 vs. 74); whereas the participants with HbA1c test had a higher 
number of participants in the duration range of 5-8 years and 8+ years than the 
group without HbA1c (105 vs. 78 and 104 vs. 84, respectively).  
 
The criteria for selecting the diabetic patients who would have HbA1c test in the 
primary care based on a good ability to control FBS < 140 mg/dl or <7.8 mmol/l in 
two of the last three visits to the primary care. Therefore, it was not surprising to 
see that the group with HbA1c test was able to control blood sugar (FBS) and 
some metabolic variables such as BMI and cholesterol levels better than the group 
without HbA1c test. In addition, the data showed that the diabetes duration and 
treatment were significantly different between the two groups. It can be observed 
that the number of participants in the group without HbA1c who had a diabetes 
duration of 1-4 years, was higher than the number of participants in the group with 
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HbA1c. However, the number of participants in the group without HbA1c who 
were on diet alone (without medication) was lower than the group with HbA1C.
 123 
 
Table 8.7: Characteristics of the clinical data   
 
Characteristics With  
HbA1c  
Without  
HbA1c  
Total P 
 n=283 n=273 N=556  
Body Mass Index(kg/m2)      
<23  
23-25 
119 (42.0%) 
47 (16.6%) 
82 (30.0%) 
68 (24.9%) 
201(36.2%) 
115(20.7%) 
0.043* 
>25+  117 (41.3%) 123 (45.1%) 240(43.2%)  
Blood Pressure (BP) 
Syatolic (mmHg) 
≤130 normal 
>130 
 
 
112 (39.6%) 
171(60.4%) 
 
 
106 (38.8%) 
167 (61.2%) 
 
 
218(39.2%) 
338(60.8%) 
 
 
0.857 
Diastolic (mmHg)     
≤80 normal 180 (63.6%) 187 (68.5%) 367(66.0%) 0.224 
>80  103 (36.4%) 86 (31.5%)  189 (34.0%)  
Fasting Blood Glucose (mg/dl 
or mmol/l) 
    
≤140 (or ≤7.8) normal 184 (65%) 98 (35.9%) 282(50.7%) 0.000** 
>140 (>7.8)  99 (35.0%) 175 (64.1%) 274(49.3%)  
Total Cholesterol (mg/dl or 
mmol/l) 
    
≤200 (or ≤11.1)  normal  150 (53.0%) 117 (42.9%) 267 48.0%) 0.017* 
>200 (>11.1) 133 (47.0%) 156 (57.1%) 289(52.0%)  
Low density lipoprotien 
(mg/dl or mmol/l) 
    
≤100 (or ≤5.5)  normal  78 (27.6%) 66 (24.2%) 144(25.9%) 0.362 
>100 (>5.5) 205 (72.4%) 207 (75.8%) 412 (74.1  
High density lipoprotien 
(mg/dl or mmol/l) 
    
> 41 (>2.2)normal 236 (83.4%) 234 (85.7%) 470(84.5%) 0.449 
≤ 40 (or ≤2.2)  abnormal   47 (16.6%) 39 (14.3%) 86 (15.5%)  
 
 
 
    
Characteristics With  
HbA1c  
Without  
HbA1c  
Total P 
 n=283 n=273 N=556  
 
Triglyceride (mg/dl or mmol/l) 
≤ 150 (or ≤8.3) normal 177 (62.5%) 161 (59.0%) 338(60.8%) 0.389 
>150 (>8.3) 106 (37.5%) 112 (41.0%) 218(39.2%)  
Duration of diabetes (years)      
1-4 74 (26.1%) 111 (40.7%) 185(33.3%) 0.003** 
5-8 105 (37.1%) 78 (28.6%) 183(32.9%)  
8+ 104 (36.7%) 84 (30.8%) 188(33.8%)  
Diabetes treatment     
Diet alone 48 (17.0%) 25 (9.2%) 73 (13.1%) 0.006** 
Oral medication+diet 225 (79.5%) 234 (89.7%) 459(82.6%)  
Insulin injection+diet 8 (2.8%) 9 (3.3.%) 17 (3.1%)  
Combined oral medication+ 
insulin injection+ diet 
2 (0.7%) 5 (1.8%) 7 (1.3%)  
Diabetes complication     
Neuropathy 11 (3.9%) 9 (3.3 %) 20 (3.6%) 0.709 
Retinopathy 46 (16.3%) 37 (13.6%) 83 (14.9%) 0.372 
Nephropathy 39 (13.8%) 30 (11.0%) 69 (12.4%) 0.318 
Co-morbid disease     
Heart disease 7 (2.5%) 12 (4.4%) 19 (3.4%) 0.213 
Hypertension 209 (53.5%) 182 (66.7%) 391(70.3%) 0.064 
Chronic obstructive pulmonary 
disease (COPD) 
4 (1.4%) 5 (1.8%) 9 (1.6%) 0.696 
Gout 6 (2.1%) 9 (3.3%) 15 (2.7%) 0.392 
Arthritis 3 (1.1%) 1 (0.4%) 4 (0.7%) 0.334 
Dyslipidemia 79 (27.9%) 72 (26.4%) 151(27.2%) 0.683 
Asthma 4 (1.4%) 2 (0.7%) 6 (1.1%) 0.438 
Others* 
 
6 (2.1%) 
 
5 (1.8%) 11 (3.9%) 0.317 
     
 
*p ≤ 0.05 **p ≤ 0.01/*Thyroid/Anemia/Tuberculosis/Thalassemia/Osteoporosis
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8.4 Prevalence study 
 
This part shows the results of the data analysis on the prevalence study of cognitive 
impairment and the prevalence study of depressive mood in the groups with and 
without HbA1c. The data is presented by calculating the percentage, p-value and 
95% confidence interval (CI) which indicates how precise the sample estimate is 
likely to be in relation to the true population value (Dos Santos Silva 1999) 
 
As shown in Table 8.8, the prevalence of probable cognitive impairment by Mini-
Cog was 65.4% in the group with HbA1c test and 64.4% in the group without 
HbA1c test. The prevalence of probable cognitive impairment by MMSE Thai 
2002 in the group with HbA1c was 12.4% and in the group without HbA1c test 
was 12.1%. The prevalence of probable depressive mood was equally 19.4% in 
both groups.  
 
Table 8.8: Estimation of the prevalence of probable cognitive impairment and 
depressive mood in the group with and without HbA1c 
 
Screening tests With HbA1c 
(N=283) 
Without HbA1c 
(N=273) 
 
P 95% CI of 
the difference 
Mini-Cog 
 
    
-Probable 
cognitive 
impaired 
 
65.4 % (185) 64.8% (177)  0.895 -0.073-0.085 
MMSE Thai 
2002 
 
    
- Probable 
cognitive 
impaired 
 
12.4% (35) 12.1%  (33) 0.920 -0.052-0.058 
TGDS 
 
    
-Probable 
depressed 
 
19.4% (55)  19.4% (53)  0.995 -0.066-0.066 
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8.5 Comparison of the prevalence of cognitive impairment and depressive 
mood between the groups with and without HbA1c test 
 
In order to check the selection bias in HbA1c test, the comparison of the 
prevalence between the two groups is analysed to see whether having or not having 
HbA1c test in this population affects the outcome measures (cognitive impairment 
and depressive mood) in the current study. 
 
As presented in table 8.8, there were no statistically significant differences in the 
prevalence of cognitive impairment by Mini-Cog (p =0.895, 95% CI 0.073, 0.085) 
and by MMSE Thai 2002 (p = 0.920, 95% CI -0.052, 0.058) between the two 
groups. Likewise, the difference of the prevalence of depressive mood by TGDS 
between the two groups was not found (p = 0.995, 95% CI -0.066, 0.066).  
 
In a descriptive epidemiology, the p-values should generally not be reported alone 
because they are designed to help deciding whether a set of observation is 
compatible with some hypothesis, and they do not provide information on the 
difference of effect (Dos Santos Silva 1999). For example, small effects of no 
epidemiological relevance can become ‘statistically significant’ with a large 
sample size, whereas important effects may be ‘statistically non-significant’ 
because the size of the sample studied was too small. In contrast, the confident 
interval (CI) provides an idea of likely difference of effects, and their width 
(margin of error) indicates the degree of uncertainty in the estimate of effect 
(Shakespeare et al. 2001). If the 95% confidence interval for a difference does not 
include the null hypothesis value of zero, then P-value is lower than 0.05. 
Conversely, if this CI includes the value of zero, i.e. one limit in positive and the 
other is negative, then P-value is greater than 0.05 (Du Prel 2009). 
 
Thus, in order to confirm the non-significant p-value of the differences in the three 
screening tests between the two groups, 95% CI for the difference between the two 
independent proportions (prevalence) was calculated. It can been observed in Table 
8.10 that the 95% confidence interval for the difference between the two 
proportions of the three screening tests included zero. As mentioned above, this 
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means that the p value is greater than 0.05 confirming a non-significant difference 
(Du Prel 2009). 
 
This result shows clearly that there is no statistically significant difference in the 
prevalence data between the groups with and without HbA1c. This means that 
neither the group with HbA1c test nor the group without HbA1c influenced the 
outcome measures (cognitive impairment and depressive mood). 
 
This result reveals that neither the group with HbA1c test nor the group without 
HbA1c influenced the outcome measures (cognitive impairment and depressive 
mood). Thus, the selection bias of HbA1c test towards the outcome measures has 
not been found in this population. Regarding the importance of focusing on 
glycaemic control by HbA1c test in this study, which was mentioned earlier in 
Chapters 1 and 7, only the data in the group with HbA1c test was used to analyse 
and represent the results of the target population in this study. The results are 
presented in Sections 8.6 – 8.8. 
 
8.6 Characteristics associated with cognitive impairment and depressive mood 
 
All univariate analyses were performed in relation to Mini-Cog scores. These 
associations were further explored to identify the potential individual predictors of 
the characteristics associated with cognitive impairment by Mini-Cog (multivariate 
logistic regression). The results were also reported as odds ratio (OR) and 
respective 95% confidence interval (CI). Odds ratios are used to compare the 
relative odds of the occurrence of the outcome of interest (e.g. cognitive 
impairment or depressive mood), and given exposure to the variable of interest 
(e.g. demographic or clinical characteristics). The odds ratio can be used to 
determine whether a particular exposure is a risk factor for a particular outcome, 
and to compare the magnitude of various risk factors for that outcome (Szumilas 
2010).   
OR=1 Exposure does not affect odds of outcome 
OR>1 Exposure associated with higher odds of outcome 
OR<1 Exposure associated with lower odds of outcome 
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The 95% CI is often used as a proxy for presence of statistical significance if it 
does not overlap the null value (e.g. OR=1) (Du Prel 2009). 
 
Univariate models describe the crude relationship between a variable (risk factor) 
and an outcome measure (cognitive impairment/ depressive mood). However, the 
crude relationship may not only reflect the effect of the viable, but may also reflect 
the effect of a confounder, which is associated with the risk factor (Heinze, 2009). 
A confounder defines as a variable that we may or may not has measured other 
than the risk factors in which we are interested that potentially affect the outcome 
measure (Field, 2009).  
 
This implies that the crude measure of effect reflects a mixture of the effect of the 
exposure and the effect of confounding factors. When confounding exists, 
analytical methods must be used to separate the effect of the exposure from the 
effects of the confounding factor(s). Multivariable modelling is one way to control. 
Thus, it has been proposed to include important factors from univariate into 
multivariable modelling to reduce the variability of the outcome measure (Heinze, 
2009). 
 
For a logistic regression model with only one independent variable, the OR is 
considered ‘‘unadjusted’’ because there are no other variables whose influence 
must be adjusted for or subtracted out. In contrast, if the logistic regression model 
includes multiple independent variables, the ORs are now ‘‘adjusted’’ because 
they represent the unique contribution of the independent variable after adjusting 
for (or subtracting out) the effects of the other variables in the model (Stoltzfus, 
2011). 
 
The analysis with MMSE Thai 2002 scores and TGDS scores was carried out in 
the same manner in order to find the independent predictors on cognitive 
impairment by MME Thai 2002 and individual predictors associated with 
depressive mood (see Chapter 7 for more details).  
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8.6.1 Association between the predictors and cognitive impairment by Mini-Cog  
 
The univariate and multivariate logistic regression revealed a number of 
associations (see Table 8.9). The characteristics of participants who were more 
likely to be reported as having cognitive impairment were as the following: they 
were 60-64 years old (OR = 3.84, 95% CI 1.92, 7.67), had attended school for 
more than 4 years (OR = 8.56, 95% CI 1.99, 36.75), and they were working      
(OR = 1.8, 95% CI 1.06, 3.09). The other clinical associations with cognitive 
impairment were BMI 23-25 kg/m
2
 and more than 25 kg/m
2
 (OR = 2.60, 95% CI 
1.18, 5.70 and OR = 1.40, 95% CI 0.82, 2.38, respectively), FBS more than 140 
mg/dl or 7.8 mmol/l (OR = 1.95, 95% CI 1.13, 3.34), total cholesterol less than 200 
mg/dl or 11.1mmol/l and  HDL less than 40 mg/dl or 2.2 mmol/l (OR = 2.20, 95% 
CI 1.04, 4.64 and OR=1.55, 95% CI 0.95, 2.53 respectively).  
 
The important independent predictors of cognitive impairment by Mini-Cog in the 
prognostic model were as the following: being aged 60-64 (OR = 3.62, 95% CI 
1.70, 7.71), being aged 65-69 (OR = 2.90, 95% CI 1.25, 6.72), being aged 70-74 
(OR = 2.39, 95% CI 1.02, 5.57), having more than 4 years in school (OR= 9.31, 
95% CI = 2.11, 41.05), with BMI 23-25 kg/m2 (OR = 2.78, 95% CI 1.21, 6.38), 
high BMI of more than 25 kg/m
2
 (OR = 1.05, 95% CI 0.58,1.89), and poor HDL of 
less than 40 mg/dl or 2.2 mmol/l (OR = 2.43, 95% CI 1.10, 5.38).  
 
As shown in Table 8.9, in the univariate analysis, having FBS of more than 140 
mg/dl or 7.8 mmol/l by its own showed a statistically significant association with 
cognitive impairment by Mini-Cog with an unadjusted OR = 1.95, 95% CI 1.13, 
3.34, P = 0.016). It showed that the participants who had an FBS of more than 140 
mg/dl or 7.8 mmol/l were 1.95 times more likely to have cognitive impairment 
than those with an FBS of more than 140 mg/dl or 7.8 mmol/l. The P value of 
0.016 was less than 0.05 indicating that the upper (3.34) and lower limits (1.13) of 
the 95% confidence interval excluded the null value. However, in the multivariable 
model logistic regression analysis, having an FBS of more than 140 mg/dl or 7.8 
mmol/l was not a statistically significant and not important contribution to the 
model (adjusted OR = 1.66, 95% CI 0.93, 2.98, P = 0.088), controlling for all other 
factors in the model. This indicates that the participants having an FBS of more 
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than 140 mg/dl or 7.8 mmol/l were not strongly associated with cognitive 
impairment by Mini-Cog. The P value at 0.08 was more than 0.05. This indicates 
that the upper (2.98) and lower limits (0.93) of the 95% confidence interval were 
close to the null value. Thus, having FBS of more than 140 mg/dl or 7.8 mmol/l 
had a low risk of cognitive impairment and may be a potential confounding 
variable in this study. Nevertheless, the lower limit of 95% CI adjusted OR of 
having an FBS of more than 140 mg/dl or 7.8 mmol/l was at 0.93, which was close 
to 1. If the alpha level was set at 10%  (P<0.1), this variable (having an FBS of 
more than 140 mg/dl or 7.8 mmol/l) might therefore be considered significant 
evidence and contributed to the model.  
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Table 8.9: Univariate and Multivariate logistic regression of Mini-Cog 
Characteristics Impair/Total (%) Univariate logistic 
regression 
 
Multivariate logistic 
regression 
OR  (95% CI) P OR  (95% CI) P 
Gender      
-Male 72/103 (69.9%) 1.38(0.82-2.31) 0.23    
-Female 113/180 (62.8%) 1    
 
Age (years) 
     
60-64 89/121 (73.6%) 3.84 (1.92-7.67)  3.62 (1.70-7.71)  
65-69 42/60 (70%) 3.22 (1.47-7.08)  2.90 (1.25-6.72)  
70-74 33/52 (63.5%) 2.40 (1.08-5.32)  2.39 (1.02-5.57)  
75+ 21/50 (42%) 1 0.002 - 0.009 
 
Education 
     
-Never attended to 
school 
10/19 (52.6%) 1    
-Attending the school 175/264 (66.3%) 1.77 (0.69-4.51) 0.232   
 
Year in school 
     
≤4 157/253 (62.1%) 1  1  
>4 28/30 (93.3%) 8.56 (1.99-36.75) 0.004 9.31 (2.11-41.05) 0.003 
 
Living alone 
     
- No 180/273 (65.9%) 1.94 (0.55-6.86) 0.306   
-Yes 5/10 (50%) 1    
 
Working  
     
-No 112/184 (60.9%) 1    
-Yes 73/99 (73.7%) 1.8 (1.06-3.09) 0.031   
 
Smoking 
     
-No 170/263 (64.6%) 1    
-Yes 15/20 (75%) 1.64 (0.58-4.66)  0.352   
 
Drinking 
     
-No 168/260 (64.6%) 1    
-Yes 17/23 (73.9%) 1.55 (0.59-4.07) 0.372   
 
Exercise 
     
-No 93/134 (69.4%) 1.41 (0.86-2.30) 0.177   
-Yes  92/149 (61.7%) 1    
 
 
Body Mass 
Index(kg/m2)  
     
<23  70/119 (58.8%) 1 0.053 1 0.045 
23-25 37/47 (78.7%) 2.60 (1.18-5.70)  2.78 (1.21-6.38)  
>25+ 78/117 (66.7%) 1.40 (0.82-2.38)  1.05 (0.58-1.89)  
 
Blood Pressure (BP) 
     
Systolic (mmHg)      
≤130 normal 74/112(66.1%) 1.05(0.64-1.74) 0.841   
>130  111/171(65%) 1    
Diastolic (mmHg)      
≤80 normal 117/180 (65%) 1    
>80  68/103 (66%) 1.05 (0.63-1.74) 0.862   
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Characteristics Impair/Total (%) Univariate logistic 
regression 
 
Multivariate logistic 
regression 
OR  (95% CI) P OR  (95% CI) P 
Fasting blood Sugar 
(mg/dl or mmol/l) 
≤140 (≤7.8) normal 111/184 (60.3%) 1  1  
>140 (>7.8) 74/99 (74.7%) 1.95 (1.13-3.34) 0.016 1.66 (0.93-2.98) 0.088 
 
Total Cholesterol 
(mg/dl or mmol/l) 
     
≤200 (≤11.1) normal  105/150 (70%) 1.55 (0.95-2.53) 0.083   
>200 (>11.1) 
 
80/133 (60.2%) 1    
Low density 
lipoprotein (LDL) 
(mg/dl or mmol/l) 
     
≤100 (≤5.6) normal  48/78 (61.5%) 1    
>100 (>5.6) 
 
137/205 (66.8%) 1.26 (0.73-2.16) 0.404   
High density 
lipoprotein  (HDL) 
(mg/dl or mmol/l) 
     
≤ 40 (≤2.2) abnormal   37/47 (78.7%) 2.20 (1.04-4.64) 0.038 2.43 (1.10-5.38) 0.028 
> 40 (>2.2) normal 
 
148/236 (62.7%) 1    
Triglyceride (mg/dl 
or mmol/l) 
     
≤ 150 (≤8.3) normal 116/177 (65.5%) 1.02 (0.62-1.69) 0.940   
>150 (>8.3) 
 
69/106 (65.1%) 1     
HbA1c (% or 
mmol/mol) 
≤ 7 (≤ 53) 
>7 (> 53) 
 
24/40(60%) 
161/243(66%) 
 
1.31(0.66-2.60) 
1 
 
0.442 
  
 
Duration of 
diabetes (years)  
     
1-4 50/74 (27%) 1.36 (0.73-2.54) 0.430   
5-8 72/105 (38.9%) 1.42 (0.80-2.51)    
8+ 
 
63/104 (34.1%) 1    
 
Diabetes treatment 
     
 
diet alone 
 
 
26/48 (54.2%) 
 
1.18 (0.70-20.01) 
 
0.317 
  
oral medication+ diet 
 
153/225 (68%) 2.13 (0.13-34.46)    
insulin injection+diet 
 
5/8 (62.5%) 1.67 (0.07-37.73)    
Combined  
(oral medication+ 
insulin injection+diet 
1/2 (50%) 1    
 
Diabetes 
complication 
     
Neuropathy      
-No 177/272 (65.1%) 1 0.603   
-Yes 8/11 (72.7%) 1.43 (0.37-5.52)    
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Characteristics Impair/Total (%) Univariate logistic 
regression 
 
Multivariate logistic 
regression 
OR  (95% CI) P OR  (95% CI) P 
 Retinopathy      
-No 160/237 (67.5%) 1.74 (0.92-3.31) 0.088   
-Yes 25/46 (54.3%) 1    
Nephropathy      
-No 159/244 (65.2%) 1    
-Yes 
 
26/39 (66.7%) 1.07 (0.52-2.19) 0.855   
Co-morbid disease      
Heart disease      
-No 179/276 (64.9%) 1    
-Yes 
 
6/7 (85.7%) 3.25 (0.39-27.40) 0.278   
Hypertension      
-No 47/74 (63.5%) 1    
-Yes 138/209 (66%) 1.12 (0.64-1.94) 0.696   
 
Chronic obstructive 
pulmonary disease 
(COPD) 
     
-No 182/279 (65.2%) 1    
-Yes 
 
3/4 (75%) 1.60 (0.16-15.58) 0.686   
Gout      
-No 179/277 (64.6%) 1    
-Yes 
 
6/6 (100%) N/A N/A   
Arthritis      
-No 183/280 (65.4%) 1    
-Yes 
 
2/3 (66.7%) 1.06 (0.1-11.84) 0.962   
Dyslipidemia      
-No 131/204 (64.2%) 1    
-Yes 
 
54/79 (68.4%) 1.2 (0.7-2.1) 0.512   
Asthma      
-No 182/279 (65.2%) 1    
-Yes  
 
3/4 (75%) 1.6 (0.16-15.58) 0.686   
Others *      
-No 183/279 (65.6%) 1.91 (0.26-13.74) 0.522   
-Yes 
 
2/4 (50%) 1    
*Thyroid/Anemia/Tuberculosis/Thalassemia/Osteoporosis 
 
N/A: The predictor could not be applied to the analysis in the multivariate logistic 
regression because the analysis requires at least 10 positives and 10 negatives variables per 
predictor (Peacock and Kerry 2007). 
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8.6.2 Association between the predictors and cognitive impairment by MMSE Thai 
2002 
 
Table 8.10 shows that the participants aged 65-69, 70-74 and more than 74 are 
more likely to have cognitive impairment than the participants aged 60-64           
(OR = 1.57, 95% CI 0.52, 4.75, OR = 1.84, 95% CI 0.61, 5.61 and OR = 6.10, 95% 
CI 2.37, 15.47). Participants who had a total cholesterol of more than 200 mg/dl or 
11.1 mmol/l seemed to have more cognitive impairment than the participant who 
had total cholesterol of less than 200 mg/dl or 11.1 mmol/l (OR = 1.82, 95% CI 
0.89, 3.75). Participants who never attended school were more probable to have 
cognitive impairment than the participants who attended school (OR = 8.24, 95% 
CI 3.01, 22.11).  
 
The important characteristics which were independently associated with cognitive 
impairment by MMSE Thai 2002 were the aged group of more than 74 and never 
attending school (OR = 4.57, 95% CI 1.72,12.14 and OR = 6.19, 95% CI 2.12, 
18.10 respectively) .  
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Table 8.10:Univariate and multivariate logistic regression of the MMSE Thai 2002 
 
Characteristics 
 
Impair/Total (%) 
 
Univariate logistic 
regression 
Multivariate logistic 
regression 
 
OR  (95% CI) 
 
P 
 
OR  (95% CI) 
 
P 
Gender      
-Male 10/103 (9.7%) 1    
-Female 
 
25/180 (13.9%) 1.5 (0.69-3.26) 0.306   
Age (years)      
60-64 8/121 (6.6%) 1 0.001 1 0.011 
65-69 6/60 (10.6%) 1.57 (0.52-4.75)  1.50 (0.49-4.58)  
70-74 6/52  (11.5%) 1.84 (0.61-5.61)  1.30 (0.40-4.21)  
75+ 
 
15/50 (30.0%) 6.10 (2.37-15.47  4.57 (1.72-12.14)  
Education      
-Never attended 
school 
9/19 (47.4%) 8.24 (3.01-22.11) 0.001 6.19 (2.12-18.10) 0.001 
-Attending school 
 
26/264 (9.8%) 1    
Year in school      
≤4 30/253 (11.9%) 1    
>4 
 
5/30 (16.7%) 1.49 (0.53-4.178) 0.452   
Living alone      
- No 35/273 (12.8%) N/A N/A   
-Yes 
 
0/10 (0%) 1    
Working       
-No 25/184(13.6%) 1.4 (0.64-3.05) 0.397   
-Yes 10/99 (10.1%)     
 
Smoking 
     
-No 32/263 (12.2%) 1    
-Yes 
 
3/20 (15%) 1.27 (0.35-4.60) 0.711   
Drinking      
-No 34/260 (13.1%) 3.31 (0.43-25.36) 0.249   
-Yes 
 
1/23 (4.3%) 1    
Exercise      
-No 20/134 (14.9%) 1.57 (0.77-3.20) 0.218   
-Yes  
 
15/149 (10.1%) 1    
Body Mass 
Index(kg/m2) 
     
<23 18/119 (15.1%) 1.72 (0.77-3.82) 0.414   
23-25 6/47 (12.8%) 1.41 (0.50-4.10)    
>25+ 
 
11/106 (9.4%) 1    
Blood Pressure (BP)      
Systolic (mmHg)      
≤130 normal 14/112(12.5%) 1.02(0.50-2.10) 0.956   
>130  21/171(12.3%) 1    
Diastolic (mmHg)      
≤80 normal 24/180 (13.3%) 1.29 (0.60-2.75) 0.515   
>80 
 
11/103 (10.7%) 1    
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Characteristics 
 
Impair/Total (%) 
 
Univariate logistic 
regression 
Multivariate logistic 
regression 
 
OR  (95% CI) 
 
P 
 
OR  (95% CI) 
 
P 
Fasting Blood Sugar 
(mg/dl or mmol/l) 
     
≤140 (≤7.8) normal 19/184 (10.3%) 1    
>140 (>7.8) 
 
16/99 (16.2%) 1.67 (0.82-3.42) 0.158   
Total Cholesterol 
(mg/dl or mmol/l) 
     
≤200 (≤11.1) normal  14/150 (9.3%) 1    
>200 (>11.1) 
 
21/133 (15.8%) 1.82 (0.89-3.75) 0.103   
Low density 
lipoprotein (LDL) 
(mg/dl or mmol/l) 
     
≤100 (≤5.6) normal  7/78 (9%) 1    
>100 (>5.6) 
 
28/205 (13.7%) 1.61 (0.67-3.84) 0.288   
High density 
lipoprotein  (HDL) 
(mg/dl or mmol/l) 
     
≤ 40 (≤2.2) abnormal   4/47 (8.5%) 1 0.380   
> 40 (>2.2) normal 
 
31/236 (13.1%) 1.63 (0.55-4.84)    
Triglyceride (mg/dl 
or mmol/l) 
     
≤ 150 (≤8.3) normal 23/177 (13%) 1.17 (0.56-2.46) 0.679   
>150 (>8.3) 12/106 (11.3%) 1    
      
HbA1c (% or 
mmol/mol) 
     
≤ 7 (≤ 53) 20/136(14.7%) 1.51 (0.74-3.10) 0.253   
>7 (> 53) 
 
Duration of diabetes 
(years)  
15/147(10.2%) 1    
1-4 10/74 (28.6%) 1.00 (0.42-2.40) 0.760   
5-8 11/105 (31.4%) 0.75 (0.32-1.74)    
8+ 
 
14/104 (40.0%) 1    
Diabetes treatment      
diet alone 
 
5/48 (10.4%) N/A 0.737   
oral medication+ 
diet) 
 
28/225 (12.4%) N/A    
insulin 
injection+diet) 
 
2/8 (25%) N/A    
Combined  
(oral medication+ 
insulin 
injection+diet) 
 
0/2 (0)%) 1    
Diabetes 
complication 
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Characteristics 
 
Impair/Total (%) 
 
Univariate logistic 
regression 
Multivariate logistic 
regression 
 
OR  (95% CI) 
 
P 
 
OR  (95% CI) 
 
P 
Neuropathy 
-No 33/272 (12.1%) 1    
-Yes 2/11 (18.2%) 1.61 (0.33-7.78) 0.554   
 
Retinopathy 
     
-No 29/237 (12.2%) 1    
-Yes 
 
6/46 (13%) 1.10 (0.42-2.76) 0.879   
Nephropathy      
-No 30/244 (12.3%) 1    
-Yes 
 
5/39 (12.8%) 1.10 (0.38-2.90) 0.926   
Co-morbid disease      
Heart disease 33/276 (12%) 1    
-No 2/7 (28.6%) 2.95 (0.55-15.80) 0.207   
-Yes 
 
     
Hypertension 8/74 (10.8%) 1    
-No 27/209 (12.9%) 1.22 (0.53-2.83) 0.636   
-Yes 
 
     
Chronic obstructive 
pulmonary disease 
(COPD) 
32/279 (11.5%) 1    
-No 32/279 (11.5%) 1    
-Yes 
 
3/4 (75%) 23.16 (2.34-229.34) 0.007
a
   
Gout      
-No 33/277 (11.9%) 1    
-Yes 
 
2/6 (33.3%) 3.70 (0.65-20.98) 0.140
a
   
Arthritis      
-No 33/280 (11.8%) 1    
-Yes 
 
2/3 (66.7%) 15.0 (1.32-169.66) 0.029
a
   
Dyslipidemia      
-No 25/204 (12.3%) 1    
-Yes 
 
10/79 (12.7%) 1.04 (0.47-2.27) 0.926   
Asthma      
-No 35/279 (12.5%) N/A N/A   
-Yes  
 
0/4 (0%) 1    
Others *      
-No 34/279 (12.2%) 1    
-Yes 
 
1/4 (25%) 2.40 (0.24-23.75) 0.454   
*Thyroid/Anemia/Tuberculosis/Thalassemia/Osteoporosis 
 
a
 and N/A : The predictor could not be applied to the analysis in the multivariate logistic 
regression because the analysis requires at least 10 positives and 10 negatives variables per 
predictor (Peacock and Kerry 2007).
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8.6.3 Association between the predictors and depression by TGDS 
 
Table 8.11 shows that the female participants (OR = 1.68, 95% CI 0.88, 3.21), the 
participants aged  65-69, 70-74 and more than 74 (OR = 1.53, 95% CI 0.68, 3.45; 
OR = 2.72, 95% CI 1.25, 5.94 and OR = 1.53, 95% CI 0.65, 3.62 respectively), 
those who had less than  4 years in school (OR = 3.71, 95% CI 0.86, 16.07), those 
who did not work (OR = 2.21, 95% CI 1.11, 4.42), and did not exercise (OR = 
1.89,  95% CI 1.04,  3.44) were also associated with depression.  
 
Other clinical associations with depression were a high total cholesterol of more 
than 200 mg/dl or 11.1 mmol/l (OR = 1.60, 95% CI 0.88, 2.89), HDL of more than 
40 mg/dl or 2.2 mmol/l     (OR = 2.26, 95% CI 0.85, 6.01), LDL of less than 100 
mg/dl or 5.6 mmol/l (OR = 1.23, 95% CI 0.17, 1.18) and having retinopathy as a 
diabetes complication (OR = 3.07, 95% CI 1.54, 6.13). 
 
Overall, the major important predictor for depression in this study was having 
retinopathy as the diabetic complication (OR = 3.28, 95% CI 1.57, 6.90). 
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Table 8.11: Univariate and Multivariate logistic regression of the TGDS 
 
Characteristics Impair/total 
(%) 
Univariate logistic 
regression 
 
Multivariate logistic 
regression 
OR (95% CI) P OR (95% CI) P 
Gender      
-Male 15/103 (14.6%) 1    
-Female 
 
40/180 (22.2%) 1.68 (0.88-3.21) 0.120   
Age (years)      
60-64 17/121 (14%) 1 0.098   
65-69 12/60 (20%) 1.53 (0.68-3.45)    
70-74 16/52 (30.8%) 2.72 (1.25-5.94)    
75+ 
 
10/50 (20%) 1.53 (0.65-3.62)    
Education      
-Never attended 
to school 
6/19 (31.6%) 2.03 (0.73-5.60) 0.173   
-Attending the 
school 
 
49/264 (18.6%) 1    
Year in school      
≤4 53/253 (20.9%) 3.71 (0.86-16.07) 0.080   
>4 
 
2/30 (6.7%) 1    
Living alone      
- No 53/273 (19.4%) 1    
-Yes 
 
2/10 (20%) 1.04 (0.21-5.03) 0.963   
Working       
-No 43/184 (23.4%) 2.21 (1.11-4.42) 0.025   
-Yes 
 12/99 (12.1%) 1 
   
Smoking      
-No 52/263 (19.8%) 1.40 (0.39-4.95) 0.605   
-Yes 
 
3/20 (15%) 1    
Drinking      
-No 52/260 (20%) 1.67 (0.48-5.82) 0.424   
-Yes 
 
3/23 (13%) 1    
Exercise      
-No 33/134 (24.6%) 1.89 (1.04-3.44) 0.038   
-Yes  
 
22/149 (14.8%) 1    
Body Mass 
Index(kg/m2)  
     
<23  26/93 (21.8%) 1.21 (0.64-2.28) 0.582   
23-25 7/40 (14.9%) 0.76 (0.30-1.91)    
>25+ 
 22/117 (18.8%) 1  
  
Blood Pressure 
(BP) 
     
Systolic (mmHg)      
≤130 normal 22/112(19.6%) 1.02(0.56-1.87) 0.943   
>130  33/171(19.3%) 1    
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Characteristics Impair/total 
(%) 
Univariate logistic 
regression 
 
Multivariate logistic 
regression 
OR (95% CI) P OR (95% CI) P 
Diastolic 
(mmHg) 
≤80 normal 37/180 (20.6%) 1.22 (0.66-2.28) 0.529   
>80 18/103 (17.5%) 1    
      
Fasting Blood 
Sugar(mg/dl or 
mmol/l) 
     
≤140 (≤7.8)  37/184 (20.1%) 1.13 (0.61-2.12) 0.696   
>140 (>7.8) 
 
18/99 (18.2%) 1 
 
  
Total 
Cholesterol 
(mg/dl or 
mmol/l) 
     
≤200 (≤11.1)  24/150 (16%) 1    
>200 (>11.1) 
 
31/133 (23.3%) 1.60 (0.88-2.89) 0.123   
Low density 
lipoprotein 
(LDL) (mg/dl or 
mmol/l) 
     
≤100 (≤5.6)  17/78 (21.8%) 1.23 (0.17-1.18) 0.103   
>100 (>5.6) 
 
38/205 (18.5%) 1    
High density 
lipoprotein  
(HDL) 
(mg/dl or 
mmol/l) 
     
≤ 40 (≤2.2)  5/47 (10.6%) 1 0.103   
> 40 (>2.2) 
 
50/236 (21.2%) 2.26 (0.85-6.01)    
Triglyceride 
(mg/dl or 
mmol/l) 
     
≤ 150 (≤8.3)  34/177 (19.2%) 1    
>150 (>8.3) 
 
21/106 (19.8%) 1.04 (0.57-1.91) 0.901   
HbA1c (% or 
mmol/mol) 
     
≤7 (≤ 53) 28/136 (20.6%) 1.15(0.64-2.08) 0.637   
>7 (> 53) 
 
27/147 (18.4%) 1    
Duration of 
diabetes (years)  
     
1-4 15/74 (27.3%) 1.07(0.51-2.26) 0.977   
5-8 20/105 (36.4%) 1.0 (0.50-1.97)    
8+ 
 
20/104 (36.4%) 1    
Diabetes 
treatment 
     
diet alone 
 
15/48 (31.2%) 0.455 (0.027-7.766) 0.132   
oral medication+ 
diet 
39/225 (17.3%) 0.210 (0.013-3.425)    
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Characteristics Impair/total 
(%) 
Univariate logistic 
regression 
 
Multivariate logistic 
regression 
OR (95% CI) P OR (95% CI) P 
 
Insulin- 
injection+diet 
 
0/8 (0%) N/A    
Combined  
(oral medication+ 
insulin 
injection+diet) 
1/2(50%) 1    
 
Diabetes 
complication 
     
Neuropathy      
-No 54/272 (19.9%) 2.48 (0.31-19.77) 0.392   
-Yes 1/11 (9.1%) 1    
Retinopathy      
-No 38/237 (16%) 1  1  
-Yes 17/46 (37%) 3.07 (1.54-6.13) 0.001 3.28 (1.57-6.36) 0.002 
Nephropathy      
-No 50/244 (20.5%) 1.75 (0.65-4.71) 0.266   
-Yes 
 
5/39 (12.8%) 1    
Co-morbid 
disease 
     
Heart disease 54/276 (19.6%) 1.46 (0.17-12.38) 0.729   
-No 1/7 (14.3%)     
-Yes 
 
     
Hypertension 13/74 (17.6%) 1    
-No 42/209 (20.1%) 1.18 (0.59-2.35) 0.637   
-Yes 
 
     
Chronic 
obstructive 
pulmonary 
disease (COPD) 
     
-No 54/279 (19.4%) 1    
-Yes 
 
1/4 (25%) 1.39 (0.14-13.61) 0.778   
Gout      
-No 53/277 (19.1%) 1 0.395   
-Yes 
 
2/6 (33.3%) 2.11 (0.38-11.84) 0.395   
Arthritis      
-No 54/280 (19.3%) 1    
-Yes 
 
1/3 (33.3%) 2.09 (0.19-23.50) 0.550   
Dyslipidemia      
-No 38/204 (18.6%) 1    
-Yes 
 
17/79 (21.5%) 1.20 (0.63-2.28) 0.582   
Asthma      
-No 55/279 (19.7%) N/A N/A   
-Yes  
 
0/4 (0%)  1    
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Characteristics Impair/total 
(%) 
Univariate logistic 
regression 
 
Multivariate logistic 
regression 
OR (95% CI) P OR (95% CI) P 
Others * 
-No 55/279 (19.7%) N/A N/A   
-Yes 
 
0/4 (0%) 1    
*Thyroid/Anemia/Tuberculosis/Thalassemia/ Osteoporosis 
 
N/A : The predictor could not be applied to the analysis in the multivariate logistic 
regression because the analysis requires at least 10 positives and 10 negatives variables per 
predictor (Peacock and Kerry 2007)
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8.7 Relationship between cognitive impairment and depressive mood 
(controlling for potential confounders) 
 
As documented in Chapter 2, the variables potentially confounding the cognitive 
screening test and depressive mood screening test in Thai population are age and 
years of education (Wongchaisuwan et al. 2005, Thaneerat et al. 2009). Thus, 
partial correlations were performed to examine the relationship between the 
cognition scores and depressive mood scores while adjusting for the effects of 
variables such as age and years of education.   
 
Age and years of education are most likely to be positive confounders. The 
association between cognitive impairment and depressive mood is more extreme. 
On controlling, this would be expected to weaken the association (Pallant 2009) 
(see Tables 8.12 - 8.14). 
 
 
Table 8.12: Correlation coefficients between cognitive function scores and TGDS 
scores (partial correlations controlling age) 
 
 
Scores 
 
Mini-Cog MMSE Thai 2002 
 
TGDS 
 
-0.2* 
 
 
-0.3** 
 
* p<0.01 ** p<0.001 
 
 
After controlling age, the depressive mood scores were significantly negative and 
correlated with cognitive scores by Mini-Cog (rs = -0.2, p<0.01). Similarly, the 
depressive mood scores were significantly negative and correlated with cognitive 
scores by MMSE Thai 2002 (rs = -0.3, p<0.001).  
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Table 8.13: Correlation coefficients between cognitive function scores and TGDS 
scores (partial correlations controlling years of education) 
 
 
Scores 
 
Mini-Cog MMSE Thai 2002 
 
TGDS 
 
-0.1* 
 
 
-0.2** 
 
* p<0.05 ** p<0.001 
 
After controlling for the years of education, the depressive mood scores were 
significantly negative and correlated with cognitive scores by Mini-Cog ( rs = -0.1, 
p<0.05). Similarly, the depressive mood scores were significantly negative and 
correlated with cognitive scores by MMSE Thai 2002 (rs = -0.2, p<0.001).  
 
 
Table 8.14: Correlation coefficients between cognitive function scores and TGDS 
scores (partial correlations controlling for age and years of education) 
 
Scores 
 
Mini-Cog MMSE Thai 2002 
 
TGDS 
 
-0.1 
 
 
-0.2* 
 
* p<0.01 
 
 
After controlling the age and years of education, the depressive mood scores were 
still significant and correlated with cognitive scores from MMSE Thai 2002           
(rs = -0.2, p<0.01) but there was no significant correlated between the depressive 
mood scores and cognitive scores from Mini-Cog (rs = -0.1, p = 0.06). 
 
Overall, the negative correlation coefficients in Tables 8.12-8.14 show that higher 
level of depression scores was associated with lower level of cognitive function. 
This implies that the participants who had high scores in depressive mood 
screening test (scores > 12 showing low mood) tended to have low level of 
cognitive function (scores ≤ 2 for Mini-Cog and scores ≤ 14 for MMSE Thai 2002 
showing low cognitive function).  
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It can be seen from Tables 8.12 - 8.14 that the scores from Mini-Cog and MMSE 
Thai 2002 were modest negatively correlated with TGDS scores. It shows that the 
higher score (cognitive impairment) in Mini-Cog and MMSE Thai 2002 were 
associated with the lower score in TGDS (depressive mood). In other words, the 
participants who had cognitive impairment seemed to have depressive mood.  
 
In order to see the correlation between Mini-Cog and MMSE Thai 2002, the 
Spearman correlation was analysed. As can be observed in Table 8.15, there was a 
significant positive correlation between the scores of Mini-Cog and MMSE Thai 
2002 with Spearman’s rank order correlation coefficient rs = 0.44, P= 0.001. It is 
clear that the scores in Mini-Cog were moderate positively correlated with the 
scores in MMSE Thai 2002. The higher score in Mini-Cog were associated with 
the higher score in MMSE Thai-2002. Therefore, it was shown that Mini-Cog and 
MMSE Thai 2002 screening tests yielded the results in the same direction. 
 
 
Table 8.15: Correlation coefficients between the scores of Mini-Cog Thai version 
and MMSE Thai 2002 
 
 MMSE Thai 2002 
 
 Spearman rho( rs ) p 
Mini-cog 0.44 
 
0.001 
 
 
 
For the agreement between Mini-Cog and MMSE Thai 2002, the kappa agreement 
was analysed. As can be seen in Table 8.16, Mini-Cog and MMSE Thai 2002 
agreed on the result of ‘impaired’ (4.9%) and ‘not impaired’ (27.2%). In 60.4% of 
the cases Mini-Cog disagreed with MMSE Thai 2002 on ‘not impaired’. In total, 
the agreement on the ‘impaired’ and ‘not impaired’ between Mini-Cog and MMSE 
was 32.1%.  The Kappa (K) statistics for the agreement between the Mini-Cog and 
MMSE Thai 2002 was less than chance agreement with  K = -0.1, p= 0.001 , 95% 
CI -0.169, -0.031 (Altman, 1991) (see Section 6.10 for the levels of agreement). 
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These findings show that Mini-Cog and MMSE Thai 2002 were in potential 
disagreement between the results of cognitive impairment. 
 
 
Table 8.16: 2x2 Table of the agreement between the Mini-Cog and MMSE Thai 
2002  
 
 
 
MMSE Thai 2002  Total N (%) 
Impaired Not impaired 
 
 
 
Mini-Cog 
 
Impaired 
 
14(4.9%)  171(60.4%) 185(65.4%) 
 
 
Not impaired 21(7.4%) 77(27.2%) 98 (34.6%) 
 
 
Total N (%) 
 
  
35(12.4%) 
 
248(87.6%) 
 
283 (100%) 
 
 
 
 
8.8 Comparison of the results (by cut-off scores) of cognitive and depressive 
mood screening tests between good and poor glycaemic control (HbA1c) 
groups 
 
In order to see that participants who had good glycaemic control (HbA1c ≤ 7% or 
53 mmol/mol) and poor glycaemic control (HbA1c > 7% or 53 mmol/mol) show 
similar or different patterns of scores in cognitive screening tests and depressive 
mood screening tests, the Man-Whitney U was conducted for the analysis. 
 
 
 
 
 
 
 
 
 
 146 
 
Table 8.17: Comparison of the score results based on the cut-off score between 
good and poor glycaemic control  
 
 Good 
glycaemic 
control 
(Hba1c ≤7% 
53 mmol/mol) 
 
(N=136) 
Poor 
glycaemic 
control 
(HbA1c > 7% 
53 mmol/mol) 
 
(N=147) 
P 95% CI of 
difference 
 
Mini-Cog  
 
 
3 (0-5) 
 
 
3 (0-5) 
 
 
0.215 
 
-0.49-0.49 
 
MMSE Thai 
2002
 
 
 
22 (12-22) 
 
22(16-22) 
 
0.362 
 
-1.10-1.10 
 
TGDS  
 
6 (0-22) 
 
 
(0-25) 
 
 
0.921 
 
-2.77-0.77 
 
*Data is presented in median (range) 
 
As can be observed in Table 8.16, the data shows that there were no differences in 
the result scores of Mini-Cog, MMSE Thai 2002 and TGDS between the good and 
poor glycaemic control groups. The above result shows that the levels of glycaemic 
control between the good ( HbA1c ≤ 7% or 53 mmol/mol) and poor (HbA1c > 7% 
or 53 momol/mol) glycaemic control might not have an impact on the score results 
of cognitive screening tests and depressive mood screening test in the current 
study. Therefore, it is unlikely that the level of glycaemic control in this study 
affects the score results of screening  tests.  
 
8.9 Summary 
 
This chapter showed the substantial level of agreement (K = 0.8, p< 0.000) 
between the researcher and the RA. This information provides the support for the 
researcher and the RA in performing all screening tools in the same manner with 
reliable results in the main study. This study found 65.4% and 12.4% prevalence of 
cognitive impairment and 19.4% of depressive mood in Thai older people with 
type 2 diabetes at the primary care settings. The potential characteristics of 
cognitive impairment by Mini-Cog test are young old age (age < 75 years), having 
 147 
 
years in school more than 4 years, high BMI (> 25 kg/m
2
, poor level of HDL (<40 
mg/dl or 2.2 mmol/l), whereas the potential characteristics of cognitive impairment 
by MMSE Thai 2002 are old age (age 75+ years) and never attending school. 
Retinopathy was found to be a strong predictor for depressive mood in the current 
study. The results also showed that cognitive impairment was related to depressive 
mood. This means that the diabetic patients who had cognitive impairment seemed 
to have depressive mood and vice versa. However, the study did not find the 
differences of score results (by the cut-off point) in cognitive and depressive mood 
screening tests between the good and poor control of glycaemic control (HbA1c). 
This shows that either good or poor level of glycaemic control did not relate to the 
cognitive impairment and depressive mood in this study. In order to see whether 
the findings in the current study support or differ from the previous studies and the 
existing knowledge, the discussion of the findings including the difference of 
prevalence rate between Mini-Cog and MMSE Thai 2002 and implications of the 
prevalence study will be presented in the next chapter. 
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Chapter 9 
Discussion 
 
 
This is the first epidemiological cross-sectional study of the prevalence of 
undiagnosed cognitive impairment and the prevalence of undiagnosed depressive 
mood in Thai older people with type 2 diabetes in Thai primary care settings. The 
aims of the study areas are the following: 
a) estimating the prevalence of cognitive impairment in rural Thai older 
people (aged 60+ years) with type 2 diabetes who have never received a 
diagnosis of cognitive impairment 
b) estimating the prevalence of depressive mood in rural Thai older people 
(aged 60+ years) with type 2 diabetes who have never received a diagnosis 
of depressive mood 
c)  examining the association between cognitive function and depressive 
mood  
d) examining the relationship between the cognitive function or depressive 
mood and glycaemic control 
 
This chapter discusses the findings of the study in relation to the relevant literature 
and existing knowledge. The discussion is presented in accordance with the 
research findings. 
9.1 The characteristics of the groups with and without HbA1c test 
 
The data of demographic and clinical characteristics between the groups with and 
without HbA1c was different in the following variables (see Tables 8.6 and 8.7 in 
Chapter 8): 
9.1.1 Living arrangement 
 
The data in Table 8.6 shows that the group without HbA1c test tended to live alone 
compared to the group with HbA1c test (p = 0.048). The criteria of diabetic 
patients who received the HbA1c test in this study setting depended on the ability 
of having a good control of blood sugar by FBS. Thus, it is possible that living 
alone might have an impact on the ability to control blood sugar. Living alone 
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influences the ability to control blood glucose level in terms of diabetic self-care of 
the patients. Diabetes is a life-long disease that requires daily planning and 
decision-making (Thorne et al. 2003). In this long process, social support is crucial 
for diabetic patients in terms of sharing emotions and feelings or receiving help 
from family and friends in everyday life to achieve a good glycaemic control (Lo 
1999, Toljamo and Hentinen 2001). In addition, it is possible that lack of social 
support may lead to less attention and adherence to self-care among patients with 
diabetes (Cameron 1996). As a result, this study supports the previous studies of 
Lo 1999, and Toljamo and Hentinen 2001 showing that living alone may have an 
impact on poor blood sugar control. Therefore, it is more likely for health care staff 
to be aware of poor control of blood sugar level in the older people who live alone.   
9.1.2 Clinical characteristics 
 
As expected, based on the selection criteria of HbA1c test in the setting, the group 
with HbA1c seemed to be healthier than the group without HbA1c test.           
Table 8.7 shows that the group with HbA1c test had a better control of BMI, FBS 
and total cholesterol than the group without HbA1c with statistically significant 
differences (p=0.043 , p=0.000, p=0.017 , respectively). The data also shows the 
significant difference in diabetes treatment and duration between the groups with 
and without HbA1c test (p=0.006, p=0.003, respectively). The difference of these 
characteristics is explained below. 
 
The number of the participants in the group with HbA1c test who were on diet 
control (no medication) was higher than the group without HbA1c test. According 
to the clinical practice guideline of diabetes in Thailand (Diabetes Association of 
Thailand 2011), diabetic patients who have a blood sugar (FBS) between 126-200 
mg/dl or 7-11.1 mmol/l do not receive medication and instead they receive self-
care knowledge from the health staff in order to reduce their blood sugar level by 
exercising or increasing physical activity and having healthy nutrition (reduced 
food that contains high levels of sugar and fat). After 3 months of self-control 
regime, the health staff checks the blood sugar level (FBS) of the patients again to 
see whether the patients should receive anti-diabetic medicine. This information 
implies that the participants in this study who were on diet alone (without 
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medication) may have the range of blood glucose level that was in an early stage of 
diabetes. Thus, the possibility is that the progress and metabolic control were not 
complicated for the individuals care, and that the disease had a low impact on 
health conditions (Turner 2008). These could be the reasons why the group with 
HbA1c test containing a higher number of participants who were on diet alone 
(without medication) had a better control of blood glucose level (FBS) and some 
clinical variables (BMI and cholesterol) than the group without HbA1c.  
 
In addition, Table 8.7 (Chapter 8) shows that there were a number of participants 
in the group without HbA1c who had a diabetes duration of 1-4 years more than 
the participants in the group with HbA1c. Snoek (2002) states that the diagnosis of 
diabetes may come as a shock, and can induce serious emotional distress in 
patients. Diabetic patients have an individual psychological adjustment varying 
from several months to one year after the diagnosis because they have to learn and 
integrate diabetes into their daily lives (Snoek 2002). For example, patients always 
have to think about what they can or cannot eat. This is found to be burdensome 
for the patients in an early state of the disease. Thus, stress and anxiety can 
seriously disrupt an ability to control blood glucose level (Engum 2007). It is 
possible that the psychological problems in the early stage of diabetes may have an 
impact on the self-control of blood sugar in this study. Therefore, compared to the 
group with HbA1c, the group without HbA1c seemed to have a poorer control of 
blood sugar. 
 
Summary of the characteristics 
Due to the lack of social support and help from family members, living alone was a 
demographic characteristic that might have an impact on the ability to control 
blood glucose in the older people. In addition, it was found that compared to the 
group without HbA1c test, the group with HbA1c test had a higher number of 
participants who were on diet alone (without medication). The treatment without 
medication may describe the early stage of diabetes with an uncomplicated 
metabolic control. Therefore the group with HbA1c test showed a better control of 
BMI, FBS and cholesterol compared to the group without HbA1c test. Moreover, 
the data indicates that the group without HbA1c test had a higher number of 
participants with a diabetes duration of 1-4 years than the group with HbA1c. It 
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could be possible that the psychological adjustment in the beginning period of 
diabetes may affect the ability to control the blood sugar level. Thus, the group 
without HbA1c had a poorer control of their blood sugar compared to the group 
with HbA1c.The information of the characteristic differences between the group 
with and without HbA1c may be useful for the health care staff to consider the 
potential factors that may affect the ability to control blood sugar level in this 
selected population. 
 
As mentioned in chapter 1, glycaemic control is fundamental in the management of 
diabetes (Llorente and Malphurs 2007). Glycaemia control by HbA1c is the most 
accepted indicator. It accurately reflects a longer-term glycaemic control (Saudek 
et al. 2006). In addition, glycaemic control (HbA1c) appears to play a role and may 
relate to cognitive impairment and depressive mood in the older people with type 2 
diabetes (see chapter 2). Therefore, it would be of interest to see whether 
glycaemic control (HbA1c) is related to cognitive impairment and depressive 
mood in this study. 
 
Not all participants in this study received HbA1c measurement. The selection bias 
was checked by comparing the prevalence of the outcome measures (prevalence of 
cognitive impairment and depressive mood) between the groups with and without 
HbA1c. The results show that there is no difference between the two groups in 
terms of the outcome measures (Mini-Cog, p = 0.895, 95% CI 0.073, 0.085, 
MMSE Thai 2002, p = 0.920, 95% CI -0.052, 0.058 and TGDS, p = 0.995, 95% CI 
-0.066, 0.066 in Table 8.8). The importance of the use of HbA1c test in the study 
protocol and methodology was mentioned in Chapters 5 and 7. In brief, this study 
intends to 1) assess the generalisability of the association between HbA1c test and 
the prevalence of cognitive impairment / depressive mood, and 2) estimate the 
effect of poor glycaemic control (indicated by the presence of HbA1c result) on the 
prevalence of both cognitive impairment and depressive mood. 
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9.2 The prevalence of possible cognitive impairment and depressive mood 
 
9.2.1 The prevalence rate of possible cognitive impairment by Mini-Cog and 
MMSE Thai 2002  
 
It was discussed in Chapter 2 that the prevalence of cognitive impairment in the 
older people with type 2 diabetes in many regions including Thailand was found to 
be 11.3% - 77.6% (see Table 2.1). The prevalence rates in each study depend on 
the study purposes, study tools and cut-off scores. It should however be noted that 
Thaneerat et al.’s 2009 study in Thailand focused on the prevalence rate of mild 
cognitive impairment (MCI) instead of cognitive impairment. Thus, the MoCA 
test, a specific tool for screening MCI, was used to estimate the prevalence rate of 
mild cognitive impairment, while the other previous studies used MMSE as a 
screening tool for screening cognitive impairment. As a result, it could be possible 
that the estimated rate of cognitive impairment in the previous study in Thailand 
show the distinctly high rate of (77.6%) compared to the other previous studies 
(Bruce et al. 2002, Bruce et al. 2003,  Munshi et al. 2006, Rajakumaraswamy et al. 
2008, Alencar et al. 2010 ). Apart from MoCA test, by using MMSE as a screening 
tool the range of estimated rate from many regions was shown to be between 11.3-
32.8% (see Chapter 2). 
 
This study estimates the prevalence of cognitive impairment in Thai older people 
with type 2 diabetes by Mini-Cog and MMSE Thai 2002 to be 65.4% (95% CI 
59.7%, 70.7%) and 12.4% (95% CI 9.0%, 16.7%), respectively (see Table 8.8). 
The prevalence rate by Mini-Cog agrees with the previous study in Thailand that 
reveals the prevalence rate of mild cognitive impairment (MCI) in the older people 
with type 2 diabetes to be 77.6% (Thaneerat et al. 2009). The previous study 
(Thaneerat et al. 2009) used MoCA as a screening tool and showed only the 
estimated rate of MCI rather than dementia. The MoCA is specifically used to 
screen the clinical state between normal cognitive ageing and mild state of 
cognitive impairment (Nasreddine et al. 2005, Smith et al. 2007). The current 
finding confirms Thaneerat et al.’s (2009) study in Thailand, and shows that the 
cognitive impairment among Thai older people with type 2 diabetes is found not 
only in the hospital setting but also in the primary care setting.  
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This study shows the estimated rate of cognitive impairment by MMSE Thai 2002 
to be 12.4% (95% CI 9.0%, 16.7%). This result is similar to the ones in the 
literature (see Chapter 2, Table 2.1) indicating that in Brazil the estimate is 12.1% 
and in Australia the rate is 15.3% (Bruce at al. 2003, Alencar et al. 2010). The rate 
of cognitive impairment in Australia is 2.9% higher than the current study. This 
may probably be due to the differences in the cut-off scores of the study tools. As 
mentioned earlier in Chapter 3, Section 3.1.1, MMSE was developed in an English 
speaking country, where education level is high with a standard cut-off score of 24, 
that is, a score of 23 or below is considered to have cognitive impairment. 
However, when using MMSE in non-English speaking countries with a high rate 
of low-educated population (Salmon and Lange 2001), it is suggested to adjust the 
cut-off score according to education levels in those countries (Liu et al. 1994, 
Caldas et al. 2011). Therefore, the study in Australia used the higher cut-off scores 
of MMSE compared to MMSE Thai 2002. Whereas, the study in Brazil used 
MMSE with the cut-off score similar to MMSE Thai 2002, particularly in subjects 
with a low level of education. Thus, the rate of cognitive impairment in Brazil is 
very close to the current study with a small difference of 0.3%.  
 
This study can be compared with the study in Sri Lanka (Rajakumaraswamy et al. 
2008), in which the prevalence of cognitive impairment in the older people with 
type 2 diabetes by MMSE is 32.8 % (see Chapter 2, Table 2.1). It is possible that 
the estimated rate in this study is 20.4 % lower than the study in Sri Lanka due to 
the high cut-off score (less than 25) in Sri Lanka’s study, yielding the high 
estimate rate of cognitive impairment. The study in Sri lanka did not report the 
education levels of subjects. As stated above, when MMSE is used in a non-
English speaking group, the cut-off score should be adjusted according to the 
variety of education levels, particularly in developing countries (Salmon and Lange 
2001). Thus, using one cut-off score for all education levels in Sri lanka’s study 
may have caused the high prevalence rate of cognitive impairment. The finding in 
this study shows a similar prevalence rate when compared to the study of Munshi 
et al. (2006) in the United States. In addition, the difference of prevalence rate in 
cognitive impairment between the Mini-Cog and MMSE in this study reveals a 
similar pattern to that of Munshi et al.’s study. The present study shows the 
prevalence rate of Mini-Cog is higher than MMSE Thai 2002 (64.5% vs. 12.4%). 
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Similarly, Munshi’s study reveals that the prevalence rate of cognitive impairment 
from clock-drawing test (CDT) (38%) and the prevalence rate of cognitive 
impairment from clock-in-a-box (CIB) (35%) are higher than the prevalence rate of 
cognitive impairment by MMSE (12.5%)  (see Chapter 2, Table 2.1). 
 
As mentioned earlier in Chapter 2, the prevalence rate of cognitive impairment in 
each study is affected by a variety of cut-off points of MMSE and sample size. The 
literature reveals the range of prevalence rate by MMSE to be between 11.3-32.8% 
(see Chapter 2, Section 2.1.3). This study supports the prevalence of cognitive 
impairment by MMSE in type 2 diabetes within the range of the previous rate and 
confirms the estimated rate of 12.4%.  
 
There is a large difference of prevalence rate in cognitive impairment between 
Mini-Cog Thai version and MMSE Thai 2002 (64.5% vs. 12.4%). The difference 
between the two tests could be described as follows: 
 
1. Since one third (10/30) of the total score in MMSE is orientation test, it is 
highly possible that the subjects who have good orientation but perform 
poorly in other cognitive domain tests would get the normal score range, 
particularly in the subjects who are illiterate or have low education level in 
which the low cut-off score would be used. For example, the orientation 
part contains 10 scores; hence, the subjects who are illiterate with good 
orientation but have poor function in other cognitive domains would easily 
get 10 scores from the total cut-off score of 14 if they pass one domain test.  
As a result, the participants who passed only one domain test (orientation 
test) of the total eleven tests could get a higher possibility of yielding the 
score result in normal range. In particular, when the lowest cut-off score is 
used in the group with illiterate or low education. 
 
2. Short term memory and executive function (judgment, decision-making, 
planning),  are found to have an impact on the early stage of cognitive 
impairment (Doerflinger 2007). The scores in these two parts are therefore 
important in the current study. With regard to the cognitive screening tests 
in this study focusing on different foci, Mini-Cog contains two tests of 
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short term memory and executive function, whereas MMSE includes a 
variety of 11 cognitive domain tests. The high score in some parts of 
MMSE may have a limitation in detecting cognitive impairment in early 
phases of dementia or mild cognitive impairment (MCI) (Blake et al. 2002, 
Bak et al. 2005, Woodford and George 2007). Thus, the subjects with good 
orientation may have poor short term memory loss, which is a significant 
initial sign of cognitive impairment and dementia (Ratchie and Lovestone 
2002, Liorente and Malphurs 2007).  
 
3. As stated earlier in Chapter 3, Section 3.1.1, MMSE is insensitive to the 
early stage of cognitive impairment or MCI (Nasreddine et al. 2005, Nazem 
et al. 2009, Aggarwal and Kean 2010). In addition, MMSE does not contain 
an executive function task which is the domain that found to be altered in 
the early stage of Alzheimer’s disease (AD) (Munshi et al. 2006, Hatfield et 
al. 2009). In contrast, Mini-Cog consists of clock drawing test (CDT) 
which is an executive function test. Therefore, it is possible that the Mini-
Cog is more likely to be sensitive than MMSE Thai 2002 in detecting 
people with an early stage of cognitive impairment or mild cognitive 
impairment. This explanation is supported by Munshi et al. (2006) stating 
that MMSE has a limitation on specificity (specificity = 64%, sensitivity = 
96%) and executive function tests (see Chapter 2). Thus, in their study the 
clock drawing test (CDT) and clock in a box (CIB) which are specifically 
designed for executive function tests, detected a higher number of people 
with cognitive impairment compare to that of MMSE. As a result, the 
prevalence rate of cognitive impairment by CDT and CIB in Munshi et al.’s 
study was higher than the prevalence rate of cognitive impairment by 
MMSE (See Chapter 2, Sections 2.1.2 and section 9.2.1). Moreover, the 
prevalence rate of cognitive impairment in this study is confirmed with the 
previous study in Thailand (Thaneerat et al. 2009) which found that the 
prevalence rate of mild cognitive impairment (MCI) in Thai older people 
with type 2 diabetes (aged 60+) in hospital setting was 77.6% (see Section 
9.2.1).   
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4. The difference of prevalence rate between the two cognitive screening tests 
may come from disease spectrum bias, which is the phenomenon of the 
sensitivity and/or specificity of a test varying with features and severity of 
disease (Sica 2006, Leeflang et al. 2009). In this study, MMSE Thai 2002 
is highly specific but less sensitive in identifying cognitive impairment, 
particularly in illiterate subjects (sensitivity = 0.35, specificity = 0.81) and 
educated primary school subjects (sensitivity = 0.57, specificity = 0.94) 
(Ageingthai 2008). As a result, the screening test of MMSE Thai 2002 may 
be unable to detect the cognitive impairment in the group with low 
education which consisted of 89.6% of the total participants (Table 8.6). 
This information is supported by previous studies which have found that 
MMSE is insensitive in subjects with an early stage of cognitive 
impairment due to the low sensitivity of the test and being less concerned 
with the subtypes of dementia (Wind et al. 1997, Nasreddine et al. 2005, 
Heiss et al. 2006, Munshi et al. 2006, Hatfield et al. 2009). Alternatively, it 
could be possible that there were a higher number of participants in the 
early stage of cognitive impairment or mild cognitive impairment (MCI) in 
the current study. 
 
In summary, the prevalence of cognitive impairment in the older people with type 
2 diabetes supports and agrees with the previous studies either in Thailand or other 
countries. However, the difference of prevalence rate between Mini-Cog Thai 
version and MMSE Thai 2002 may result from the low sensitivity of MMSE Thai 
2002 in detecting cognitive impairment in the low education group and at the early 
stage of cognitive impairment or mild cognitive impairment (MCI). It is possible 
that in the current study, Mini-Cog is more likely to be sensitive and identify a 
higher number of participants with an early stage of cognitive impairment than 
MMSE Thai 2002 due to a high number of participants with an early stage of 
cognitive impairment or MCI.   
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9.2.2 The prevalence of possible depressive mood by TGDS 
 
The estimated rate of depression in this study was found to be 19.4% in the older 
people with type 2 diabetes (Table 8.8). This finding agrees with the previous 
studies that showed the prevalence of depression in diabetes between 13.2%-33.4%             
(see Chapter 2). However, compared with the previous study in Thailand, the 
figure rate in the current study is lower and this is probably due to the difference in 
study setting and screening tool. The previous study in Thailand was conducted in 
a hospital setting where the number of depressed patients may be higher than the 
primary care setting, particularly in an urban area (Akepakorn et al. 2007, Suttajit 
et al. 2010). Another explanation is that the previous study used the Hospital 
Anxiety Depression Scale (HAD) as the screening tool for depression. Therefore, it 
could be possible that the screening tool in the previous study detected not only 
depression but also anxiety in the patients with type 2 diabetes (Snaith 2003). It is 
difficult to compare the estimated rate in this study with those of other studies in 
literature because of the different assessments. Although one study from the United 
States (Munshi et al. 2006) used the same depressive mood-screening test, the 
depression rate could not be clearly compared due to the small sample size (60 
subjects) of the previously mentioned study.  
 
Similar to the prevalence of cognitive impairment in type 2 diabetes, the wide 
range of reported prevalence of depression in type 2 diabetes is not only from the 
assessments but also due to several factors such as the characteristics of the sample 
size, the age range of the sample, the clinical symptom of depressive disorders and 
the study setting. Overall, the finding demonstrates that the prevalence rate 
(19.4%) of depressive mood concurs with the previous studies and that depression 
appears to be a common co-morbid health problem in the primary care patients 
with type 2 diabetes. In the present study, 19.4% of the older patients with type 2 
diabetes were undiagnosed of depressive mood in the primary care setting at San-
sai district. In addition, the prevalence rate is concordant with the range of 
depressive mood at the primary care setting in the previous studies in which the 
rate showed between 14.2-33.0% (see Chapter 2).  
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9.3 Predictors associated with possible cognitive impairment and depressive 
mood 
9.3.1 Major predictors associated with possible cognitive impairment   
 
This section reveals the important characteristics associated with cognitive 
impairment by Mini-Cog Thai version and MMSE Thai 2002 (see Tables 8.9-
8.11). Each characteristic will now be discussed in turn. 
 
a) The aged group  
One of the important factors for cognitive impairment by Mini-Cog is being aged 
less than 75.This study is in contrast with the study of Scanlan et al. (2007) which 
is the only study that used Mini-Cog in the older people with type 2 diabetes (16 % 
of the total subjects) and found that cognitive impairment increas with age. This 
contradiction is probably due to the difference in age group between this study and 
the previous studies. This study shows the mean age of 67 whereas the mean age in 
the previous study was 75. In addition, the highest proportion (40%) of the 
individual age group in the current study was the younger old aged (60-64 years 
old). It can be observed that this study had a sample with the mean age lower than 
the previous studies and also had a high proportion of sample in the younger old 
age; hence, the result in this study may rely on the younger old age (less than 75 
years old). In addition, the Thai older people had the average life expectancy of 74 
in both female and male, thus most of the older people subjects in this study were 
younger old age (less than 75 years old) (United Nations 2011). Compared to the 
previous study, it could be possible that the Thai older people had a life expectancy 
shorter than the previous study conducted in Italy (78 vs. 85 for females, 71 vs.79 
for males) (United Nations 2011). Therefore the Italian older subjects in the 
previous study seem to be healthier and live longer than the older people subjects 
in Thailand.   
 
Unlike the individual characteristics associated with cognitive impairment by 
Mini-Cog, old age (aged more than 74 years old) was found to be a strong 
predictor related to cognitive impairment by MMSE Thai 2002. This is probably 
because the older people (over 65 years of age) with the chronic diseases are 
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generally found to be impaired in learning and verbal memory as well as in 
psychomotor functioning (Asimakopoulou and Hampson 2002, Worrall et al. 
1993). In addition,  Ryan and Geckle (2000) proposed that learning and memory 
impairment in older adults with type 2 diabetes may be the result of “a synergistic 
interaction between diabetes-related metabolic derangements and the structural and 
functional changes occurring in the central nervous system that are part of the 
normal aging process” (p. 308). Thus, it could be possible that the diabetic subjects 
aged more than 74 in this study may fail in learning and memory parts of MMSE 
Thai 2002. 
 
Although age group was found to be a strong predictor associated with cognitive 
impairment in both Mini-Cog and MMSE Thai 2002, the range of the age group 
was different. The younger old age (less than or equal 74 years) was an individual 
characteristic for Mini-Cog, while the old age (more than 74 years) was the strong 
predictor in MMSE Thai 2002. This difference is probably because MMSE Thai 
2002 was unable to detect the early state of cognitive impairment (see Section 
9.2.1). In addition, it could be possible that the participants in the younger old age 
group (less than 75 years) had a mild cognitive impairment, while the old age 
group (more than 75 years) had a moderate to severe cognitive impairment, which 
is the level MMSE could clearly detect better than the mild level of cognitive 
impairment.    
 
b) Never attending school 
Never attending school is a strong predictor for cognitive impairment by MMSE 
Thai 2002. This finding is in line with the study of Ishizaki et al. (1998) which 
investigated the cognitive impairment in a community based data and found that 
ageing and poor education are the risk factors for cognitive impairment by MMSE. 
They demonstrated that not only the education level not only influences the total 
score on MMSE but affects the clinical care of the participants. This might have an 
impact on health and cognitive function. This explanation agrees with the previous 
studies which support that participants with a low education have a reduced 
cognitive reserve and lead to an earlier manifestation of the distinctive signs and 
symptoms of dementia in the screening test (Scarmeas et al. 2006, Musicco et al. 
2009). This information implies and supports the unclear MMSE result when used 
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in the low education group. Although this study used the cut-off score with the 
level of education in Thai subjects, low sensitivity of cut-off score in the illiterate 
group may provide ambiguous results. Thus, a further study using a 
neuropsychological test battery such as the Addenbrooke’s Cognitive 
Examination-Revised (ACE-R), an extended version of MMSE which covers a 
wider range of cognitive domains (Hodges, 2007) may be needed to produce 
clearer results of MMSE in illiterates. 
 
c) Years in school  
More than 4 years of attending school is a potential predictor for cognitive 
impairment by Mini-Cog. Although the original version of Mini-Cog  (English 
version) is not affected by education (Borson et al. 2000), this study finds out that 
the participants who attended school for more than 4 years showed an increased 
possibility of having cognitive impairment. 89% of the participants had less than 4 
years of school and 11 % of the participants had more than 4 years of school (see 
Table 8.6). When compared to the study of Mini-Cog in the non-English version 
(Italian) which contains average years in school similar to this study (5 years), the 
study in Italy shows that 33% of the subjects have less than 4 years of school, 54% 
with 5-8 years in school and 13% with more than 9+ years in school (Scanlan et al. 
2007). Thus, it can be seen that the data in the current study does not contain 
homogeneous distribution with regard to the level of education compared to the 
previous study in Italy. As a result, a huge difference in the proportion of years in 
school provides the wide range of confidence interval (CI) around the odd ratio 
(OR= 9.31, 95% CI= 2.11, 41.05). The data implies that this study still needs a 
larger sample to investigate the effect of education on the cognitive impairment as 
measured by Mini-Cog.  
 
d) High BMI  
This study reveals that a high range of BMI (BMI 23-25 kg/m
2
 and more than 25 
kg/m
2
) is one of the predictors of cognitive impairment by Mini-Cog. This finding 
agrees with the review study of Berge et al. (2009) on the effect of obesity related 
to cognitive impairment. The review assesses six population-based study designs 
which used BMI cut-off 25 kg/m
2
 and over as a measure of obesity and compared 
cognitive performance in the individual subjects. Overall, they found that the 
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association between obesity and cognition differ across the individual domains: 
cognitive flexibility was significantly affected in 67%, perception and construction 
was affected in 50%, memory 40%, and processing speed 33%. In addition, the 
study of Gustafson (2003) reveals an association between being overweight (BMI 
≥ 25 kg/m2) and the age of 70 increasing the risk of Alzheimer’s disease (AD) in 
women. They show that after controlling a number of potential confounders, the 
relationship between BMI and AD still remained. Moreover, three previous studies 
have shown that midlife obesity measured by BMI was approximately two to five-
fold and increased the risk of mild cognitive impairment (MCI) and dementia 
(Rosengren et al. 2005, Whitmer et al. 2005, Lu et al. 2012). This information 
shows that obesity or high BMI affects cognitive function and is related to 
cognitive impairment. 
 
The link between obesity or high BMI and cognitive impairment could be 
explained with the following possibilities. First, people with high BMI may have a 
higher adipose tissue which underlines many of cardiovascular diseases such as 
hypertension, cardiovascular disease including diabetes. Thus, it is possible that 
the high BMI may lead to these conditions that could aggravate the process of 
dementia (Gustafson et al. 2003). Second, adipose tissue is an active endocrine 
organ that produces adipokines known to have both pro and anti-inflammatory 
properties including adiponectin, leptin, resistin, as well as pro-inflammatory 
cytokines such as interleukin-6 (IL-6) (Trujillo et al. 2005). A high level of IL-6 is 
associated with accelerated cognitive impairment in older adults with metabolic 
syndrome (Yaffe et al. 2004). In addition, two studies have shown that decreasing 
brain levels of proinflammatory cytokines can reverse memory deficits (Balschun 
et al. 2004, Gemma et al. 2005). Therefore, these mechanisms in body could affect 
the cognitive function in the brain. 
 
It is possible that obesity or high BMI has an impact on Mini-Cog score through 
these mechanisms, particularly in the memory part. Therefore, the current study 
reinforces the role of obesity or high BMI associated with the risk of dementia. 
 
It is important to mention that in this study BMI of 23 kg/m
2
 and higher are 
moderate to high health risk. The cut-off BMI in this study is different from an 
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international classification of BMI, which defines the BMI of 23- 25 kg/m
2
 as low 
to moderate health risk (World Health Organisation (WHO) 2000). The view of 
BMI cut-off at 23 kg/m
2 
in this setting area is based on the recommendation from 
WHO expert consultation, which suggest that the percentage of body fat different 
BMIs varies within populations. They suggest that for many Asian populations 
trigger points for public health action are identified to be 23 kg/m
2
 and higher 
(WHO expert consultant, 2004). Therefore, BMI of 23 kg/m
2
 is set as the cut-off 
for moderate health risk in this setting area. 
 
e) The level of HDL 
Low level of HDL (less than 40 mg/dl or 2.2 mmol/l) is one of the clinical 
predictors of cognitive impairment by Mini-cog in this study. This result is in 
accordance with the study of Singh-Manoux et al. (2010) that found the low level 
of HDL (< 40 mg/dl or 2.2 mmol/l) is related to poor memory in middle-aged 
adults. They showed the association between low HDL and poor memory (OR = 
1.73; 95% CI 1.20, 2.50) remained after the effect of education, occupation, 
prevalent disease, medication use and APOE4. A potent risk of Alzheimer’s 
disease (AD) was adjusted. Total cholesterol and triglycerides levels did not show 
any association with memory decline in their study (P= 0.49 and P= 0.37, 
respectively). Considering that HDL plays a critical role in the maintenance of 
neuronal functions in the hippocampal neurons, there is a plausibility of a link 
between mild cognitive impairment (MCI) or AD and HDL (Michikawa 2003).  
 
There are a number of possible mechanisms connecting the low level of HDL to 
memory. First, HDL is one of the important lipoproteins in the brain (Olesen and 
Dago 2000). It involves the regulation of Amyloid Beta (Aβ), protein metabolism 
and deposition in the brain (Reiss et al. 2004). Aβ has an essential role in the 
mechanisms of synaptic protein that underline learning and memory (Koudinov 
and Berezov 2004). The deposition of amyloid protein in the brain is the 
pathogenesis of AD. Second, a low level of HDL in the neurodegenerative process 
might involve its anti-inflammatory (Gauthier et al. 2006) or antioxidant properties 
(Singh-Manoux et al. 2008). Moreover, HDL can bind the excess Aβ and inhibit its 
oligomerisation (Olesen and Dago 2000), a step in the transformation of the 
monomeric nontoxic peptide to the aggregated neurotoxic form, which can account 
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for memory impairment (Lesne et al. 2006). Therefore, HDL may link to AD and 
poor memory through the variable biochemical mechanisms in the brain. 
 
Overall, it could be summarised that the potential characteristics associated with 
cognitive impairment by Mini-Cog in this study are the younger old age group 
(equal or less than 74 years), attending school for more than 4 years, high BMI 
(more than 23 kg/m
2
) and poor level of HDL (less than 40 mg/dl or 2.2 mmol/l). 
Meanwhile, the strong predictor associated with cognitive impairment by MMSE 
Thai 2002 includes those who never attended school and the old age group (more 
than 75 years). Since it is possible that Mini-Cog and MMSE Thai 2002 consist of 
different foci of the domain test including the limitation of MMSE Thai 2002 in 
the low education group (see section 9.2.1), it is not surprising to see the different 
results of the characteristics related to cognitive impairment between the two tests.  
More importantly, the current study shows that the potential clinical characteristics 
(BMI and HDL) of cognitive impairment by Mini-Cog are related to mild 
cognitive impairment (MCI). Therefore, this may confirm that Mini-Cog could 
detect the people with MCI. It also shows higher number of cognitive impairment 
than MMSE Thai 2002. However, the potential characteristic of years in school in   
Mini-Cog test needs a larger sample to confirm the results. The predictor of the 
characteristic of never attending school for MMSE Thai 2002 may also have 
limitations in the illiterate group. A further investigation using a diagnostic test 
would provide a clearer trend of the results.   
9.3.2 The major predictor of depression  
 
An important predictor of depression in the current study is retinopathy as a 
diabetes complication. This result agrees with a cohort study of depression and 
diabetic retinopathy in the United States which found that co-morbid depression 
has a significantly higher risk of developing diabetic retinopathy in 2,359 adults 
with type 2 diabetes (mean age 64) in the primary care settings. After five years of 
following up, their data showed that severity of depression was associated with the 
risk of retinopathy (OR = 1.026, 95% CI 1.002, 1.051). This information may 
imply that improving diabetic retinopathy treatment in the primary care could 
contribute to depressive mood prevention or vice versa. This finding is also 
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consistent with the study of Grot et al. (2001) which found that depression had a 
clinically significant association with retinopathy (P < 0.00006), nephropathy          
(P < 0.0002), neuropathy (P < 0.0002) and macro-vascular disease P < 0.00001) in 
a meta-analysis of 27 studies.  
 
The results in this study are different from the previous study in Thailand which 
found that nephropathy is a strong predictor of depression in Thai older people 
with type 2 diabetes in the hospital setting (Thaneerat et al. 2009). The different 
result is probably due to the difference in the study settings. The current study was 
conducted in a primary care setting where medical resources and equipment were 
limited compared to the hospital setting. Thus, the suspected patient with diabetic 
nephropathy in the primary care will refer to the hospital care. Therefore, the 
number of diabetic retinopathy patients in primary care settings was higher than 
the number of diabetic retinopathy patients in the hospital settings (Nitiyanant 
2007). 
 
The link between diabetic retinopathy and depression may come from the 
malfunctioning of the hypothalamic-pituitary-adrenal axis, activation of the 
sympathetic nervous system and an increase in pro-inflammatory factors       
(Katon et al. 2005, Golden et al. 2007, Lustman et al. 2007). Depression, through 
the increase of cortisol (Miller et al. 2002, Katon et al. 2005) accompanied with 
inflammation may increase insulin resistance and glycaemic fluctuation which play 
roles in the progression of micro-vascular and macro-vascular complications in the 
patients with type 2 diabetes (Golden et al. 2007). Furthermore, it could be 
possible that in depressed patients, retinopathy could reflect the changing of 
cerebral micro-vascular associated with depression (Ding et al. 2010).  
 
As mentioned in Chapter 1, depression and depressive symptoms might affect the 
neuroendocrine system and diabetes self-care behaviour. This could lead to an 
uncontrolled or increase in blood sugar level (hyperglycaemic) and glucose 
alteration in vascular system. Hence, type 2 diabetic patients are at risk of 
accelerated atherosclerosis and microvascular disease (Leiter 2005). Many clinical 
complications of diabetes are caused by small and large vessel pathology 
throughout the body. In addition, small vessels throughout the body are affected by 
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diabetes, including those in the brain, heart, and peripheral vascular system 
(Rambhade 2011). Normally, the vascular smooth muscle receives continuous 
regulatory nerve signals and a continual supply of vasodilating nitric oxide (NO) 
from blood vessels. These regulatory mechanisms adjust microvascular flow 
instantaneously to meet the metabolic needs of the tissue. A prolonged 
hyperglycaemia causes a thickening of capillary basement, which is found as a 
structural hallmark of diabetic microvascular disease. The thickening of the 
basement membrane impairs the amount and selectivity of transport of metabolic 
products and nutrients between the circulation and the tissue (Dokken 2008). 
 
Overall, depression has an impact on diabetic retinopathy through biochemical 
processes leading to macro and micro-vascular lesions. This study therefore, 
reinforces the probability of diabetic retinopathy as a predictor of depressive mood 
in type 2 diabetes. 
 
9.4 Correlation between cognitive impairment and depressive mood 
 
The scores of both cognitive screening tests (Mini-Cog and MMSE Thai 2002) are 
negatively correlated with the score of depressive mood test (TGDS) in this study. 
This implies that the participants who had high scores in cognitive tests (showing 
possible cognitive impairment) seem to have low scores in depressive mood 
screening test (showing depressive mood). This study is consistent with the 
previous studies  of Munshi et al. (2006),  Zrebiec (2006), Katon (2010).  
 
In addition, the association between the scores of cognitive screening tests and 
depressive mood screening test persisted after controlling age, years in school and 
potential confounding factors in cognitive and depressive mood screening test 
(Wongchaisuwan et al. 2005 Thaneerat et al. 2009). The correlation between 
cognitive impairment by Mini-Cog and depressive mood seem not to correlate after 
controlling age and years in school. As stated earlier in Section 9.2, this study has 
limitations in the heterogeneity of education in the population. The vast majority of 
the sample in this study (89%) had equal or less than 4 years in school. Therefore, 
the evidence is still ambiguous in the variable of years in school.  However, the 
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result shows the trend of the correlation between cognitive impairment and 
depressive mood.  
 
 
Depressive mood may relate to cognitive impairment in many possible ways. First, 
prolonged hypercortisolemia associated with depressive symptom may have 
negative impact on memory through hippocampal damage (O'Brien et al. 1996, 
Jacobson and Sapolsky 1991). Second, depressive symptoms are common in 
diabetic patients and may hinder their ability to adhere to diet, physical activity and 
medication and therefore cause poor glucose control (hyperglycaemia) which may 
also affect vascular and brain function (Ciechanowski et al. 2000, Park et al. 2004, 
Wang et al. 2008). Lastly, hyperglycaemia and hyperinsulinaemia can affect brain 
tissue and its metabolism by decreasing the neurotransmitter function, which 
induce organ damage (Kodl and Seaquist 2008). 
 
The current finding indicates a poor score on cognitive tests in depressed 
individuals (poor score in depressive mood test). It is supported that depression is 
more common in people with type 2 diabetes and could be the reversible causes of 
memory impairment and people with diabetes (Lustman et al. 2002). Thus, it 
would be of interest to propose that when cognitive impairment is suspected, 
screening depression is recommended. As the literature in this area suggests, the 
prevalence of depression is found among people with type 2 diabetes. Moreover, 
depression could be the reversible cause of memory impairment and people with 
diabetes (Lustman et al. 2002). Treatment of depression may improve the cognitive 
function, which may also support self-care management and behaviour of the older 
people with type 2 diabetes (Rubin and Peyrot  2001). 
 
9.5 Correlation between Mini-Cog and MMSE Thai 2002  
 
As mentioned in Chapter 4, Mini-Cog is recently new and has not been validated 
in Thai population. Thus, in order to propose Mini-Cog as a new cognitive 
screening tool in Thailand, it is necessary to compare the results of Mini-Cog with 
MMSE Thai 2002, which is a known reference standard in Thailand (Lorentz 
2002).  
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The data in this study shows that both Mini-Cog and MMSE Thai 2002 seem to 
detect the cognitive impairment in the same direction.  The results clearly indicate 
that the scores in Mini-Cog are moderate positively correlated (rs = 0.44, p = 
0.001) with the result the scores of MMSE Thai 2002 (Table 8.15). This finding 
demonstrates significant correlations between Mini-Cog as a new test and MMSE 
Thai 2002 as a standard test in Thailand. This means that Mini-Cog seems to 
perform adequately with MMSE Thai 2002, a standard test, for screen cognitive 
impairment in this study. However, the disagreement between Mini-Cog and 
MMSE Thai 2002 (Table 8.16) could be explained in two possible ways. The first 
possibility is that MMSE Thai 2002 could not detect an early state of cognitive 
impairment or mild cognitive impairment (MCI) due to the lack of an executive 
function test. This explanation is supported by the study of Munshi et al. (2006) 
stating that MMSE has a limitation on specificity (specificity = 64%, sensitivity = 
96%) and executive function tests (see Chapter 2). The second possibility is that 
kappa value can be strongly influenced by prevalence (the relative frequency of the 
condition of interest) (Fleiss 2003). It is possible that this study may have a high 
number of people with MCI or an early state of cognitive impairment, which 
MMSE is not sensitive to detect at this state (Allen et al. 2004, Munshi et al. 2006). 
In summary, an overall disagreement kappa value in the results of cognitive 
impairment between Mini-Cog and MMSE Thai 2002 might come from the 
differences of foci in cognitive domain tests and the prevalence of MCI. 
 
With regard to the different foci on cognitive domain tests between Mini-Cog and 
MMSE Thai 2002 (Chapter 3 and Section 9.2.1), it is possible that the participants 
with the early stage of cognitive impairment or MCI can detected by Mini-Cog. 
Mini-Cog consists of short term memory and executive function tests (judgment, 
decision-making, planning), while MMSE Thai 2002 has seven category tests: 
orientation to time, orientation to place, registration of three words, attention and 
calculation , recall of three words, language and visual construction. Apart from 
short term memory, executive function is found to have an impact on the early 
stage of cognitive impairment (Doerflinger 2007). The major reason for MMSE’s 
inability in detecting early phases of dementia or mild cognitive impairment (MCI) 
could be its limitation as an executive function test (Blake et al. 2002, Bak et al. 
2005, Woodford and George 2007) . 
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9.6 Cognitive impairment and depressive mood with the degree of good and 
poor glycaemic control (HbA1c)  
 
Previous studies have found that glycaemic control (HbA1c) is associated with 
cognitive function in type 2 diabetes (Cukierman-Yaffe et al. 2009, Grober et al. 
2011, Makkakaeo et al. 2011) (see Chapter 2). In particular, uncontrolled 
glycaemic control can lead to hyperglycaemia which may cause slow and 
progressive functional and structural abnormalities in the brain affecting cognitive 
function (Biessels et al. 2006). Thus, the levels of glycaemic control (HbA1c) 
show the association with cognitive function. HbA1c divides the level into 
controlled (HbA1c ≤ 7 or 53 mmol/mol) and inadequately controlled (HbA1c > 7 
or 53 mmol/mol) (American Diabetes Association, 2009, Grober et al. 2011).  
 
This study investigated and compared whether there was a difference between the 
levels of good (control (HbA1c ≤ 7% or 53 mmol/mol) and poor (HbA1c > 7% or 
53 mmol/mol) glycaemic control and the cut-off score in the all screening tools. 
The study showed that there was no difference in the scores of cognitive and 
depressive mood screening tests between the group with good (HbA1c ≤ 7% or 53 
mmol/mol) and poor (HbA1c > 7% or 53 mmol/mol) control. The finding from this 
study either agrees or disagrees with the literatures. Following are the details.  
 
The current finding is controversial with the literature which mostly showed that a 
better glycaemic control is associated with a less cognitive impairment in the older 
people with type 2 diabetes (Cukierman-Yaffe et al. 2009, Grober et al. 2011, 
Mahakaeo et al. 2011). However, the literature could not provide a clear answer 
that whether a better glycaemic control is related to a better cognitive functioning 
due to the limitations of each study. By contrast, this study shows the similar 
results and agrees with the three previous studies which found no association 
between glycaemic control measured by HbA1c and cognitive screening test 
(MMSE) in the evaluation period (Munshi et al. 2006, Bruce et al. 2008, Alencar et 
al. 2010). However, there is no study in the literature, to the best of the researcher’s 
knowledge, on the association between the level of glycaemic control (HbA1c) and 
cognitive impairment measured by Mini-Cog.  
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According to the results of HbA1c test, it is important to mention that HbA1c test 
result in this study was recorded from medical profile and HbA1c was measured 
before the administration of the screening tests. Thus, the value of HbA1c on the 
day of administering the tests may have varied from the previously recorded test in 
the medical profile. Moreover, this study was limited to the information of the 
medicine used in individual treatments. It could be possible that some of the 
diabetic patients changed the anti-diabetic agent and some of them used other 
classes of medication such as anti-hypertensive medicine or alternative medicines 
after the HbA1c measurement. These conditions may have affected the cognitive 
function in older people with type 2 diabetes (Wu et al. 2003, Logroscino et al. 
2004).  
 
Regarding depression, this result is also in line with the study of Munshi et al. 
(2006) that observed no correlation between depression and depressive mood 
screening test (GDS). However, this finding contradicts with some studies in the 
literature that found HbA1 correlated with depressive symptoms (Sotiropoulos et 
al. 2008, Tsai et al. 2008, Thaneerat et al. 2009). As stated earlier, the results of 
depression studies have to be cautious due to the variety of depressive mood 
screening tests, the purpose of the study including the definition of depression in 
each study.  
 
9.7 Summary 
 
This prevalence study has documented the undiagnosed cognitive impairment and 
depressive mood in the older people with type 2 diabetes in the primary care 
setting. The prevalence of cognitive impairment by Mini-Cog and MMSE was 
found to be  65.4 % and 12.4 % respectively. With regard to the executive function 
test in Mini-Cog, it could be possible that Mini-Cog could detect the number of 
people with an early stage of cognitive impairment or mild cognitive impairment 
(MCI), whereas MMSE Thai 2002 has a limitation on executive test. Therefore, 
MMSE Thai 2002 may be not be able to detect the participants with the early stage 
of cognitive impairment or MCI. Hence, this may be a major reason for the 
difference of prevalence rate between the two tests. The prevalence of depressive 
mood was found to be 19.4%. The prevalence of cognitive impairment and 
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depressive mood amongst Thai older people was consistent with the previous 
studies in many regions of the world. This study further highlighted the possibility 
of early cognitive impairment in Thai older people, particularly the younger old 
age of less than 75. This study revealed the associated characteristics of the older 
people with type 2 diabetes that may result from cognitive impairment and 
depressive mood. Although age and education variables may need further study to 
confirm the results, other variables of clinical indicators such as BMI, HDL and 
diabetes retinopathy may contribute to the increased risk of cognitive impairment 
and depressive mood in Thai older people at the primary care setting. In addition, 
BMI and HDL are the clinical risk factors of MCI and Alzheimer’s disease (AD) 
(Michikawa 2003, Whitmer et al. 2005). This study found that these two clinical 
factors were the potential clinical characteristics of cognitive impairment by Mini-
Cog. Thus, this may be a supportive reason for the difference of prevalence rate 
between Mini-Cog and MMSE.  
 
Although this study had a limitation in accessing the HbA1c test result at the same 
time and date of the assessment of the screening tests, it should be noted that a 
long term of poor glycaemic control (hyperglycaemia) may affect the macro and 
micro-vascular system in the brain and body and could indirectly influence 
cognitive impairment and depressive mood (Biessels et al. 2006).  
 
The findings of this study are significant for Thai older people with type 2 diabetes 
in a community or rural areas. The information implies that inadequately 
recognised cognitive impairment and depressive mood in diabetic patients may 
lead to health problem and affect self-care diabetes management. It is important 
that health care staff at the primary care setting be aware of undiagnosed cognitive 
impairment and depressive mood in the older people with type 2 diabetes. An 
appropriate program for prevention and care with any signs of cognitive 
impairment or depressive mood is needed to provide either the diabetic patients or 
family members for the good quality of life.  
 
In the next chapter the strengths and limitations of the study will be provided 
including recommendation for other implications and further research studies.  
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Chapter 10 
Summary and Recommendations 
 
This chapter is divided into four parts. The first part is an overall summary of the 
study. The second part presents the strengths and limitations of this study.  The 
third part includes recommendations and implications for clinical or health care 
professionals. The last part provides some ideas for further research 
 
10.1 Overall summary 
 
The present study demonstrated the prevalence of Thai older people with type 2 
diabetes who were undiagnosed with cognitive impairment (65.4% for Mini-Cog 
and 12.4% for MMSE Thai 2002) and undiagnosed with depressive mood (19.4%) 
in Thai rural areas. This study revealed that the individual potential characteristics 
related to predicting cognitive impairment by Mini-Cog are younger old age group 
(equal or less than 74 years), more than 4 years of attending school, a high level of 
BMI (more than 23 kg/m2) and a low level of HDL (less than 40 mg/dl or 2.2 
mmol/l). The individual characteristics associated with cognitive impairment by 
MMSE Thai 2002 were old age (more than 75 years) and never attending school. 
An important predictor for depressive mood was retinopathy. This study found an 
association between cognitive impairment and depressive mood. The patient with 
cognitive impairment was likely to have depressive mood and vice versa. 
However, the levels of glycaemic control, which were divided into the good and 
poor levels, did not show the differences between the performance of cognitive and 
depressive mood tests.  
 
This study entailed the development of a Thai version of Mini-Cog test, a brief 
cognitive screening test specifically used in primary care settings (Borson et al. 
2000, Lorentz et al. 2002, Ismail et al. 2010). In addition, the Thai Mini-Cog test 
was developed to address the need for short cognitive screening test specifically 
used in primary care settings where time for health care services is limited (Borson 
et al. 2000, Wilber et al. 2005, Lotrakul et al. 2006, Brodaty et al. 2007). The 
validity and reliability studies demonstrated that Mini-Cog Thai version is reliable 
to screen cognitive impairment in the study subjects. The results of Mini-Cog 
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demonstrated significant correlation with MMSE Thai 2002, a standard Thai 
cognitive screening test. This information implies that Mini-Cog yield the result in 
the same direction with the standard test in Thailand. Thus, Mini-Cog seemed to 
perform acceptable to a Thai standard cognitive screening test. Short memory and 
executive function are cognitive domains that are found to changes in an early 
stage of cognitive impairment or mild cognitive impairment (MCI). As mentioned 
in Chapter 9, MMSE Thai 2002 has limitation on specificity and execution 
function test which may not detect the MCI. Mini-Cog, on the contrary, contains 
the executive function test. Therefore, it could be possible that Mini-Cog is more 
likely to detect MCI cases and, therefore, has a higher prevalence rate of cognitive 
impairment than MMSE Thai 2002.  
 
10.2 Strengths and limitations of the study 
10.2.1 Strengths of the study 
 
There is one study conducted by Thaneerat (2009) which is carried out in a 
hospital setting in the urban area of Thailand and focuses on mild cognitive 
impairment (MCI).  Apart from that, this is the first study to investigate the 
prevalence of cognitive impairment and depressive mood including the potential 
factors and the association between cognitive impairment and depressive mood 
among Thai older people with type 2 diabetes in primary care settings. It shows the 
number of older diabetic patients who have cognitive impairment and depressive 
mood in primary care settings in rural areas. The study of diabetic older people at 
primary care setting in rural areas is important because 70 % of Thai older people 
live in rural areas (The National Commission on the Elderly 2009) (Chapter 1, 
Section 1.6.3). Moreover, primary care setting is the first gateway to access health 
service and plays an important role in improving equity in health  (Prakongsai et al. 
2009) (Chapter 1 , Section 1.6.2). 
 
This study initially developed a Thai version of Mini-Cog, a brief cognitive 
screening test originally based on its utility in primary care settings (Borson et al. 
2000). This test is practical, convenient to administer and only requires a pen or a 
pencil and a piece of paper, no special equipment. The test takes 5 minutes to 
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implement and can be administered by health care staff with a minimal training 
and a simple scoring system. The use of cross-cultural translation ensures the 
equivalence of meaning and concept between Mini-Cog original (English) and its 
Thai version. The study of the inter-rater reliability of the Thai version of Mini-
Cog contained a high agreement value (Kappa (K) = 0.8, p < 0.001, 95% CI 0.54, 
1.06). It indicates a reliable test to use between the raters (Altman, 1991). Finally, 
the study of the concurrent validity of Mini-Cog test (r = 0.47, p = 0.007, 95% CI 
0.37, 0.55) and MMSE Thai 2002 increases the likelihood of the test to be 
practically useful in Thailand.   
10.2.2 Limitations of the study  
 
This study shows the empirical prevalence of cognitive impairment and depressive 
mood in the older people with type 2 diabetes. However, considerations need to be 
given to the factors that may have influenced the results of this study.  
 
 
- Research design 
The results in the current study are reported on the basis of the data from 
the cross-sectional study collected at a specific point of time. However, the 
conditions of cognitive impairment and depressive mood are likely to be 
changeable, which might cause patients’ cognition and depressive mood to 
change over time (Gagliardi 2008). Therefore, the results of this research 
may not reflect the prevalence of cognitive impairment and depressive 
mood over a period of time. 
 
In addition, since the present study is a cross-sectional design in which 
participants are assessed at the same instant in time, it is implausible to 
interpret and discuss the findings in terms of cause and effect (Sutton 
2002). The potential risk factor and outcome measures (cognitive 
impairment and depressive mood) are measured at the same time, and it is 
not usually possible to determine a temporal relationship between the two 
(Sutton 2002). In this study, the research design (cross-sectional study) 
could not inform the causation of cognitive impairment and depressive 
mood in the subjects; however the findings could show the potential 
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associations between the individual characteristics and cognitive 
impairment, and the potential associations between individual 
characteristics and depressive mood.  
 
- HbA1c test result 
The results of the glycaemic control level by HbA1c were the limitation in 
this study. As mentioned earlier, HbA1c was not measured on the same 
date of the administration of the screening test.  Therefore, we should be 
aware that the real levels of glycaemic control (HbA1c) results on the day 
of administering the tests might vary from the medical record. This is 
because the blood glucose level varies from day to day (American Diabetes 
Association 2009) in response to changes in diet and life style (Nitin 2010). 
Moreover, changing medication and treatment may affect HbA1c level in 
diabetic patients (Logroscino et al. 2004, Sherifali et al. 2010). 
 
Regarding the limitation of HA1c test in Thai primary care centres, 
postprandial blood glucose (PPG), a measure of oral glucose tolerance, can 
be used to diagnose diabetes and monitor diabetes management. Since 
postprandial hyperglycaemia develops early in type 2 diabetes that is often 
found before observing fasting hyperglycaemia (Sikaris 2009), PPG 
remains a more sensitive (and specific) marker of glucose intolerance. In 
addition, approximately 92% of all patients with type 2 diabetes are insulin 
resistant (Parkin and Brooks 2002).PPG depends altogether on insulin 
resistance, hepatic glucose output, and insulin secretory capacity of the 
pancreas in response to meals (Dinneen et al. 1992). Whereas, FBG 
concentrations are fairly stable in type 2 diabetic patients but can vary by 
about 15 percent from day to day (Ollerton et al. 1999). Thus, PPG rather 
than FBG would better reflect the overall pathophysiological process of the 
disease, i.e., insulin resistance, inadequately suppressed hepatic glucose 
output, and defective insulin response to meals (Avignon et al. 1997). 
Moreover, PPG is a marker of glycaemic burden and is as predictive of the 
risk for diabetic complications when compared with FPG(Avignon et al. 
1997). Furthermore, PPG levels have been found to correlate with HbA1c 
better than fasting levels (Avignon et al. 1997, Rosediani et al. 2006). 
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Therefore, it is important to identify and utilize the PPG where possible in 
the primary care centres in order to monitor the glycaemic control level and 
risk of diabetic complications more accurately. Nevertheless, PPG is not 
recommended to be used in a standard practice of diabetes care in Thailand 
because clinical practice of diabetes care and treatment in Thailand is based 
on the American Diabetes Association (ADA) guidelines, which uses only 
HbA1c test as a monitor of diabetes management (Diabetes Association 
Thailand 2012). 
 
- The coexistence of depression  
As stated in Chapter 1, depression is a reversible cognitive impairment 
(Zrebiec 2006). This study focused on the prevalence of cognitive 
impairment and depressive mood. Thus, depression was not definitely 
excluded. This means that the results of cognitive impairment could have 
been influenced by the presence of an underlying depressive condition and 
vice versa. However, this study intended to show the prevalence rate of 
undiagnosed depression in order to encourage an awareness of depression 
as a co-morbidity in diabetic older people for a further appropriate 
treatment. 
 
- Diagnostic test 
This study did not use a complete battery of neurological instruments to 
establish a diagnosis of dementia or mild cognitive impairment in order to 
ensure the accuracy of screening tests. There is no report of an empirical 
data of the prevalence rate of cognitive impairment and depressive mood of 
the older people with type 2 diabetes in the community level. This study 
focused on the potential number of outcome measures in order to give an 
overview trend and blueprint of the existing problem of the health care in 
taking care of diabetic patients. The data of this study should be used as the 
primary data for future prospective studies. 
 
- Generalisation of findings 
This study only examined a sample of Thai older people from one district 
in the north part of Thailand. The results were based on one community 
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(San-sai district) where most of the subjects were located in the rural areas 
with the limitation of HbA1c test. Therefore, the findings may not be 
generalisable to all the community dwellings of Thai older people, 
particularly the urban areas. 
10.3 Clinical implication  
10.3.1 Implication of Mini-Cog  
 
Mini-Cog can be used when there is a suspicion of cognitive impairment or during 
a routine screening of an older adult (Borson et al. 2006, Brodaty et al. 2006). In 
particular the test consists of short memory and executive function tests which are 
found to decline in an early stage of cognitive impairment (Doerflinger 2007). The 
strength of this tool is its efficiency, brevity (3-5 minutes of administration) and 
cost-effectiveness in equipment (only a pen and a piece of paper needed). Another 
advantage is that the test is not complicated and requires minimal training before 
use (Scanlan and Borson 2001, Borson et al. 2003). Thus, Mini-Cog can be used as 
a screening tool to facilitate early identification of cognitive impairment (Borson et 
al. 2006, Borson et al. 2007) in primary care settings. 
 
Three studies suggest that the use of a combination of a brief cognitive screening 
test with MMSE resulted in a higher sensitivity and greater accuracy in identifying 
a case that was achieved by MMSE alone (Flicker et al. 1997, Xu et al. 2002, 
Palmqvist et al. 2009). Thus, it could be possible to use Mini-Cog and MMSE Thai 
2002 in combination in order to ensure the accuracy of the screening tests to each 
other. 
 
The patients identified as positive in one or more screening tools should be aware 
of early cognitive impairment. In addition, this early detection would help the 
health care staff to make diagnostic and treatment decisions by further referring to 
qualified professionals (Boustani 2003). An early diagnosis provides patients and 
families with an appropriate care and sufficient time to prepare for future care 
while the patients still have the capacity to participate in the process (Leifer 2009). 
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To the researcher’s knowledge, this is the first investigation of cognitive 
impairment in diabetic patients in Thai rural areas.  Most of the diabetic patients in 
this study may have an early or mild symptom of cognitive impairment. The range 
of the findings represents a potential limitation for generalisability to more 
severely impaired subjects. Although, without additional neuropsychological 
testing, it is difficult to provide accurate results and further research will be needed 
to support this evidence. Nevertheless, the findings in this research support the 
previous study by Thaneerat et al. (2009) in Thailand, which reported a similar 
percentage of mild cognitive impairment of Thai older diabetic patients in hospital 
(77.6%). In addition, this study agrees with the finding of Munshi et al. (2006) 
suggesting that MMSE fails to sample the executive function test adequately, with 
a corresponding loss of sensitivity to an early state of cognitive impairment.  
 
In primary care centres with a limited time and specialist availability, it is vital that 
cognitive impairment be screened reliably, using a tool that requires minimal or 
little training so that further service can be arranged in time. Even though MMSE 
Thai 2002 is considered to be the gold-standard for assessing cognitive impairment 
but this assessment is too time-consuming to be done routinely and requires trained 
assessors in primary care centres. Moreover, MMSE Thai 2002 misses the point of 
mild cognitive impairment because of its lack of executive function test, a first 
domain test of cognitive decline. However, the score results of Mini-Cog are 
significantly positive in correlation with the score results of MMSE Thai 2002. For 
all these reasons, Mini-Cog might be the preferred screening measure because it is 
practically less time-consuming, and because it assesses an early state of cognitive 
impairment or detects subtle deficits in the specific cognitive domains (short 
memory and executive function tests), associated with mild cognitive impairment 
in individuals with diabetes at primary care centres. However, the results of 
MMSE Thai 2002 in this study may have detected the group of moderate to severe 
cognitive impairment. Therefore, Mini-Cog might be used as a cognitive screening 
test to detect an early state of cognitive impairment, or to monitor cognitive 
function at primary care centres. 
 
 
 
 178 
 
10.3.2 Implication for clinical and health care professionals 
 
The clinical implications from these findings are as follows: 
 
 
- Health care professionals should be trained according to the current 
knowledge of cognitive screening tests for an early recognition of cognitive 
impairment. Screening of cognitive impairment may help the health care 
professionals with further reference to diagnostic and treatment decisions. 
Effective screening allows health care staff to anticipate problems in self-
care management of a diabetic patient. 
 
- Routine screening or monitoring of cognitive impairment and depressive 
mood are recommended to prevent and delay the onset of cognitive 
impairment and depressive mood in the older people with type 2 diabetes. 
This is particularly important in patients with memory problems since 
memory problems are the first sign of cognitive impairment (Llorente and 
Malphurs 2007). More significantly, the patients with executive impairment 
may be at greatest risk for conversion to a diagnosis of dementia (Shulman 
and Feinstein, 2003, Petersen et al. 2004), highlighting the need to identify 
these individuals for early care and treatment when it might be most 
effective (Gauthier 2006). Moreover, based on this study, health care 
providers should be aware that a mild state of dementia might occur at 
younger old age groups (60-64 years). Early recognition of cognitive 
impairment allows health care professional to anticipate the problems that 
diabetic patients may have in understanding and adhering to self-care 
management. This information may also be useful for the patients’ care-
givers and their family members in helping to anticipate and plan for the 
future problems that may develop as a result of progressive cognitive 
impairment 
 
- For the diabetic patients whose cognitive impairment is not suspected, 
health care clinicians should assess cognitive function whenever adherence 
or deterioration of self-care management is suspected. This should be based 
on direct observation or concerns raised by family members. 
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- This study finds the rate of undiagnosed cognitive impairment and 
undiagnosed depressive mood. This information shows that health care 
professionals may benefit from educational interventions aimed at 
improving the detection of cognitive impairment and depressive mood. 
They should be encouraged to refer the patients to specialist services for 
assessment. 
 
 
- The effect of depression may be indirect, but result in cognitive impairment 
leading to poor self-care management or vice versa (Lustman 2002). 
Although the link between depression and diabetes may be understandable, 
it is not inevitable. Depression may indirectly affect self-care behaviour in 
diabetic older people patients by resulting in poor self-care behaviours, 
such as overeating, drinking alcohol, not exercising, skipping medication or 
failing to keep medical appointments. Therefore, efforts to identify and 
treat depression in the diabetic older people should been encouraged and 
strongly recommended (Trief 2007).  
 
- It is important for health care providers to review the diabetic patients with 
a poor depression score, to rule out other possible reversible causes of 
cognitive impairment. This is because the initial poor screening score of the 
cognitive test may have been due to transient diagnoses such as depression 
(Mohs 2000). 
 
- In order to minimise or delay the development of risk factors that might 
predispose to cognitive impairment or depressive mood, health care 
professionals should promote a healthy and active lifestyle to every 
patients. 
 
- An early detection of cognitive impairment can improve the quality of care 
and life and reduce care expenditures for the diabetic patients and their 
families (American Diabetes Association 2009).  
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- More importantly, this study shows that even the participants in the group 
with HbA1c were likely to be healthier than the group without HbA1c in 
which cognitive impairment and depressive mood were found. Thus, health 
care professionals should be seriously concerned about the cognitive 
function and mood observed in the group without HbA1c as well. Due to 
the poor health condition and uncontrolled blood sugar in the group without 
HbA1c, there may be a high possibility of having cognitive impairment and 
depressive mood.  Thus, a routine screening of these symptoms is 
recommended in the diabetic patients in clinical setting. 
 
- The results of this study, particularly when associated with the clinical 
characteristics of cognitive impairment and depressive mood, could be 
generalised to older diabetic patients in Thailand because more than half of 
diabetic patients (64%) in San-sai district was the same age group (60-69) 
as the diabetic adults who were found to have a highest prevalence rate 
(16.7%) in Thai national health survey (Akeplakorn et al. 2011). 
Particularly, in rural areas where all primary care centres in Thailand have 
the same policy under the Universal Healthcare Coverage Scheme, chronic 
diseases (e.g. diabetes, hypertension and heart disease) are a major problem 
of non-communicable diseases (NCD) in ageing population (National 
Statistical Office of Thailand 2011). Since subtle changes in cognition, 
especially executive function, are difficult to detect during a short visit at a 
primary care centre, the screening tools such as Mini-Cog might be used to 
identify vulnerable individuals with cognitive decline quickly. This study 
shows that some clinical variables such as BMI and HDL may strongly 
associate with cognitive impairment. Hence, this information might be 
useful for the health care staff to screen and monitor cognitive function in 
patients with high BMI and a low level of HDL in each visit. It could be 
possible that a better control of these potential factors might modulate and 
improve cognitive function of individuals. Likewise, health care staff 
should be aware of microvascular complications such as retinopathy which 
may potentially trigger depressive mood in diabetic patients at primary care 
centres. As mentioned in Chapter 1, diabetes self-care and management 
could be indirectly affected by depression. This problem will also increase 
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healthcare use and expenditures in primary care centres. In summary, the 
results of this study suggest that in order to support an effective diabetes 
care, older patients at primary care centres in rural areas may need to be 
checked for cognition and mood. In particular, the health care staff should 
raise awareness in the group of patients with high BMI, low level of HDL 
and retinopathy, which are found as the potential factors of cognitive 
impairment and depressive mood in this study.  
 
10.4   Implication for future research 
 
- The present study is just an initial step towards exploring factors that are 
associated with the use of a brief cognitive screening test. There is 
necessary for similar or larger scale studies to consolidate the much-needed 
empirical evidence on factors that have an impact on the use of brief 
cognitive screening tests. Further studies may focus on Mini-Cog in other 
chronic diseases such as hypertension and heart disease affecting cognitive 
functions. This tool can also be studied in diabetes in other communities 
and regions of Thailand to see any differences in the results. 
 
- In order to see whether age groups and the level of education in Thai older 
people influence the results of Mini-Cog, a further study of Mini-Cog is 
required in order to test the Thai older people living in urban areas where 
the heterogeneous nature of individual age groups and the level of 
education could provide a clearer trend of these factors.  
 
- A further longitudinal study such as a prospective cohort study will be 
carried on a group of older people with type 2 diabetes with a 6+ years of 
follow-up. As this illness duration has been found an association with 
cognitive impairment in type 2 diabetes (Gregg et al. 2000, Cosway et al. 
2001, Asimakopoulou and Hampson, 2002, Awad et al. 2004). Baseline of 
cognitive function will be assessed in all participants at the beginning of the 
study. In order to investigate the association between cognitive impairment 
and potential risk factors (demographic and clinical characteristics), the 
follow up data of the subjects with and without cognitive impairment will 
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be compared. Linear regression models will be used to estimate the mean 
change in cognitive outcomes over the follow-up period according to 
explanatory variables such as sociodemographic factors (age, sex, 
education), clinical variables (BMI, Cholesterol, HbA1c, use of diabetes 
medications, duration of diabetes, diabetic complications, medical 
conditions such as vascular diseases and depression; and life style such as 
alcohol intake and smoking history. Confounding variables such as age and 
education between the first two assessments will also be adjusted in the 
model. 
 
- Limited research has been conducted into the prevalence and potential 
factors strongly associated with cognitive impairment and depressive mood 
in this target population. Thus, conducting further on the psychometric 
properties of Mini-Cog would expand the efficiency of the test and sharpen 
its accuracy in identifying of cognitive impairment in Thai population.  
 
10.5 Summary 
 
 
This study contributes to the estimated rate of cognitive impairment and depressive 
mood in Thai older people with type 2 diabetes in a primary care setting. Since 
cognitive function is one of the crucial factors in self-care management in diabetes, 
an early detection becomes more clinically relevant. This leads to the use of 
screening tools to help the early detection and these tools gain importance. This 
study focused on simulating the real world situation in a primary care setting with 
the well-known restraints of time and resources. Mini-Cog test, a cognitive 
screening test designed for use in primary care settings, was applied in order to 
promote the detection of suspected cognitive impairment in the older people with 
type 2 diabetes. Nevertheless, this study did not aim to compare the efficiency of 
Mini-Cog or MMSE Thai 2002 in detecting cognitive impairment against a ‘gold 
standard’ that would require a battery of neuropsychological tests.  
 
Depression can cause an reversible cognitive impairment. This study showed that 
depression is also detected in diabetic patients.  These results can enhance the 
understanding of how providing the optimal approaches to the diabetic patients 
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with cognitive impairment or depressive mood enhance the abilities of patients in 
performing diabetes self-management. It also provides useful information for 
family members to support patients in self-care management.   
  
Type 2 diabetes is a major and complex public health problem accompanied with 
several complications and co-morbidities. Depression and cognitive decline are 
common, but often overlooked (Biessels et al. 2007).This study is important 
because findings show that older Thai people with type 2 diabetes in the 
community are found to have undiagnosed cognitive impairment and depressive 
mood. A possibility of individual characteristics at an increased risk for developing 
cognitive impairment and developing depressive mood are pointed out. This study 
stimulates the health care providers’ awareness and understanding of the link 
between type 2 diabetes and cognitive function as well as the link between type 2 
diabetes and depressive mood. A need for a routine assessment and monitoring of 
cognitive function with Mini-Cog Thai version can ultimately lead to 
improvements in the long-term outcomes of self care diabetes. Mini-Cog Thai 
version is a new reliable and simple tool fitting in 5 minutes and is practical to use 
in primary care centres. 
 
A further longitudinal study is required to fully determine whether the associated 
variables are risk factors for cognitive impairment. In order to fulfil the 
development of Mini-Cog Thai version, the measures of psychometric properties 
compared with a neurological instrument such as Cambridge Cognitive 
Assessment (CAMCOG), a standardised neurological screening test (Ruth et al. 
1986, Kwa et al. 1986), to establish a diagnosis of dementia are recommended for a 
new ideal dementia screening test.   
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Appendix B: Translation of Mini-Cog  
Appendix B1: Step 1: Forward translation  
Appendix B1.1 forward translator 1  
 
MINI-COG-PS Version 
 
1) ใหผู้ป้ว่ยตัง้ใจฟงั จากนัน้พูดว่า “ฉนัจะพดูค า 3 ค าใหจ้ าตอนน้ีและภายหลงั ค า
เหล่านัน้ไดแ้ก่ 
บ้าน  แมว   สีเขียว 
บอกฉนัตอนน้ีว่ามคี าอะไรบา้ง” (ใหผู้ป้ว่ยตอบได ้3 ครัง้ ถา้ผูป้ว่ยไมส่ามารถตอบได้
หลงัจาก 3 ครัง้ไปแลว้ ใหไ้ปทีห่วัขอ้ถดัไป) 
(พบักระดาษตามเสน้ประ 2 เสน้ขา้งล่างเพื่อใหเ้ป็นพืน้ทีว่่างและเพื่อปกปิดค าทีใ่ห้
จ า ยื่นดนิสอ/ปากกาใหผู้ป้ว่ย) 
2) พดูประโยคต่อไปนี้ตามล าดบั: “วาดรปูนาฬกิาในพืน้ทีว่่างขา้งล่างนี้ เริม่วาดวงกลม
ใหญ่ก่อน” (หลงัจากผูป้ว่ยวาดวงกลมเสรจ็ พดูว่า) “ใส่เลขทัง้หมดในวงกลม” (เมือ่
ผูป้ว่ยวาดเสรจ็ พดูว่า) “เอาล่ะ ใส่เขม็นาฬกิาบอกเวลา 11:10 (สบิเอด็นาฬกิาสบิ
นาท)ี” ถา้ผูป้ว่ยไมส่ามารถวาดนาฬกิาเสรจ็ใน 3 นาท ีใหห้ยดุท าและถามหวัขอ้
ความจ า 
-------------------------------------------------------------------------------------------------------- 
 
 
 
 
 
 
3) พดูว่า: “ค า 3 ค าทีใ่หจ้ ามอีะไรบา้ง?” 
_______________         _______________     ______________ (ให ้
1 คะแนนในแต่ละหวัขอ้) คะแนนความจ า 3 หวัขอ้  
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คะแนนวาดนาฬกิา (ดกูารใหค้ะแนนในอกีหน้า): นาฬกิาปกต ิ 2 
คะแนนนาฬกิาผดิปกต ิ 0                    คะแนนนาฬกิา  
      
คะแนนรวม = คะแนนความจ า 3 หวัขอ้บวกคะแนนนาฬกิา  
0, 1, หรอื 2 อาจมคีวามบกพรอ่ง; 3, 4, หรอื 5 ไมม่คีวามบกพรอ่ง 
 
 
 
 
 
 
 
การให้คะแนนนาฬิกา 
 
นาฬกิาปกตติอ้งมสี่วนต่าง ๆ ต่อไปนี้ครบถว้น 
 มเีลข 1-12 ครบ, มเีลขแต่ละตวัเพยีง 1 ตวั, เลขทุกตวัเรยีงตามล าดบัและมี
ทศิทางทีถู่กตอ้ง (ตามเขม็นาฬกิา) ภายในวงกลม 
 มเีขม็สัน้และยาวโดยเขม็สัน้ชีท้ีเ่ลข 11 เขม็ยาวชีท้ีเ่ลข 2 
 
 
 
รปูนาฬกิาใด ๆ ทีม่สี่วนต่าง ๆ ดงักล่าวไมค่รบถอืว่าเป็นนาฬกิาผดิปกต ิผูป้ว่ยทีไ่ม่
ยอมวาดใหถ้อืว่าเป็นนาฬกิาผดิปกต ิ
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วางเขม็ไมถู่ก 
 
 
 
    ตวัเลขนาฬกิาไมค่รบ 
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Appendix B1.2 forward translator 2 
 
MINI-COG ™ - PS Version  
 
 
1) ให้ผู้ป่วยตั้งใจฟัง บอกผู้ป่วยว่า “ฉัน (ผม) จะบอกค า 3 ค าขอให้คุณ .....จ าไว้ในตอนนีแ้ละจะถามอกี
คร้ังในเวลาต่อมา” 
ค ำ 3 ค ำนัน้ได้แก่ ค ำวำ่“บ้ำน” “แมว” “สีเขียว” 
ขอให้คณุ......ชว่ยบอกฉัน (ผม)วำ่ค ำ3 ค ำนัน้คือค ำว่ำอะไรบ้ำง (ผู้ ป่วยพยำยำมตอบได้ 3 ครัง้หำกไม่สำมำรถ
ตอบได้ถูกต้องหลังจำกพยำยำม 3ครัง้แล้ว ให้ทดสอบในหวัข้อตอ่ไป) 
 
พบักระดำษไปด้ำนหลงัตำมรอยปรุ 2แถวด้ำนลำ่ง ให้เหลือกระดำษเป็นพืน้ที่วำ่งและไมใ่ห้เห็นสว่นของค ำที่ใช้
ทดสอบควำมจ ำ สง่ปำกกำหรือดินสอให้คนไข้ 
2) พดูวลีตอ่ไปนีโ้ดยเรียงตำมล ำดบั:” ให้คณุ ....วำดนำฬิกำในพืน้ที่วำ่งบนกระดำษ เร่ิมจำกวำดวงกลมวง
ใหญ่ๆ” เม่ือผู้ ป่วยท ำเสร็จแล้ว บอกผู้ ป่วยวำ่ “ใสต่วัเลขในวงกลมให้ครบถ้วน” เม่ือผู้ ป่วยท ำเสร็จ บอกผู้ ป่วย 
“ให้วำดเข็มนำฬิกำชีไ้ปที่เวลำ 11:10 น. (สิบเอ็ดโมงสิบนำที) หำกผู้ ป่วยไมส่ำมำรถวำดนำฬิกำได้เสร็จ
เรียบร้อยภำยใน 3 นำที ให้หยดุกำรทดสอบ จำกนัน้กลบัมำถำมผู้ ป่วยซ ำ้ถึงค ำ3 ค ำที่บอกให้ผู้ ป่วยจ ำใน
ชว่งแรก 
  
 
 ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------  
 
 
 
 
 
3) พดูกบัผู้ ป่วยวำ่ “ ค ำ 3 ค ำที่ดฉิัน (ผม)ให้คณุ ....จ ำไว้มีค ำวำ่อะไรบ้ำง” 
  _       
   (ให้1 คะแนนตอ่ 1 ค ำ)        คะแนนกำรระลกึค ำ 3 ค ำ  
 
คะแนนวำดรูปนำฬิกำ (ดคู ำแนะน ำกำรให้คะแนนในหน้ำถดัไป):  
วำดนำฬิกำถกูต้อง  2  คะแนน   
คะแนนวำดรูปนำฬิกำ วำดนำฬิกำไมถ่กูต้อง           0 คะแนน   
 
รวม = คะแนนกำรระลกึค ำ3 ค ำรวมกบัคะแนนวำดรูปนำฬิกำคะแนน 
คะแนน0, 1, หรือ 2  น่ำจะมีควำมบกพร่อง; 3, 4, หรือ 5 ไมมี่ควำมบกพร่อง
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การให้คะแนนการวาดรูปนาฬิกา 
 
นำฬิกำปกติ (วำดถกูต้อง) 
 
 
 
 
 
 
นำฬิกำปกติ (วำดถกูต้อง) ต้องมีองค์ประกอบดงัตอ่ไปนี ้
ครบถ้วน: 
ในวงกลมมีตวัเลข 1-12 โดยตวัเลขแตล่ะตวั
ปรำกฏเพียงครัง้เดียว เรียงล ำดบัและทิศทำง 
(ตำมเข็มนำฬิกำ) ถกูต้อง 
มีเข็มนำฬิกำ 2 อนั เข็มหนึ่งชีไ้ปที่เลข 11 สว่นอีก
เข็มชีไ้ปที่เลข 2 
 
หำกนำฬิกำรูปใดขำดองค์ประกอบข้อใดข้อหนึง่
ข้ำงต้นให้คะแนนเป็นนำฬิกำท่ีวำดไมถ่กูต้อง 
และหำกผู้ ป่วยปฏิเสธกำรวำดรูปนำฬิกำให้ให้
คะแนนเป็นวำดไมถ่กูต้อง 
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ตวัอยำ่งนำฬิกำท่ีผิดปกติ (วำดไมถ่กูต้อง)     
   
 
 วำงต ำแหนง่เขม็นำฬิกำไมถ่กูต้อง
   
  
  
 ตวัเลขขำดหำยไป 
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Appendix B2: Synthesis of forward translation 
 
MINI-COG ™ - PS Version  
 
 
1) ใหผู้ป่้วยตั้งใจฟังแลว้บอกผูป่้วยวา่ “ดิฉนั (ผม) จะบอกค า 3 ค าซ่ึงอยากใหคุ้ณ (ช่ือ ป้า ลุง ยาย ตา) 
จ าตอนน้ีแลว้ก็จ าไวต้่อไปนะคะ (นะครับ) ค าเหล่าน้ีไดแ้ก่ 
   บ้ำน  แมว สีเขียว  
ไหนลองพดูออกมำให้ฟังสิคะ (ครับ)” (ให้โอกำสผู้ ป่วยลองท ำ 3 ครัง้ หำกไมส่ำมำรถท ำได้หลงัจำกพยำยำม 3 
ครัง้ ให้ท ำข้อตอ่ไป) 
 
พบัหน้ำนีไ้ปทำงด้ำนหลงัตำมรอยประ 2 แถวด้ำนลำ่งเพ่ือให้เกิดพืน้ที่วำ่งและบงัค ำที่ให้จ ำไว้ สง่ดินสอ/ปำกกำให้
ผู้ ป่วย 
2) พดูวลีตอ่ไปนีต้ำมล ำดบั:” ชว่ยวำดรูปนำฬิกำลงบนทีว่ำ่งด้ำนลำ่งนีห้น่อยนะคะ (ครับ) เร่ิมจำกวำดวงกลม
วงใหญ่ๆ คะ่ (ครับ)” (เม่ือเสร็จแล้วให้บอกวำ่) “ใสต่วัเลขลงไปในวงกลมให้ครบเลยคะ่ (ครับ)” (เม่ือเสร็จ
แล้วให้บอกวำ่) “ทีนีใ้ห้ตัง้เวลำ โดยให้เข็มนำฬิกำชีบ้อกเวลำ 11:10 น. (สิบเอ็ดนำฬิกำสิบนำท)ี คะ่ 
(ครับ)” หำกผู้ ป่วยไมส่ำมำรถวำดนำฬิกำได้เสร็จภำยใน 3 นำที ให้หยดุท ำแล้วไปถำมค ำที่ให้จ ำไว้ 
  
 ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------  
 
 
 
 
 
 
3) พดูวำ่: “ค ำ 3 ค ำที่ดิฉัน (ผม)ให้คณุ (ชือ่ ป้ำ ลงุ ยำย ตำ)จ ำไว้มีอะไรบ้ำงคะ (ครับ)” 
  _       
   (ให้1 คะแนนตอ่ 1 ค ำ)        คะแนนกำรระลกึค ำ 3 ค ำ  
 
ให้คะแนนรูปนำฬิกำ (ดคู ำแนะน ำอีกหน้ำหนึ่ง):   
คะแนนรูปนำฬิกำปกต ิ  2  คะแนน   
คะแนนรูปนำฬิกำผิดปกต ิ  0 คะแนน   
   
คะแนนรวม  = คะแนนการระลึกค า 3 ค ารวมกบัคะแนนรูปนาฬิกา  
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คะแนน0, 1, หรือ 2 น่าจะมีความบกพร่อง; 3, 4, หรือ 5 ไม่มีความบกพร่อง 
การให้คะแนนรูปนาฬิกา 
 
นำฬิกำปกติ  
 
 
นำฬิกำปกติจะมีองค์ประกอบดงัตอ่ไปนีค้รบถ้วน: 
ตวัเลขครบ1-12 ไมซ่ ำ้กนั อยู่อยำ่งถกูล ำดบัและทิศทำง (ตำมเข็มนำฬิกำ) ภำยในวงกลม  
เข็มนำฬิกำมี2 อนั อนัหนึ่งชีท้ี่เลข 11 และอนัหนึ่งชีท้ี่เลข 2 
รูปนำฬิกำทีข่ำดองค์ประกอบข้อใดข้อหนึง่เหลำ่นีใ้ห้ถือวำ่ผิดปกต ิกำรปฏิเสธท่ีจะวำดรูปนำฬิกำให้ถือวำ่
ผิดปกต ิ
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ตวัอยำ่งของนำฬิกำที่ผิดปกต ิ
 
 
 
   เข็มนำฬิกำผิดปกต ิ
 
   
   
 
 
 
 
                                        ตวัเลขไมค่รบ 
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Appendix B3: Backward translation 
Appendix B3.1 : Back translator 1  
 
MINI-COG ™ - PS Version  
 
1) ใหผู้ป่้วยตั้งใจฟังแลว้บอกผูป่้วยวา่ “ดิฉนั (ผม) จะบอกค า 3 ค าซ่ึงอยากใหคุ้ณ (ช่ือ ป้า ลุง ยาย ตา) 
จ าตอนน้ีแลว้ก็จ าไวต้่อไปนะคะ (นะครับ) ค าเหล่าน้ีไดแ้ก่ 
บ้ำน แมว สีเขียว 
ไหนลองพดูออกมำให้ฟังสิคะ (ครับ)” (ให้โอกำสผู้ ป่วยลองท ำ3 ครัง้หำกไม่สำมำรถท ำได้หลังจำกพยำยำม 3
ครัง้ ให้ท ำข้อตอ่ไป) 
 
พบัหน้ำนีไ้ปทำงด้ำนหลงัตำมรอยประ2แถวด้ำนลำ่งเพ่ือให้เกิดพืน้ที่วำ่งและปิดค ำทีใ่ห้จ ำไว้ สง่ดินสอ/ปำกกำให้
ผู้ ป่วย 
2) พดูวลีต่อไปน้ีตามล าดบั:” ช่วยวาดรูปนาฬิกาลงบนท่ีวา่งดา้นล่างน้ีหน่อยนะคะ (ครับ) เร่ิมจากวาด
วงกลมวงใหญ่ๆ ค่ะ (ครับ)” (เม่ือเสร็จแลว้ใหบ้อกวา่) “ใส่ตวัเลขลงไปในวงกลมใหค้รบเลยค่ะ 
(ครับ)” (เม่ือเสร็จแลว้ใหบ้อกวา่) “ทีน้ีใหต้ั้งเวลา โดยใหเ้ขม็นาฬิกาช้ีบอกเวลา 11:10 น. (สิบเอด็
นาฬิกาสิบนาที) ค่ะ (ครับ)” หากผูป่้วยไม่สามารถวาดนาฬิกาไดเ้สร็จภายใน 3 นาที ใหห้ยดุท าแลว้
ไปถามค าท่ีใหจ้ าไว ้
  
1. Make sure that the patient is paying attention, then tell him/her that “I will tell 
you 3 words and I would like you to memorize them". These words are HOUSE, 
CAT, GREEN. 
 
 
Let them try to say these words. (Give the patient at least 3 attempts and if  he/she 
can not do it after trying three times, then continue onto the next step. 
Fold this page to the back, following the 2 rows of ---------below to make a space 
and cover the three words. Pass a pen/ pencil to the patient. 
2. Say these phrases in order: “ Please draw a clock on the space below, begin 
by  draw a big circle". When he/ she has finished, tell them "please put numbers 
around the circle". When they have finished, say “ Can you set the time at 
11.10am?"  If the patient cannot draw a correct clock within three minutes, let 
him/her stop and ask questions. 
 
 
_________________________________________________________ 
3) พดูวำ่: “ค ำ 3 ค ำที่ดิฉัน (ผม)ให้คณุ (ชือ่ ป้ำ ลงุ ยำย ตำ)จ ำไว้มีอะไรบ้ำงคะ (ครับ)” 
  _       
(ให้1 คะแนนตอ่ 1 ค ำ)         
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คะแนนกำรระลกึค ำ 3 ค ำ  
 
 
ให้คะแนนรูปนำฬิกำ (ดคู ำแนะน ำอีกหน้ำหนึ่ง): รูปนำฬิกำปกต ิ  2  คะแนน  
   รูปนำฬิกำผิดปกต ิ  0 คะแนน   
คะแนนรวม  = คะแนนการระลึกค า 3 ค ารวมกบัคะแนนรูปนาฬิกา  
คะแนน0, 1, หรือ 2 อาจจะมีความบกพร่อง; 3, 4, หรือ 5 ไม่มีความบกพร่อง 
  
3) Say “What are those words that I asked you to remember”  
(1 mark per word) 3 marks for all the words 
Give marks for clock drawing (see recommendation on the other side): a normal 
clock = 2 marks, not normal clock = 0 
Total marks = mark from remembering the 3 words and marks from the clock 
picture. 
0,1 or 2 marks may reflect on some disability, whereas 3,4 or 5 marks is normal. 
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การให้คะแนนรูปนาฬิกา how to mark clock picture 
 
นำฬิกำปกติ normal clock 
 
 
นำฬิกำปกติจะมีองค์ประกอบดงัตอ่ไปนีค้รบถ้วน: 
ตวัเลขครบ1-12 ไมซ่ ำ้กนั อยู่อยำ่งถกูล ำดบัและ
ทิศทำง (ตำมเข็มนำฬิกำ) ภำยในวงกลม  
เข็มนำฬิกำมี2 อนั อนัหนึ่งชีท้ี่เลข 11 และอนัหนึ่ง
ชีท้ี่เลข 2 
 
รูปนำฬิกำทีข่ำดองค์ประกอบข้อใดข้อหนึง่เหลำ่นีใ้ห้
ถือวำ่ผิดปกติ กำรปฏิเสธท่ีจะวำดรูปนำฬิกำให้ถือวำ่
ผิดปกติ
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A normal clock should have the following: 
Numbers running from 1-12, without any repetition and in order (following the 
clock hand) within the circle.There are two clock hands one is at number 11 and 
the other is at number 2. 
Any clock pictures that don’t have the requirement above are considered as not 
normal.  Refusal to draw a clock picture is also considered as not normal. 
 
 
ตวัอยำ่งของนำฬิกำท่ีผิดปกตEิxample of a not normal clock    
   
 
     
  
   
เข็มนำฬิกำผิดปกต ิHand is not correct  
 
 
 
 
 
 
ตวัเลขไมค่รบ numbers are incomplete. 
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Appendix B3.2: Back translator 2  
 
MINI-COG ™ - PS Version  
 
 
1) ใหผู้ป่้วยตั้งใจฟังแลว้บอกผูป่้วยวา่ “ดิฉนั (ผม) จะบอกค า 3 ค าซ่ึงอยากใหคุ้ณ (ช่ือ ป้า ลุง ยาย ตา) 
จ าตอนน้ีแลว้ก็จ าไวต้่อไปนะคะ (นะครับ) ค าเหล่าน้ีไดแ้ก่ 
บา้น แมว สีเขียว 
ไหนลองพดูออกมาใหฟั้งสิคะ (ครับ)” (ใหโ้อกาสผูป่้วยลองท า 3 คร้ังหากไม่สามารถท าไดห้ลงัจาก
พยายาม 3 คร้ัง ใหท้ าขอ้ต่อไป) พบัหนา้น้ีไปทางดา้นหลงัตามรอยประ 2 แถวดา้นล่างเพ่ือใหเ้กิด
พ้ืนท่ีวา่งและปิดค าท่ีใหจ้ าไว ้ส่งดินสอ/ปากกาใหผู้ป่้วย 
 
2) พดูวลีต่อไปน้ีตามล าดบั:” ช่วยวาดรูปนาฬิกาลงบนท่ีวา่งดา้นล่างน้ีหน่อยนะคะ (ครับ) เร่ิมจากวาด
วงกลมวงใหญ่ๆ ค่ะ (ครับ)” (เม่ือเสร็จแลว้ใหบ้อกวา่) “ใส่ตวัเลขลงไปในวงกลมใหค้รบเลยค่ะ 
(ครับ)” (เม่ือเสร็จแลว้ใหบ้อกวา่) “ทีน้ีใหต้ั้งเวลา โดยใหเ้ขม็นาฬิกาช้ีบอกเวลา 11:10 น. (สิบเอด็
นาฬิกาสิบนาที) ค่ะ (ครับ)” หากผูป่้วยไม่สามารถวาดนาฬิกาไดเ้สร็จภายใน 3 นาที ใหห้ยดุท าแลว้
ไปถามค าท่ีใหจ้ าไว ้
__________________________________________________ 
 
1) Ask the patient to listen as you say “I will tell you 3 words in which I 
would like you (name of aunt/uncle/grandparent) to memorize. The 
words are as follow: House   Cat      Green 
Please repeat the words to me (Allow the patient 3 attempts at this. 
If after 3 attempts this cannot be achieved, move on to the next 
question). 
Fold this page along the 2 dotted lines below to create a blank area 
and to hide the words to be memorized. Pass the pencil/pen to the 
patient. 
 
2) Say the following sentence in this order: “Please draw a picture of a 
clock in the blank area below. Start from drawing a large circle” 
(Once completed, say) “Please place all the numbers into the circle” 
(Once completed, say) “Now set the time by showing the clock 
hands at 11.10 (ten minutes past eleven)” 
If the patient is not able to draw a clock within 3 minutes, discontinue 
with the task and ask them to recall the words they were asked to 
memoriZe.  
3) พดูวำ่: “ค ำ 3 ค ำที่ดิฉัน (ผม)ให้คณุ (ชือ่ ป้ำ ลงุ ยำย ตำ)จ ำไว้มีอะไรบ้ำงคะ (ครับ)” 
  _       
   (ให้1 คะแนนตอ่ 1 ค ำ)        คะแนนกำรระลกึค ำ 3 ค ำ  
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ให้คะแนนรูปนำฬิกำ (ดคู ำแนะน ำอีกหน้ำหนึ่ง): รูปนำฬิกำปกต ิ  2  คะแนน  
   รูปนำฬิกำผิดปกต ิ  0 คะแนน   
คะแนนรวม  = คะแนนการระลึกค า 3 ค ารวมกบัคะแนนรูปนาฬิกา  
คะแนน0, 1, หรือ 2 อาจจะมีความบกพร่อง; 3, 4, หรือ 5 ไม่มีความบกพร่อง 
 
 
3) Say: “What are the 3 words I asked you (name of 
aunt/uncle/grandparent) to memorize?” 
(1 mark per 1 word)    Mark for memorizing the 3 words 
 
Mark for the picture of the clock (see introduction on another 
page): Normal picture of a clock. Abnormal picture of a clock.  
Mark for picture of the clock. 
Total mark = mark for memorizing the 3 words plus mark for 
picture of the clock.  
 A mark of 0,1or 2 may suggest defective; 3, 4 or 5 suggesting no  
abnormality
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การให้คะแนนรูปนาฬิกา How to mark the picture of the clock 
 
นำฬิกำปกติ normal clock 
 
 
นำฬิกำปกติจะมีองค์ประกอบดงัตอ่ไปนีค้รบถ้วน: 
ตวัเลขครบ1-12 ไมซ่ ำ้กนั อยู่อยำ่งถกูล ำดบัและ
ทิศทำง (ตำมเข็มนำฬิกำ) ภำยในวงกลม  
เข็มนำฬิกำมี2 อนั อนัหนึ่งชีท้ี่เลข 11 และอนัหนึ่ง
ชีท้ี่เลข 2 
 
รูปนำฬิกำทีข่ำดองค์ประกอบข้อใดข้อหนึง่เหลำ่นีใ้ห้
ถือวำ่ผิดปกติ กำรปฏิเสธท่ีจะวำดรูปนำฬิกำให้ถือวำ่
ผิดปกต ิ
 224 
 
A normal clock will have all of the following features: 
Complete set of numbers of 1-12, without repetition, in the correct order 
and position (clockwise) within the circle. 
Two clock hands, one pointing at the number 11 and the other at number 2 
A picture of a clock without any of these features is held to be abnormal. 
A refusal to draw a clock is held to be abnormal.  
 
ตวัอยำ่งของนำฬิกำท่ีผิดปกต ิAn example of an abnormal clock     
   
 
     
  
   
เข็มนำฬิกำผิดปกต ิ abnormal clock hands                               
 
 
 
 
 
ตวัเลขไมค่รบ incomplete set of numbers 
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Appendix C: Information Sheets and consent forms 
Appendix C1: Information Sheets and consent forms in English 
 
 
 
Participant Information Sheet 
 
Research title: The prevalence of undiagnosed cognitive impairment and 
undiagnosed depressive mood in over 60’s with type 2 diabetes in a Thai 
community: a cross-sectional study. 
Researcher:  Miss Supaporn Trongsakul, a post-graduate research student at the 
School of Allied Health Professions, Faculty of Health, University of East Anglia, 
United Kingdom 
Workplace address (in Thailand): School of Health Science, Mae Fah Luang 
University, 333 M.1 Tasud, Muang, Chaing Rai, Thailand 57000 
Workplace address (in the United Kingdom):  School of Allied Health Professions, 
Faculty of Health, University of East Anglia, United Kingdom, NR4 7TJ 
Mobile phone number (in Thailand) 087-5585312  
Home phone number (in Thailand) 053-890238 extension 5403  
Mobile phone number (in the United Kingdom)   +44-07-791541214 
 
What is the study rationale?  
Type 2 Diabetes Mellitus (DM) diabetes is one of the long-term (chronic) diseases 
which cause a health problem in Thai older people. The important self-care 
activities to ensure healthy lifestyle in diabetic patients are control of blood sugar 
level, regularly exercise, and keep taking medicine and properly diet e.g. low in 
fat, sugar and salt with plenty of fruit and vegetables. However, these activities 
may not succeed if the patients have poor memory or depressive mood. Therefore, 
screening of memory function and depressive mood in the Thai older people with 
type 2 DM will provide the information for the further suitable care.  
What is the purpose of the study? 
The purpose of this study is to investigate whether patients with type 2 Diabetes 
Mellitus (DM), aged 60 years old or more have difficulty with memory and/or 
mood changes such as depression. This is important because these may be linked 
to control of blood glucose and good management of their diabetes 
 
Why have I been chosen? 
You have been chosen because you are in the group of Thai people who are aged 
60 and over, and who have registered as a patient with type 2 DM at a Primary 
Care Unit in the San-sai district at the time of the study. You are therefore eligible 
to be considered for the study 
What will happen to me if I take part? 
If you decide you would like to take part in the study I, the researcher, will ask the 
nurse some questions about you such as whether you have any problems in hearing 
or seeing. After this, I will meet you in the Diabetic Clinic you normally attend. I 
will ask you about your mood and memory. The assessment will take about 30 
minutes 
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What is the possible benefit of taking part? 
The information from this study may help the staff at Primary Care Units to 
provide more targeted care and without delay for the person who has been 
identified with cognitive impairment and depressive mood at the early state.  
Are there any potential benefits to your community?  
The results from this study may give  information  to  the heath care services in 
your community for  future planning to provide early advice, management and 
support for older people with type 2 DM who have early stage poor memory and 
depressive mood.  
What is the possible risk of taking part? 
There is no physical risk to you but you may feel uncomfortable answering some 
questions or you may feel weary from the tests during the study.  
How to prevent the possible risk? 
You do not have to answer any questions that you feel uncomfortable about and 
you can have a break during the study tests if you feel tired. If an emerging mental 
or health problems are identified during the study by the researcher, the researcher 
will, with the consent of the patient, notify a clinical member of staff within the 
Primary Care Unit to enable appropriate care to be provided. If necessary, any 
interview will be terminated. 
Will my taking part in this study be kept confidential? 
All information, which is collected about you, will be treated as strictly 
confidential in a locked cupboard in each primary care unit (this has already been 
negotiated with each of the primary care units) to which only the researcher has 
access or password protected on the researcher’s computer. Nobody will see it 
except the researcher, the researcher’s supervisors and a supervisory panel of 
academics. No individual will be identifiable from any report resulting from this 
research. All the information I collect about you will be destroyed 5 years after the 
study has finished. 
Will I be paid for being in the study?  
You will not be paid for participating in this study but I will give you a small 
refreshment (one bottle of soya milk) as a “thank you’’ for your participation. 
Are there any costs to being in the study?  
There are no costs to you for any activities in this study but you have to spend an 
extra 30 minutes at DM clinic on your regular basis to participate in the study. 
Do I have to take part? 
No, it is entirely up to you whether you wish to take part or not. If you decide to 
take part you are still free to withdraw at anytime without giving a reason. 
Withdrawal will not affect your care in anyway and you have the right to not 
answer any question that you do not wish to answer. 
Contact details of the field mentor  
If you should have any question regarding this study, please contact Dr. Nahathai 
Wongpakaran, a geriatric psychiatrist and the field mentor who has the role to 
monitor and ensure that the research method does not present any undue risks to 
the participants.     
For any concerns with your participation in this study, please contact: 
 Nahathai Wongpakaran, MD  
Assistant Professor 
Geriatric Psychiatry Unit 
Department of Psychiatry, Faculty of Medicine 
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Chiang Mai University, 110 Intawaroros Rd., Sripoom, A. Muang, Chiang 
Mai,50200. 
Telephone number: 053-945422 and Fax number:  053-945426 (working hours) 
Mobile phone number: 08-66702400 (Non-working hours)          
Who can answer my questions about the study? 
For questions about your rights while taking part in this study, 
The Office of the Secretary, 
Ethical Review Committee for Research in Human Subjects, 
Department of Medical Services, 
3th floor of the Building No.2, Ministry of Public Health 
Tiwanond Road, Nonthaburi 11000 
Telephone number 02-590-6171-2 (working hours) 
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Research title:The prevalence of undiagnosed cognitive impairment and 
undiagnosed depressive mood in over 60’s with type 2 diabetes in a Thai 
community: a cross-sectional study. 
                         
Consent date................................................... 
 
Before signing the consent, the study’s purpose, procedures, risks and 
possible benefits have been clearly explained to me by the researcher and I 
understand them.  
The researcher has agreed to answer completely and honestly all questions 
to my satisfaction. 
I am free to withdraw my consent and terminate my participation at any 
time without my medical care or legal rights being affected. 
The researcher has guaranteed that all information I give will remain 
confidential and only shared amongst the research study team 
The researcher has confirmed that I will not receive any compensation for 
the possible risks or disabilities that may happen to me during the study but I will 
be received the universal health care. I can contact Miss Supaporn Trongsakul at 
No 52 Soi 12 Sukkasem, Muang, Chaing Mai 503000, Mobile phone number 087-
5585312 (24 hours)or Dr. Nahathai Wongpakaran, the field mentor of this research 
study, at Department of Psychiatry, Faculty of Medicine, ChiangMaiUniversity, 
110 Inthravarorot, Sripoom, Chiang Mai,50200, Mobile phone number: 08-
66702400 (24 hours) 
 
The person who takes responsibility for this research isMiss Supaporn Trongsakul 
with the contact details at No 52 Soi 12 Sukkasem, Muang, Chaing Mai 50300, 
Mobile phone number 087-5585312 (24 hours) 
I have read the information, or it has been read to me. I clearly understand what is 
involved and consent voluntarily to participate in this research. 
Signature 
/Thumbprint...................................................................................Participant 
Full name…………………………………………………………………… 
   
 (Date…………month...........................year..................) 
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Signature................................................................................................................... 
Researcher 
Full name…………………………………………………………………… 
   
 (Date…………month...........................year..................) 
Signature.........................................................................................................Witness 
Full name…………………………………………………………………… 
   
 (Date…………month...........................year..................) 
 
Signature....................................................................................................... Witness 
Full name…………………………………………………………………… 
   
 (Date…………month...........................year..................) 
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Appendix C2: Information Sheets and consent forms in Thai 
 
เอกสารแนะน าส าหรับอาสาสมัคร 
โครงการวิจยัเร่ือง”อตัราชุกของภาวะพุทธิปัญญาบกพร่องหรือภาวะซึมเศร้าในผูป่้วยเบาหวานชนิดท่ี
สอง: กรณีศึกษาเฉพาะหน่วยปฐมภูมิ อ  าเภอสนัทราย จงัหวดัเชียงใหม่” 
นางสาวสุภาพร ตรงสกลุ นกัศึกษาปริญญาเอก มหาวิทยาลยัอีสแอนเกลีย ประเทศองักฤษ ผูว้ิจยัหลกั  
สถานท่ีปฎิบติังานส านกัวิชาวิทยาศาสตร์สุขภาพ มหาวิทยาลยัแม่ฟ้าหลวงเลขท่ี 333 หมู่ 1 ต าบลท่าสุด 
อ าเภอเมืองจ.เชียงราย 57000 
หมายเลขโทรศพัทเ์คล่ือนท่ี087-5585312 (24 ชัว่โมง) 
หมายเลขโทรศพัทท่ี์บา้น 053-890238 ต่อ 5403 (24 ชัว่โมง) 
เหตุผลและความจ าเป็นท่ีตอ้งท าการวิจยั 
โรคเบาหวานชนิดท่ี 2 เป็นหน่ึงในโรคเร้ือรังท่ีเป็นปัญหาทางสุขภาพท่ีพบไดม้ากในผูสู้งอายไุทย การ
ควบคุมระดบัน ้าตาลในเลือดใหเ้หมาะสมอยูเ่สมอร่วมกบัการรับประทานยาอยา่งต่อเน่ือง รวมทั้งการ
รับประทานอาหารและออกก าลงักายอยา่งถูกตอ้ง เป็นส่ิงท่ีจ าเป็นอยา่งยิ่งต่อการดูแลรักษาตนเองของ
ผูป่้วยโรคเบาหวานทั้งน้ีหากผูป่้วยเบาหวานมีภาวะความจ าบกพร่องหรือมีภาวะซึมเศร้ากจ็ะท าใหไ้ม่
สามารถควบคุมระดบัน ้าตาลในเลือดและดูแลรักษาตนเองไดอ้ยา่งถกูตอ้งเหมาะสม ดงันั้นการรู้ถึง
ภาวะทางความจ าและภาวะซึมเศร้าในผูสู้งอายุท่ีป่วยเป็นโรคเบาหวานชนิดท่ี2  จึงมีความจ าเป็นเพ่ือ
ส่งเสริมใหมี้การรักษาดูแลสุขภาพใหเ้หมาะสมต่อไป  
วตัถุประสงคข์องการศึกษาวิจยั 
การศึกษาน้ีมีวตัถุประสงคเ์พ่ือส ารวจดูวา่ผูป่้วยเบาหวานชนิดท่ี 2 อายตุั้งแต่ 60 ปีข้ึนไป จะมีภาวะ
บกพร่องทางความจ าหรือภาวะซึมเศร้าหรือไม่  ซ่ึงภาวะดงักล่าวมีความส าคญัและมีส่วนเก่ียวขอ้งต่อ
การควบคุมระดบัน ้าตาลในเลือดและการดูแลรักษาตนเองต่อโรคเบาหวาน  
ท าไมท่านจึงถกูเลือก 
เน่ืองจากท่านอยูใ่นกลุ่มผูป่้วยเบาหวานชนิดท่ี 2 ท่ีมีอายตุั้งแต่ 60 ปีข้ึนไป ท่ีไดม้ารับการดูแลรักษาท่ี
สถานีอนามยั ในเขตพ้ืนท่ี อ  าเภอ สนัทราย จงัหวดัเชียงใหม่ ซ่ึงเป็นเขตพ้ืนท่ีท่ีท าการศึกษาวิจยั 
วิธีการศึกษาวิจยั 
หากท่านตดัสินใจเขา้ร่วมงานวิจยั ผูวิ้จยักจ็ะถามพยาบาลหรือบุคลากรทางการแพทยท่ี์ดูแลรักษาท่าน
เลก็นอ้ยเก่ียวกบัตวัท่าน เช่น ท่านมีปัญหาทางดา้นการฟังหรือการมองเห็นหรือไม่ หลงัจากนั้นผูวิ้จยัก็
จะไปพบท่าน ในวนัท่ีท่านมารับการตรวจดูแลรักษาโรคเบาหวาน ท่ีคลินิกเบาหวานของสถานีอนามยั 
โดยผูวิ้จยัจะเป็นผูใ้ชแ้บบประเมินสอบถามท่านเก่ียวกบัภาวะความจ าและภาวะซึมเศร้าของท่านเป็น
เวลาโดยประมาณ 30 นาที  
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ประโยชนท่ี์ท่านอาจจะไดรั้บต่อการเขา้ร่วมงานวิจยั  
ขอ้มลูท่ีไดจ้ากงานวิจยัน้ีอาจช่วยใหบุ้คลากรทางการแพทยใ์นสถานีอนามยัท่ีดูแลท่านน าขอ้มลูไป
ปรับใชเ้พ่ือใหก้ารดูและรักษาท่ีเหมาะสมและส่งเสริมใหท่้านสามารถดูแลรักษาตนเองต่อ
โรคเบาหวานใหดี้ยิ่งข้ึนและหากท่านมีความกงัวลใจในเร่ืองความจ าและภาวะซึมเศร้า การเขา้ร่วมการ
วิจยัน้ีอาจช่วยใหท่้านลดความสงสยัและกงัวลใจในภาวะดงักล่าว 
ประโยชนท่ี์ชุมชนของท่านจะไดรั้บจากงานวิจยัน้ี 
ผลการวิจยัท่ีไดจ้ะเป็นประโยชนต่์อการวางแผนเพ่ือใหบ้ริการทางดา้นสุขภาพในชุมชนของท่านต่อ
การใหค้ าแนะน า ดูแลและจดัการ กลุ่มผูป่้วยเบาหวานสูงอายุท่ีป่วยเป็นโรคเบาหวานชนิดท่ี 2 ท่ีเร่ิมจะ
มีภาวะความจ าบกพร่องและภาวะซึมเศร้าไดแ้ต่เน่ินๆ  
ความเส่ียงท่ีคาดวา่จะเกิดข้ึนกบัอาสาสมคัรในการเขา้ร่วมการศึกษา 
ท่านจะไม่ไดรั้บความเส่ียงจากการใชเ้คร่ืองมือทางการแพทยห์รือการใหย้าท่ีเป็นอนัตรายต่อร่างกาย 
แต่การสมัภาษณ์เป็นระยะนานๆ อาจท าใหท่้านเบ่ือหน่ายหรือเหน่ือยลา้ได ้บางขอ้ค าถามอาจเป็น
ความรู้สึกส่วนตวั ท่านอาจรู้สึกอึดอดั ไม่สบายใจ 
การป้องกนัความเส่ียง และการแกไ้ขกรณีเกิดปัญหา 
หากท่านเกิดความเหน่ือยลา้จากการตอบแบบสอบถาม ผูวิ้จยัจะไม่เร่ง และจะใหท่้านพกัระหวา่งการ
ตอบแบบสอบถาม หากท่านล าบากใจต่อขอ้ค าถามใดๆ ท่านไม่จ าเป็นตอ้งตอบในขอ้ค าถามนั้น 
ขอบเขตการดูแลรักษาความลบัของขอ้มลูต่างๆของอาสาสมคัร 
ขอ้มลูทุกอยา่งของท่านจะถูกเก็บรวบรวมเป็นความลบัอยา่งเคร่งครัด จะมีเพียง ผูวิ้จยั อาจารยท่ี์ปรึกษา
วิทยานิพนธ์ และกรรมการท่ีปรึกษาวิทยานิพนธ์ เพียงเท่านั้นท่ีจะไดเ้ห็นขอ้มลูงานวิจยั โดยในรายงาน
ผลการวิจยัจะไม่มีการระบุช่ือหรือขอ้มลูส่วนตวัของผูเ้ขา้ร่วมงานวิจยั  
การตอบแทนแก่อาสาสมคัร 
ท่านจะไม่ไดรั้บค่าตอบแทนในการเขา้ร่วมงานวิจยัน้ี แต่ท่านจะไดรั้บ อาหารวา่ง (นมถัว่เหลือง 1 
กล่อง) เป็นการแสดงความขอบคุณต่อการเขา้ร่วมการศึกษาวิจยัน้ี 
ค่าใชจ่้ายของท่านในการเขา้ร่วมการวิจยั 
ท่านไม่ตอ้งเสียค่าใชจ่้ายใดๆทั้งส้ินในการเขา้ร่วมงานวิจยัน้ี  
ท่านจ าเป็นตอ้งเขา้ร่วมงานวิจยัหรือไม่ 
ท่านไม่จ าเป็นตอ้งเขา้ร่วมการวิจยัคร้ังน้ีหากท่านไม่สมคัรใจ และหากท่านเขา้ร่วมงานวิจยั ท่านมีสิทธิ
ท่ีจะถอนตวัหรือยกเลิกการเขา้ร่วมการศึกษาวิจยัไดทุ้กเม่ือ โดยไม่จ าเป็นตอ้งบอกเหตุผล และ การ
ถอนตวัจากการศึกษาจะไม่มีผลกระทบใดๆต่อการรักษาไม่ว่าในกรณีใดๆทั้งส้ิน อีกทั้งท่านมีสิทธิ
อยา่งเตม็ท่ีในการไม่ตอบค าถามขอ้ใดกไ็ดท่ี้ท่านไม่ตอ้งการท่ีจะตอบ  
ช่ือ ท่ีอยู ่เบอร์โทรศพัทข์องแพทย ์สามารถติดต่อไดส้ะดวก ทั้งในและนอกเวลาราชการ กรณีมีเหตุ
จ าเป็นหรือฉุกเฉิน  
งานวิจยัน้ีมี ผูช่้วยศาสตราจารยแ์พทยห์ญิง ณหทยั วงศป์การันย ์จิตแพทยผ์ูเ้ช่ียวชาญดา้นจิตเวชศาสตร์
ผูสู้งอาย ุเป็นท่ีปรึกษาการเก็บขอ้มลูพ้ืนท่ีวิจยัและเป็นนกัวิจยัพ่ีเล้ียง โดยท าหนา้ท่ีก ากบัดูแลการเกบ็
 232 
 
ขอ้มลูงานวิจยัในประเทศไทย ใหด้ าเนินการตามวิธีการและหลกัการของคุณภาพงานวิจยัท่ีดี ดงันั้น
หากท่านมีค าถามหรือขอ้สงสยัเก่ียวกบัการเขา้ร่วมงานวิจยัน้ี ท่านสามารถติอต่อ  
ผูช่้วยศาสตราจารยแ์พทยห์ญิง ณหทยั วงศป์การันย ์
ท่ีอยู ่ภาควิชาจิตเวชศาสตร์  คณะแพทยศาสตร์  มหาวิทยาลยัเชียงใหม่  
หมายเลขโทรศพัท ์053-945422  และหมายเลขโทรสาร 053-945426 (ในเวลาราชการ ( 
โทรศพัทเ์คล่ือนท่ี 086-6702400 (นอกเวลาราชการ) 
ช่ือท่ีอยูเ่บอร์โทรศพัทติ์ดต่อเร่ืองการสอบถามขอ้มลูหรือสิทธิและผลประโยชนข์องผูเ้ขา้ร่วมการวิจยัน้ี 
ท่านสามารถสอบถามขอ้มลูหรือสิทธิและผลประโยชนข์องการขา้ร่วมวิจยัน้ีไดท่ี้ 
ส านกังานเลขานุการคณะกรรมการพิจารณาการศึกษาวิจยัในคน กระทรวงสาธารณสุข อาคาร 2 ชั้น 3 
ตึกกรมการแพทย ์ถนนติวานนท ์อ าเภอเมือง จงัหวดันนทบุรี  11000  
หมายเลขโทรศพัท ์02-590-6171-2 (ในเวลาราชการ) 
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                   ใบยนิยอมด้วยความสมคัรใจ 
การวิจยัเร่ืองอตัราชุกของภาวะพุทธิปัญญาบกพร่องหรือภาวะซึมเศร้าของผูป่้วยสูงอายุ
เบาหวานชนิดท่ีสองในชุมชน: กรณีศึกษาเฉพาะหน่วยปฐมภูมิ อ  าเภอสนัทราย จงัหวดัเชียงใหม่ 
 
วนัท่ีใหค้ ายินยอม วนัท่ี................เดือน.................................พ ศ. ...   ...  
 
ก่อนท่ีจะลงนามในใบยินยอมใหท้ าการวิจยัน้ีขา้พเจา้ไดรั้บการอธิบายจากผูว้ิจยัถึง
วตัถุประสงคข์องการวิจยั วิธีการวิจยั อนัตรายหรืออาการท่ีอาจเกิดข้ึนจากการวิจยัหรือจากยาท่ีใช ้
รวมทั้งประโยชนท่ี์จะเกิดข้ึนจากการวิจยัอยา่งละเอียด และมีความเขา้ใจดีแลว้ 
 
ผูวิ้จยัรับรองวา่จะตอบค าถามต่างๆท่ีขา้พเจา้สงสยัดว้ยความเตม็ใจ ไม่ปิดบงั ซ่อนเร้น จน
ขา้พเจา้พอใจ 
 
ขา้พเจา้มีสิทธิท่ีจะบอกเลิกการเขา้ร่วมในโครงการวิจยัเม่ือใดกไ็ดแ้ละเขา้ร่วมโครงการวิจยัน้ี
โดยสมคัรใจและการบอกเลิกการเขา้ร่วมการวิจยัน้ี จะไม่มีผลต่อการรักษาโรคท่ีขา้พเจา้จะไดรั้บต่อไป 
 
ผูวิ้จยัรับรองวา่จะเก็บขอ้มลูเฉพาะเก่ียวกบัตวัขา้พจา้เป็นความลบัและจะเปิดเผยไดเ้ฉพาะ
สรุปผลการวิจยัหรือการเปิดเผยขอ้มลูต่อผูมี้หนา้ท่ีท่ีเก่ียวขอ้งกบัการสนบัสนุนและก ากบัดูแลการวิจยั
เท่านั้น 
 
ขา้พเจา้ไดอ่้านขอ้ความขา้งตน้แลว้ และมีความเขา้ใจดี 
 
 
ลงนาม.............................................................................................ผูย้ินยอม 
ตวับรรจง………………………………………………………………………….. 
วนัท่ี...................เดือน............................พ.ศ…………… 
 
ลงนาม ....................................................................................................ผูว้ิจยั 
ตวับรรจง………………………………………………………………………. 
วนัท่ี ................... เดือน...........................พ.ศ…………… 
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ลงนาม .................................................................................................พยาน 
ตวับรรจง………………………………………………………………………. 
วนัท่ี...................เดือน ........................... พ.ศ…………… 
 
ลงนาม ........................................................................................พยาน 
ตวับรรจง………………………………………………………………………. 
วนัท่ี...................เดือน.......................พ.ศ…………… 
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Appendix D: Instruments of the study (English and Thai) 
Appendix D1:Mini-Cog -Thai version 
 
MINI-COG ™ - PS Version  
 
2) ให้ผู้ป่วยตั้งใจฟังแล้วบอกผู้ป่วยว่า “ดิฉัน (ผม) จะบอกค า 3 ค าซ่ึงอยากให้คุณ (ช่ือ ป้า 
ลุง ยาย ตา) จ าตอนนีแ้ล้วกจ็ าไว้ต่อไปนะคะ (นะครับ) ค าเหล่านีไ้ด้แก่ 
บ้าน แมว สีเขียว 
ไหนลองพดูออกมาใหฟั้งสิคะ (ครับ)” (ใหโ้อกาสผูป่้วยลองท า3 คร้ังหากไม่สามารถ
ท าไดห้ลงัจากพยายาม3คร้ังใหท้  าขอ้ต่อไป) 
 
พบัหนา้น้ีไปทางดา้นหลงัตามรอยประ2แถวดา้นล่างเพื่อใหเ้กิดพื้นท่ีวา่งและปิดค าท่ีให้
จ  าไวส่้งดินสอ/ปากกาใหผู้ป่้วย 
3) พดูวลีต่อไปน้ีตามล าดบั:” ช่วยวาดรูปนาฬิกาลงบนท่ีวา่งดา้นล่างน้ีหน่อยนะคะ 
(ครับ) เร่ิมจากวาดวงกลมวงใหญ่ๆค่ะ (ครับ)” (เม่ือเสร็จแลว้ใหบ้อกวา่) “ใส่
ตวัเลขลงไปในวงกลมใหค้รบเลยค่ะ (ครับ)” (เม่ือเสร็จแลว้ใหบ้อกวา่) “ทีน้ีให้
ตั้งเวลาโดยใหเ้ขม็นาฬิกาช้ีบอกเวลา11:10 น. (สิบเอด็นาฬิกาสิบนาที) ค่ะ 
(ครับ)” หากผูป่้วยไม่สามารถวาดนาฬิกาไดเ้สร็จภายใน3 นาทีใหห้ยดุท าแลว้
ไปถามค าท่ีใหจ้  าไว ้
  
 
 
 
 
 
 
 
 
4) พดูวา่: “ค า 3 ค าท่ีดิฉนั (ผม)ใหคุ้ณ (ช่ือป้าลุงยายตา)จ าไวมี้อะไรบา้งคะ (ครับ)” 
  _       
   (ให1้ คะแนนต่อ1 ค า)         
คะแนนการระลึกค า3 ค า  
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ใหค้ะแนนรูปนาฬิกา (ดูค  าแนะน าอีกหนา้หน่ึง):  รูปนาฬิกาปกติ 
 2 คะแนน     
 รูปนาฬิกาผดิปกติ
 0 คะแนน 
 
 คะแนนรูปนาฬิกา  
   
 
คะแนนรวม  =  
 
คะแนนการระลึกค า 3 ค า รวมกบัคะแนนรูปนาฬิกา   
 
คะแนน 0, 1, หรือ 2 อาจจะมคีวามบกพร่อง; 3, 4, หรือ 5 ไม่มีความบกพร่อง 
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การใหค้ะแนนรูปนาฬิกา 
 
 นาฬิกาปกติ 
 
นาฬิกาปกติจะมีองคป์ระกอบดงัต่อไปน้ีครบถว้น: 
ตวัเลขครบ1-12ไม่ซ ้ ากนัอยูอ่ยา่งถูกล าดบัและทิศทาง (ตามเขม็นาฬิกา) ภายในวงกลม 
เขม็นาฬิกามี2 อนัอนัหน่ึงช้ีท่ีเลข11 และอนัหน่ึงช้ีท่ีเลข2 
 
ตวัอยา่งของนาฬิกาท่ีผดิปกติ     
   
 
 เข็มนำฬิกำผิดปกต ิ   
 
 
 
                                                               ตวัเลขไมค่รบ 
 
รูปนาฬิกาท่ีขาดองคป์ระกอบขอ้ใดขอ้หน่ึงเหล่าน้ีใหถื้อวา่ผดิปกติ การปฏิเสธท่ีจะวาดรูปนาฬิกาให้
ถือวา่ผดิปกติ 
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Mini-CogTMลิขสิทธ์ิ S Borson. Mini-Cog PS ออกแบบมาเพ่ือใชก้บัผูใ้หญ่ท่ีจบการศึกษาระดบัประถมศึกษาพิมพซ์ ้าโดยไดรั้บ
อนุญาตจากเจา้ของเพื่อใชใ้นงานวิจยัของสุภาพรตรงสกุล (School of Allied Health Professions, University of East 
Anglia, UK) ในงานวิจยัเก่ียวกบัความบกพร่องดา้นพทุธิปัญญาของผูป่้วยเบาหวานชาวไทยไม่อนุญาตให้ปรับปรุงหรือใชใ้น
วตัถุประสงคอ่ื์นเวน้แต่ไดรั้บอนุญาตจากเจา้ของ (soob@u.washington.edu). สงวนลิขสิทธ์ิ 
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Appendix D1:Mini-Cog -English version 
 
MINI-COG ™ - PS Version   
 
1) GET THE PATIENT’S ATTENTION, THEN SAY: “I am 
going to say three words that I want you to remember 
now and later.  The words are  
House  Cat   Green. 
 
Please say them for me now.”  (Give the patient 3 tries to repeat 
the words.  If unable after 3 tries, go to next item.) 
(Fold this page back at the TWO dotted lines BELOW to make a 
blank space and cover the memory words.  Hand the patient a 
pencil/pen).  
 
1) SAY ALL THE FOLLOWING PHRASES IN THE ORDER 
INDICATED: “Please draw a clock in the space below.  Start by 
drawing a large circle.”  (When this is done, say) “Put all the 
numbers in the circle.” (When done, say)  “Now set the hands 
to show 11:10 (10 past 11).” If subject has not finished clock 
drawing in 3 minutes, discontinue and ask for recall items.  
 
 ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------  
 
 
 
 
 
 
 
 
 
 
 
  
  
2) SAY: “What were the three words I asked you to remember?” 
 
 _      __ 
 
               Score 1 point for each)      3-Item Recall Score   
 
  
Score the clock (see other side for instructions):  
Normal clock   2 points    
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Abnormal clock            0 point  
 
 
Clock Score    
  
    
 
 
Total Score = 3-item recall plus clock score   
0, 1, or 2  possible impairment;  
3, 4, or 5 suggests no impairment 
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CLOCK SCORING 
NORMAL CLOCK 
 
 
 
A NORMAL CLOCK HAS ALL OF THE FOLLOWING ELEMENTS: 
All numbers 1-12, each only once, are present in the correct order and 
direction (clockwise) inside the circle. 
Two hands are present, one pointing to 11 and one pointing to 2. 
 
ANY CLOCK MISSING ANY OF THESE ELEMENTS IS SCORED 
ABNORMAL.  REFUSAL TO DRAW A CLOCK IS SCORED ABNORML 
 
 
SOME EXAMPLES OF ABNORMAL CLOCKS  
 
      ABNORMAL HANDS 
 
 
 
 MISSING NUMBER 
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Mini-CogTM .  Copyright S Borson. Mini-Cog PS designed for adults 
with a primary school education. Reprinted with permission of the 
author, solely for research by S. Trongsakul (School of Allied Health 
Professions, University of  East Anglia, UK) for test of  cognitive 
impairment in Thai diabetics. May not be modified or used for other 
purposes unless approved by the author (soob@u.washington.edu). 
All rights reserved.   
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Appendix D2: MMSE Thai 2002 in Thai  
แบบทดสอบ  MMSE – Thai  2002* 
Mini – Mental State Examination : Thai version (MMSE – Thai  2002) 
 
1. Orientation  for  time( 5  คะแนน )  บนัทึกค าตอบไวทุ้กคร้ัง คะแนน 
(ตอบถูกขอ้ละ 1 คะแนน) (ทั้งค  าตอบท่ีถูกและผดิ) 
1.1 วนัน้ีวนัท่ีเท่าไร ………………………..    
1.2 วนัน้ีวนัอะไร ………………………..   
1.3 เดือนน้ีเดือนอะไร ………………………..   
1.4 ปีน้ีปีอะไร ………………………..   
1.5 ฤดูน้ีฤดูอะไร ………………………..   
 
2. Orientation  for  place  ( 5  คะแนน )(ให้เลือกขอ้ใดขอ้หน่ึง) 
(ตอบถูกขอ้ละ 1 คะแนน 
 2.1 กรณีอยูท่ี่สถานพยาบาล 
 2.1.1  สถานท่ีตรงน้ีเรียกวา่  อะไร  และ......ช่ือวา่อะไร ………………………..  
  2.1.2 ขณะน้ีท่านอยูท่ี่ชั้นท่ีเท่าไรของตวัอาคาร ………………………..  
  2.1.3 ท่ีอยูใ่นอ าเภอ -  เขตอะไร     ………………………..  
  2.1.4 ท่ีน่ีจงัหวดัอะไร ………………………..  
  2.1.5 ท่ีน่ีภาคอะไร ………………………..  
  
 
2.2 กรณีท่ีอยูท่ี่บา้นของผูถู้กทดสอบ 
  2.2.1 สถานท่ีตรงน้ีเรียกวา่อะไรและบา้นเลขท่ีอะไร ………………………..  
  2.2.2 ท่ีน่ีหมู่บา้น  หรือละแวก/คุม้/ยา่น/ถนนอะไร ………………………..  
  2.2.3 ท่ีน่ีอ  าเภอเขต / อะไร ………………………..  
  2.2.4 ท่ีน่ีจงัหวดัอะไร ………………………..  
  2.2.5 ท่ีน่ีภาคอะไร ………………………..  
3. Registraion ( 3 คะแนน ) 
   ต่อไปน้ีเป็นการทดสอบความจ า  ดิฉนัจ าบอกช่ือของ 3 อยา่ง คุณ (ตา , ยาย....) ตั้งใจ 
ฟังใหดี้นะเพราะจะบอกเพียงคร้ังเดียว ไม่มีการบอกซ ้ าอีก  เม่ือ  ผม  (ดิฉนั)  พูดจบ  ให ้ คุณ 
(ตา,ยาย....)พูดทบทวนตามที่ได้ยนิ  ให้ครบ  ทั้ง 3 ช่ือ  แลว้พยามจ าไวใ้หดี้ เด๋ียวดิฉนัจะถาม 
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ซ ้ า 
 การบอกช่ือแต่ละค าใหห่้างกนัประมาณหน่ึงวินาที  ตอ้งไม่ชา้หรือเร็วเกินไป    
( ตอบถูก 1 ค าได ้1 คะแนน )   
    ดอกไม ้  แม่น ้า   รถไฟ ………………………..  
4.  Attention/Calculation ( 5  คะแนน )(ให้เลือกขอ้ใดขอ้หน่ึง) 
 ขอ้น้ีเป็นการคิดเลขในใจเพื่อทดสอบสมาธิ  คุณ (ตา,ยาย....) คิดเลขในใจเป็นไหม ? 
 ถา้ตอบคิดเป็นท าขอ้ 4.1 ถา้ตอบคิดไม่เป็นหรือไม่ตอบให้ท าขอ้ 4.2 
4.1 “ขอ้น้ีคิดในใจเอา 100 ตั้ง ลบออกท่ีละ 7  
ไปเร่ือยๆ ไดผ้ลเท่าไรบอกมา        ……  ……  ……  ……    ……  ……    ……  
……     
บนัทึกค าตอบตวัเลขไวทุ้กคร้ัง (ทั้งค  าตอบท่ีถูกและผดิ) ท าทั้งหมด 5คร้ัง 
ถา้ลบได ้1,2,หรือ3 แลว้ตอบไม่ได ้ ก็คิดคะแนนเท่าท่ีท าได ้ ไม่ตอ้งยา้ยไปท าขอ้ 
4.2 
 4.2 “ผม (ดิฉนั) จะสะกดค าวา่ มะนาว ใหคุ้ณ (ตา , ยาย....) ฟังแลว้ใหคุ้ณ (ตา , ยาย 
....) สะกดถอยหลงัจากพยญัชนะตวัหลงัไปตวัแรก  ค าวา่มะนาวสะกดวา่ มอมา้- 
สระอะ-นอหนู-สระอา-วอแหนว ไหนคุณ(ตา,ยาย....)สะกอถอยหลงั  ใหฟั้งซิ 
 ……  ……  ……  ……  ……     
     
วา  น   ะ ม 
 
5. Recall ( 3 คะแนน) 
 เม่ือสักครู่ท่ีใหจ้  าของ 3 อยา่งจ าไดไ้หมมีอะไรบา้ง” ( ตอบถูก 1 ค าได ้1 คะแนน ) 
    ดอกไม ้  แม่น ้า   รถไฟ ………………………..  
6.  Naming ( 2 คะแนน) 
6.1  ยืน่ดินสอใหผู้ถู้กทดสอบดูแลว้ถามวา่ 
  “ของส่ิงน้ีเรียกวา่อะไร”  ………………………..  
6.2 ช้ีนาฬิกาขอ้มือใหผู้ถู้กทดสอบดูแลว้ถามวา่ 
  “ของส่ิงน้ีเรียกวา่อะไร”  ………………………..  
 
7. Repetition (1 คะแนน) 
  (พดูตามไดถู้กตอ้งได ้1 คะแนน) 
  ตั้งใจฟังผม (ดิฉนั) เม่ือผม (ดิฉนั) พดูขอ้ความน้ี 
  แลว้ใหคุ้ณ (ตา,ยาย)พดูตาม ผม (ดิฉนั) จะบอกเพียงคร้ังเดียว  
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  “ใครใคร่ขายไก่ไข”   ………………………..  
 
8.  Verbal command ( 3 คะแนน) 
 ขอ้น้ีฟังค าสั่ง “ฟังดีๆ นะเด๋ียวผม (ดิฉนั)จะส่งกระดาษให้คุณ แลว้ใหคุ้ณ (ตา , ยาย....) 
 รับดว้ยมือขวา  พบัคร่ึงกระดาษ  แลว้วางไวท่ี้............”(พื้น,โตะ๊,เตียง) 
 ผูท้ดสอบแสดงกระดาษเปล่าขนาดประมาณ เอ-4 
 ไม่มีรอยผบั  ใหผู้ถู้กทดสอบ 
   รับดว้ยมือขวา    พบัคร่ึง    วางไวท่ี้”(พื้น,โตะ๊,เตียง) ………………………..  
9. Written  command (1 คะแนน) 
ต่อไปเป็นค าสั่งท่ีเขียนเป็นตวัหนงัสือ  ตอ้งการให้คุณ (ตา , ยาย....) อ่าน 
แลว้ท าตาม (ตา , ยาย....)  จะอ่านออกเสียงหรืออ่านในใจ 
       ผูท้ดสอบแสดงกระดาษท่ีเขียนวา่ “หลบัตาได”้  หลบัตาได…้.……………………..  
 
 
10. Writing (1 คะแนน) 
ขอ้น้ีจะเป็นค าสั่งให ้“คุณ (ตา , ยาย....) เขียนขอ้ความอะไรก็ก็ท่ีอ่านแลว้รู้เร่ือง 
หรือมีความหมายมา 1ประโยค”  ............................... 
      ประโยคมีความหมาย          ………………………..  
 
11. Visuoconstruction (1 คะแนน) 
  ขอ้น้ีเป็นค าสั่ง“จงวาดภาพใหเ้หมือนภาพตวัอยา่ง” 
(ในช่องวา่งดา้นขวาของภาพตวัอยา่ง)  ………………………..  
 
 
หลบัตา 
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............................................................................คะแนนเต็ม 30 
 
 
 
ระดบัการศึกษา คะแนน 
จุดตดั เตม็ 
ไม่ไดเ้รียนหนงัสือ(อ่านหนงัไม่ออก) ≤  14 23 
จบประถมศึกษา ≤ 17 30 
สูงกวา่ประถม ≤ 22 30 
 
*สถาบนัเวชศาสตร์ผูสู้งอายุกรมการแพทยก์ระทรวงสาธารณสุข 
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Appendix D2: Translation of MMSE Thai 2002 from Thai to English 
Mini - Mental State Examination Thai 2002 (MMSE Thai 2002) * 
 
Questions  
 
Points 
1. What is the :  
Year? Season? Month? Day? Date? 
5 
 
2. Where are we :  
Province? Country? District? Hospital? Floor?  
5 
3. Name three objects (flower, river, train) taking one second to 
say each 
Then ask the patient to tell you the three. Repeat the answer until 
the patient learns all three words. 
3 
4. Attention/Calculation 
4.1 Serial 7’s. Subtract 7 from 100, then subtract 7 from that 
number, and then subtract 7 from that number, etc. Stop after five 
answers. 
4.2 Alternative : Spell Ma-nao (lemon in Thai) backwards. 
5 
5. Ask for the names of the three objects learned in # 3.  3 
6. Point to a pencil and a watch. Have the patient name them as 
you point.  
2 
7. Have the patient repeat “Kray-Krai-Kaii-Kai-Gai 1 
8. Have the patient follow a three-stage command : “Take the 
paper  
in your right hand. Fold the paper in half. Put the paper on the 
floor” 
3 
9. Have the patient read and obey to following : “CLOSE YOUR 
EYES”  
(write it in large letters). 
หลบัตา 
 
1 
10.Have the patient write a sentence of his or her own choice.  
 
1 
11. Have the patient copy the following design (overlapping 
pentagons).  
 
1 
 
 
…………………………………………………….TOTAL points 30 
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Level of education Point(s) 
Cut-off score 
 
Total score 
Illiterate 
 
≤  14 23 
Primary school ≤ 17 30 
More than primary school 
 
≤ 22 30 
 
* Institute of Geriatric Medicine, Ministry of Public Health, Thailand  
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Appendix D3: TGDS in Thai 
แบบคัดกรองภาวะซึมเศร้าในผู้สูงอายุของไทย (Thai Geriatric Depression Scale –TGDS)* 
………1. คุณพอใจกบัชีวติความเป็นอยูต่อนน้ี  
……....2. คุณไม่อยากท าในส่ิงท่ีเคยสนใจหรือเคยท าเป็นประจ า  
……....3. คุณรู้สึกชีวติของคุณช่วงน้ีวา่งเปล่าไม่รู้จะท าอะไร               
………4. คุณรู้สึกเบ่ือหน่ายบ่อย ๆ                                  
………5. คุณหวงัวา่จะมีส่ิงท่ีดีเกิดข้ึนในวนัหนา้     
………6. คุณมีเร่ืองกงัวลตลอดเวลา และเลิกคิดไม่ได ้   
………7.ส่วนใหญ่แลว้คุณรู้สึกอารมณ์ดี     
………8. คุณรู้สึกกลวัวา่จะมีเร่ืองไม่ดีเกิดข้ึนกบัคุณ     
………9. ส่วนใหญ่คุณรู้สึกมีความสุข     
………10. บ่อยคร้ังท่ีคุณรู้สึกไม่มีท่ีพ่ึง   
………11. คุณรู้สึกกระวนกระวาย  กระสบักระส่ายบ่อย ๆ   
……….12. คุณชอบอยูก่บับา้นมากกวา่ท่ีจะออกนอกบา้น     
……….13.บ่อยคร้ังท่ีคุณรู้สึกวติกกงัวลเก่ียวกบัชีวติขา้งหนา้    
……….14. คุณคิดวา่ความจ าของคุณดีไม่เท่าคนอ่ืน     
……….15. การท่ีมีชีวติอยูถึ่งปัจจุบนัน้ีเป็นเร่ืองน่ายนิดีหรือไม่    
………..16. คุณรู้สึกหมดก าลงัใจหรือเศร้าใจบ่อย ๆ     
………..17. คุณรู้สึกวา่ชีวติคุณค่อนขา้งไม่มีคุณค่า     
………..18. คุณรู้สึกกงัวลมากกบัชีวติ ท่ีผา่นมา    
………..19. คุณรุ้สึกวา่ชีวติน้ียงัมีเร่ืองน่าสนุกอีกมาก   
………..20. คุณรู้สึกล าบากท่ีจะเร่ิมตน้ท าอะไรใหม่ ๆ     
………..21. คุณรู้สึกกระตือรือร้น       
………..22. คุณรู้สึกส้ินหวงั        
………..23. คุณคิดวา่คนอ่ืนดีกวา่คุณ       
………..24. คุณอารมณ์เสียง่ายกบัเร่ืองเลก็ ๆ นอ้ย ๆ อยูเ่สมอ     
……….25. คุณรู้สึกอยากร้องไหบ่้อย     
……….26. คุณมีความตั้งใจในการท าส่ิงหน่ึงส่ิงใดไดไ้ม่นาน    
……….27. คุณรู้สึกสดช่ืนในเวลาต่ืนนอนตอนเชา้     
……….28. คุณไม่อยากพบปะพดูคุยกบัคนอ่ืน 
……….29. คุณตดัสินใจอะไรไดเ้ร็ว      
………..30. คุณมีจิตใจสบาย  แจ่มใสเหมือนก่อน    
คะแนนรวม ……….............. 
* กลุ่มฟ้ืนฟสูมรรถภาพสมอง (2537)  
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Appendix D3: Translation of TGDS from Thai to English 
 
Thai Geriatric Depression Scale (TGDS)* 
……1. Are you basically satisfied with your life?  
……2. Have you dropped many of your activities and interests?  
……3. Do you feel that your life is empty?  
…....4. Do you often get bored?  
……5. Are you hopeful about the future?  
…….6. Are you bothered by thoughts you can t get out of your head?  
…….7. Are you in good spirits most of the time?  
…….8. Are you afraid that something bad is going to happen to you?  
…….9. Do you feel happy most of the time?  
…….10. Do you often feel helpless?  
…….11. Do you often get restless and fidgety?  
…….12. Do you prefer to stay at home, rather than going out and doing new 
               things?  
…….13. Do you frequently worry about the future?  
…….14. Do you feel you have more problems with memory than most?  
…….15 Do you think it is wonderful to be alive now?  
…….16 Do you often feel downhearted and blue?  
…….17 Do you feel pretty worthless the way you are now? 
……18 Do you worry a lot about the past?  
……19 Do you find life very exciting?  
……20 Is it hard for you to get started on new projects?  
……21 Do you feel full of energy?  
……22 Do you feel that your situation is hopeless?  
……23 Do you think that most people are better off than you are?  
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……24 Do you frequently get upset over little things?  
……25 Do you frequently feel like crying?  
……26 Do you have trouble concentrating?  
……27 Do you enjoy getting up in the morning?  
……28 Do you prefer to avoid social gatherings?  
……29 Is it easy for you to make decisions?  
……30 Is your mind as clear as it used to be? 
 
Total score…………………. 
*Train the Brain Forum Committee (1994)  
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Appendix E1: Participant record form 
Participant recording form  
PCU code   
ID number  
Part I: Demographic data  
Gender 
0.male 
1.female 
Sex (…) 
Age  
0.60-64 
1.65-69 
2.70-74 
3.75-79 
4.80-84 
5.over 85  
Age (…) (…) 
 
Age group (…) 
Education 
0. uneducated 
1. primary school (year(s) in school…..) 
2. secondary school (year(s) in school…..) 
3. high school (year(s) in school…..) 
4. bachelor’s degree and over  
Edu (…) 
 
Yr in sch(…) 
 
 
 
Ethnic 
0.Thai 
1. Hill tribe 
Ethnic (…) 
 
Marital status 
0. single 
1. married 
2. separated 
3. divorced 
4. widow 
Marital status (…) 
Living arrangement 
0.live aloneno  yes 
1. spouseno  yes 
2. daughter/sonno  yes 
3. grandchildrenno yes 
4. parentsno  yes 
5. relativesno  yes 
6.Others- specify.................................................................... 
Liv. Status (…) 
 
Liv oth (……) 
Income 
0.none 
1. pension 
2. government support (500 baht) 
3.saving 
4. working 
5. others-specify............................................ 
Eco. Statuc (…) 
 
Eco oth (…..) 
Health care service 
0.health care coverage-30 baht scheme (national health 
insurance) 
1.Social/Welfare health care 
2.Self-funding 
Health support 
(…) 
 
Heath oth (……) 
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3. Family support (specify who….) 
4. Others-specify............................................. 
Health behaviour in present  
1.alcohol drinkingno  yes 
2.Smoking no yes 
3. Exercise at least 30 minutes no yes 
Health Behaviour  
Drinking 
1. drinking (…) 
 
2. Smoking (…) 
3. exercise (…) 
Part II: Medical record  
Height ...........................cms H (…) (…) (…) 
Weight………… kgs. W (…) (…) 
Body Mass Index (BMI)..................... BMI (…) (…) 
Blood pressure mg/Hg 
Systolic (....) 
Diastolic (….) 
BP 
S (.....) 
D (….) 
Fasting Blood Sugar (FBS)  mg/dl or mmol/l 
last visits; 
Date…….FBS……mg/dl or mmol/l 
FBS (…)  
 
date (…) 
HbA1C…………….% (mmol/mol) HbA1C (…) 
HbA1c date................................... 
HbA1c duration time from the study……….months 
HbA1c date 
……… 
HbA1c dur 
time................ 
Total Cholesterol ……..(mg/dl or mmol/l)  
Low density lipoprotein (LDL)…….. (mg/dl or mmol/l) 
High density lipoprotein (HDL)……… (mg/dl or mmol/l) 
Triglyceride…………..(mg/dl or mmol/l) 
Total Chol(…) 
LDL (…) 
HDL (…) 
Trigly (…) 
DM treatment 
1.No medicine/on diet  
2.Medicine (oral) 
3.Insulin injection 
4.Combine treatment (Medication+Insuline injection) 
DM treatment 
(…) 
DM duration (year) 
1.1-5  
2. 6-10 
3.11-15 
4.15-20 
5. over 20 years 
DM duration (…) 
Complications 
1.Diabetic neuropathy no yes 
Yes How long……years and date…. 
2.Diabetic retinopathy no yes 
Yes How long……years and date…. 
3.Diabetic nephropathy no yes 
Yes How long……years and date…. 
4. Others specify ……………… 
Compli (..........) 
History of Chronic disease 
1.Heart disease 
Before DM no yes 
Chronic disease 
(…) 
Before DM (…) 
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How long…..year (s) and date ………….. 
2.Hypertension 
Before DM no yes 
How long…..year (s) and date………….. 
3.COPD 
Before DM no yes 
How long…..year (s) and date………….. 
4. Osteoporosis 
Before DM no yes 
How long…..year (s) and date………….. 
5. Arthritis  
Before DM no yes 
How long…..year (s) and date………….. 
6.Others specify………………… 
Before DM no yes 
How long…..year (s) and date………….. 
 
Time (….) 
Part II: Score from questionnaire test  
MMSE …… /Cog result……. 
Mini-Cog…… /Cog result……….. 
TGDS……. 
 
MMSE (…) 
CogMM……. 
Mini-Cog (…) 
CogMC……. 
TGDS (…) 
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Appendix E2:Codes of variables 
 
Code of variables 
 
Variables Measurement  Type  
Part I: Demographic data   
Gender 
 
0 = male 
1 = female 
Categorical data 
Age  Numeric   Continuous data 
Age group 
 
0 = 60-64  
1 = 65-69 
2 = 70-74 
3 = 75-79 
4 = 80-84 
5 = 85+ 
Categorical data 
Education 
 
0 =uneducated 
1= Primary school  
2= Junior school  
3= High school  
4= Bachelor’s degree and 
over  
 
Categorical data 
Years in school  Numeric Continuous data 
Ethnic 
 
0 = Thai 
1 = Hill tribe 
Categorical data 
Marital status 
 
0 = single 
1=  married 
2 = separated 
3 = divorced 
4 = widowed 
Categorical data 
Living arrangement 
 
0 = living alone   
1= not living alone  
Categorical data 
Income 
 
0 = none 
1 = pension 
2 = government support 
(500 baht or £ 10)/ month) 
3 = bank saving 
4 = working 
 
Health care service 
 
0 = health care coverage-
30 baht scheme (national 
health insurance) 
1 = Social/Welfare health 
care 
2 = Self-funding 
3 = Family support  
Categorical data 
Part I: Demographic 
data(continued) 
  
Current health behaviour   
drinking 0 = no Categorical data 
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1 = yes 
smoking 0 = no 
1 = yes 
Categorical data 
exercise 0 = no 
1 = yes 
Categorical data 
Part II: Medical record   
Height (centimetres) Numeric Continuous data 
Weight (kilograms) Numeric Continuous data 
Body Mass Index  (kg/m
2
) Numeric Continuous data 
Body Mass Index  (kg/m
2
) 0 = < 23  
1 = 23-25 
2 = 25+ 
Categorical data 
Systolic blood pressure (mg/Hg) 0 ≤ 130  
1 > 130+ 
Continuous data 
Diastolic blood pressure 
(mg/Hg) 
0 ≤ 80  
1 > 80+ 
Categorical data 
Fasting Blood Sugar (mg/dl or 
mmol/l) 
Numeric Continuous data 
Fasting Blood Sugar (mg/dl or 
mmol/l) 
 
0 ≤ 140 (7.8) 
1 > 140+ (7.8+) 
Categorical data 
HbA1C (% )  Numeric Continuous data 
HbA1C (% or mmol/mol ) 0 ≤ 7 (53) 
1 > 7+ (53+) 
Categorical data 
duration time of HbA1c before 
recruitment  (months) 
Numeric Continuous data 
Part II: Medical record 
(continued) 
  
Total Cholesterol (mg/dl or 
mmol/l)  
Numeric Continuous data 
Total Cholesterol group (mg/dl 
or mmol/l) 
0 ≤ 200 (11.1) 
1 > 200+ (11.1+) 
Categorical data 
Low density lipoprotein (mg/dl 
or mmol/l) 
Numeric Continuous data 
Low density lipoprotein group 
(mg/dl or mmol/l) 
0 ≤ 100 (5.6) 
1 > 100+ (5.6+) 
Categorical data 
High density lipoprotein (mg/dl 
or mmol/l) 
 
Numeric 
 
Continuous data 
High density lipoprotein group 
(mg/dl or mmol/l) 
 
0 ≤ 40 (2.2) 
1 > 40+ (2.2+) 
Categorical data 
Triglyceride (mg/dl or mmol/l) Numeric Continuous data 
Triglyceride  group (mg/dl or 
mmol/l) 
0 ≤ 150 (8.3) 
1 > 150+ (8.3+) 
Categorical data 
DM treatment   
On diet alone  0 = no  
1 = yes  
Categorical data 
Oral medication+ on diet  0 = no  Categorical data 
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1 = yes 
Insulin injection + on diet 0 = no  
1 = yes 
Categorical data 
Combine treatment 
(Medication+Insuline 
injection+on diet) 
0 = no  
1 = yes 
Categorical data 
DM duration (year) Numeric Continuous data 
DM duration group (year) 
 
0 = 1-4  
1 = 5-8 
2 = 8+ 
Categorical data 
Part II: Medical record 
(continued) 
  
Diabetic complication   
Diabetic neuropathy  
 
0 = no 
1 = yes 
Categorical data 
Diabetic retinopathy  
 
0 = no 
1 = yes 
Categorical data 
Diabetic nephropathy 
 
0 = no 
1 = yes 
Categorical data 
Co-morbid disease    
Heart disease 0 = no 
1 = yes 
Categorical data 
Hypertension 0 = no 
1 = yes 
Categorical data 
Chronic Obstructive Pulmonary 
Disease (COPD) 
0 = no 
1 = yes 
Categorical data 
Gout 0 = no 
1 = yes 
Categorical data 
Arthritis 0 = no 
1 = yes 
Categorical data 
Dyslipidemia 0 = no 
1 = yes 
Categorical data 
Asthma 0 = no 
1 = yes 
Categorical data 
Others (specify) character Categorical data 
Part III: score and result  from  
screening tests 
  
Mini-Cog (scores) Numeric Continuous data 
Result of Mini-Cog 0 = normal 
1 = impair 
Categorical data 
MMSE Thai 2002 (scores) Numeric Continuous data 
Result of MMSE Thai 2002 0 = normal 
1 = impair 
Categorical data 
TGDS (scores) Numeric Continuous data 
Result of TGDS 0 = normal 
1 = impair 
Categorical data 
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Appendix F1: Normality test of data  
Test of normality (1) 
 
having HbA1c 
result  
Kolmogorov-Smirnov
a
 
 Statistic df Sig. 
gender no .436 273 .000 
yes .411 283 .000 
age no .156 273 .000 
 yes .159 283 .000 
year in school no .424 273 .000 
 yes .430 283 .000 
live alone no .537 273 .000 
 yes .540 283 .000 
working no .395 273 .000 
 yes .418 283 .000 
height no .063 273 .012 
 yes .094 283 .000 
weight no .091 273 .000 
 yes .063 283 .009 
body mass index no .070 273 .002 
 yes .060 283 .016 
blood pressure_systolic no .084 273 .000 
 yes .072 283 .001 
blood pressure_diastolic no .075 273 .001 
 yes .058 283 .024 
fasting blood sugar 3  no .098 273 .000 
 yes .104 283 .000 
High density lipoprotein 
(mg/dl or mmol/l) 
no 
.133 273 .000 
 yes .091 283 .000 
Triglyceride (mg/dl or 
mmol/l) 
no 
.137 273 .000 
 yes .159 283 .000 
   
a. Lilliefors Significance Correction 
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Test of normality (2) 
 having 
HbA1c 
result  
Kolmogorov-Smirnov
a
 
 
Statistic df Sig. 
DM treatment_on diet 
(no medication) 
 
no .522 273 .000 
yes 
.497 283 .000 
DM treatment_oral 
medication 
no 
.515 273 .000 
 yes .500 283 .000 
DM treatment_insulin 
injection 
no 
.540 273 .000 
 yes .539 283 .000 
DM treatment_oral 
medication+insulin 
injection 
no 
.536 273 .000 
 yes .526 283 .000 
years for DM duration no .187 273 .000 
 yes .162 283 .000 
duration of year for 
having diabetic 
neuropathy 
no 
.518 273 .000 
 yes .521 283 .000 
duration of year for 
having diabetic 
retinopathy 
no 
.464 273 .000 
 yes .465 283 .000 
duration of year for 
having diabetic 
nephropathy 
no 
.508 273 .000 
 yes .485 283 .000 
History of Chronic 
disease1_Heart disease 
no 
.541 273 .000 
 yes .538 283 .000 
   
a. Lilliefors Significance Correction 
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Appendix F2: Table of Multicollinearity test 
Coefficients
a
 
Model 
Collinearity Statistics 
Tolerance VIF 
1 age .687 1.456 
year in school .913 1.095 
body mass index .813 1.230 
blood pressure_systolic .730 1.371 
blood pressure_diastolic .710 1.408 
fasting blood sugar  .650 1.537 
HbA1c results .669 1.495 
total cholesterol (mg/dl or mmol/l) .224 4.458 
Low density lipoprotein (mg/dl or mmol/l) .280 3.568 
High density lipoprotein (mg/dl or mmol/l) .641 1.560 
Triglyceride (mg/dl or mmol/l) .657 1.522 
years for DM duration .641 1.561 
duration of year for having diabetic 
neuropathy 
.896 1.116 
duration of year for having diabetic 
retinopathy 
.819 1.222 
duration of year for having diabetic 
nephropathy 
.860 1.163 
duration of year for having heart disease  .982 1.018 
duration of year for having hypertension .589 1.698 
duration of year for having COPD .964 1.038 
duration of year for having gout .952 1.050 
duration of year for having arthritis .959 1.043 
duration of year for having6 dyslipidemia .905 1.105 
duration of year for having7 asthma .913 1.096 
duration of year for having8 other .962 1.040 
a. Dependent Variable: Mini-Cog total score 
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Coefficients
a
 
Model 
Collinearity Statistics 
Tolerance VIF 
1 age .687 1.456 
year in school .913 1.095 
body mass index .813 1.230 
blood pressure_systolic .730 1.371 
blood pressure_diastolic .710 1.408 
fasting blood sugar  .650 1.537 
HbA1c results .669 1.495 
total cholesterol (mg/dl or mmol/l) .224 4.458 
Low density lipoprotein (mg/dl or 
mmol/l) 
.280 3.568 
High density lipoprotein (mg/dl or 
mmol/l) 
.641 1.560 
Triglyceride (mg/dl or mmol/l) .657 1.522 
years for DM duration .641 1.561 
duration of year for having diabetic 
neuropathy 
.896 1.116 
duration of year for having diabetic 
retinopathy 
.819 1.222 
duration of year for having diabetic 
nephropathy 
.860 1.163 
duration of year for having heart 
disease  
.982 1.018 
duration of year for having 
hypertension 
.589 1.698 
duration of year for having COPD .964 1.038 
duration of year for having gout .952 1.050 
duration of year for having arthritis .959 1.043 
duration of year for having6 
dyslipidemia 
.905 1.105 
duration of year for having7 asthma .913 1.096 
duration of year for having8 other .962 1.040 
a. Dependent Variable: MMSE total score  
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Coefficients
a
 
Model 
Collinearity Statistics 
Tolerance VIF 
1 age .687 1.456 
year in school .913 1.095 
body mass index .813 1.230 
blood pressure_systolic .730 1.371 
blood pressure_diastolic .710 1.408 
fasting blood sugar  .650 1.537 
HbA1c results .669 1.495 
total cholesterol (mg/dl or mmol/l) .224 4.458 
Low density lipoprotein (mg/dl or 
mmol/l) 
.280 3.568 
High density lipoprotein (mg/dl or 
mmol/l) 
.641 1.560 
Triglyceride (mg/dl or mmol/l) .657 1.522 
years for DM duration .641 1.561 
duration of year for having diabetic 
neuropathy 
.896 1.116 
duration of year for having diabetic 
retinopathy 
.819 1.222 
duration of year for having diabetic 
nephropathy 
.860 1.163 
duration of year for having heart disease  .982 1.018 
duration of year for having hypertension .589 1.698 
duration of year for having COPD .964 1.038 
duration of year for having gout .952 1.050 
duration of year for having arthritis .959 1.043 
duration of year for having6 
dyslipidemia 
.905 1.105 
duration of year for having7 asthma .913 1.096 
duration of year for having8 other .962 1.040 
a. Dependent Variable: TGDS total score  
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